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Background: Many women who have received treatment for breast cancer have a high risk of 
developing late side effects or persistent cancer-related symptoms (CRS). Although massage 
therapy (MT) showed to provide positive results in the management of CRS, only a few studies 
have been conducted to examine persistent CRS in breast cancer survivors (BCS). Additionally, 
more robust examinations of the biological effects of most integrative therapies, including MT, 
remains needed. Objective: To investigate the effects of an 8-week Swedish massage program on 
quality of life (QoL), sleep, stress, fatigue, cortisol, c-reactive protein (CRP) and pro-
inflammatory cytokines in BCS. Methodology: Females over 18 years who were diagnosed with 
breast cancer - stages I to III and have completed the treatment in the last six months were 
recruited. Participants underwent a one-hour session of MT once a week. Subjects were assessed 
for QoL, fatigue, stress, sleep and inflammatory markers before the beginning of the study 
(baseline), every two weeks during intervention period (assessment 1 and 2) and one week after 
the program (endpoint). The Functional Assessment of Cancer Therapy Fatigue was chosen to 
measure QoL and fatigue, and the Perceived Stress Scale was used to measure stress. Circadian 
sleep-wake rhythms were measured noninvasively through Actigraphy. Saliva was collected to 
detect the following markers: cortisol, CRP, IL-1β, IL-6, TNF-α and IFN-!. Oximetry, heart rate 
and blood pressure were measured pre and post every MT session. Results: A total of 24 
participants completed the study. The average age of participants was 56.9 (±9.3). QoL 
improvements were significantly associated with time after cancer treatment completion and 
cancer stage. Changes in fatigue scores were significantly associated with sleep aids in use and 
comorbidities. Stress levels significantly improved at endpoint in comparison to baseline, 
regardless of any covariates tested. Wake after sleep onset showed improvement at endpoint. 
Sleep onset latency improvement was only significant for Stage III patients. Sleep duration did 
not show any significant improvement. Subjects showed superior sleep efficiency at the end of 
the program, however, changes did not attain statistical significance. Overall, all the biomarkers 
decreased at endpoint in comparison to baseline; however, only cortisol, IL-1β and TNF-α 
reached significant changes, with IL-1β showing important associations with cancer stage and 
hormone therapy. Heart rate and oxygen levels improved right after sessions, and blood pressure 
slightly increased. Conclusion: This study reveals evidence of a positive effect of MT in QoL, 
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1.1  General Introduction  
 
Breast tumors are the most feared type of tumor among women. Besides the stigma 
around breast cancer (BC), breast tumors affect a main symbol of femininity and can compromise 
not only the patients’ physical condition, but also their mental health, as they can affect their self-
perceived image (da Silva & Riul, 2011; Fiorentino, Rissling, Liu, & Ancoli-Israel, 2011). As a 
result of the increased number of cancer survivors, one of the most significant challenges in 
oncology today is how to best care for these individuals after treatment. Besides the immediate 
treatment-related symptoms, cancer and its treatment can cause persistent disruptions for years 
after cure (Brem & Kumar, 2011; Dupont, Bower, Stanton, & Ganz, 2014; Stanton, Rowland, & 
Ganz, 2015). 
Breast Cancer Survivors (BCS) are at risk of developing persistent cancer-related 
symptoms (CRS) either during the immediate or long-term period after treatment (Brem & 
Kumar, 2011). Persistent CRS might lead to premature mortality and morbidity and compromise 
patient's QoL (Brem & Kumar, 2011). The term "persistent CRS" refers to persistent or long-term 
CRS that last for a number of weeks, months, or even years after the completion of cancer 
treatment. Most BCS experience prolonged CRS, followed by a period of symptoms resolution 
until they return to full normal activity. Hence, these individuals may be said to be experiencing 
persistent CRS (Billhult, Bergbom, & Stener-Victorin, 2007; Billhult, Stener-Victorin, & 
Bergbom, 2007; Hernandez-Reif et al., 2005; Pruthi, Degnim, Bauer, DePompolo, & Nayar, 
2009).  
 Persistent CRS can be divided as psychological and physiologic effects. The 
psychological symptoms might include fatigue, fear, loss of self-esteem, sleep problems, anxiety, 
psychological stress and depression. The physiological symptoms might include hair loss, 
lymphedema, pain, numbness, cognitive impairment, weight gain, spontaneous menopause, 
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peripheral neuropathy and reduced libido (Brem & Kumar, 2011; Penttinen et al., 2014; Stanton 
et al., 2005). 
 Among these symptoms, fatigue, pain, psychological stress and sleep problems are 
recognized as the most prevalent CRS (Campos, Hassan, Riechelmann, & Del Giglio, 2011; 
Couzi, Helzlsouer, & Fetting, 1995; Davidson, MacLean, Brundage, & Schulze, 2002; Lindley, 
Vasa, Sawyer, & Winer, 1998; Miaskowski et al., 2010). They can significantly impair the 
quality of life (QoL) of patients for many years, even after the treatment (Campos et al., 2011; 
Gordon & Siminoff, 2010; Lee et al., 2013; Miaskowski et al., 2010; Penttinen et al., 2014). In 
this context, the length and quality of survival have become an important endpoint. In order to 
assist BC patients that completed their treatment to achieve the best survival outcomes, the CRS 
screening and management need to be closely investigated (Brem & Kumar, 2011; Lopez, 
Williams, & Larkin, 2015). 
 Besides the negative impact of these symptoms on patients’ QoL, they also play an 
immunosuppressive effect by changing levels of biological markers such as cytokines, cortisol 
and α-amylase (Pagel, & Pandi-Perumal, 2007; Illi et al., 2012; Miaskowski et al., 2010; Miller, 
Cohen, & Ritchey, 2002; Moreno-Smith, Lutgendorf, & Sood, 2010; Reyes-Gibby et al., 2008). 
For instance, sleep problems and fatigue have been linked to increased function of pro-
inflammatory cytokines, such as interleukin-1, tumor necrosis factor-α and interleukin-6 (Illi et 
al., 2012; Lyon, Mccain, Pickler, Munro, & Elswick, 2011; Miaskowski et al., 2010; Reyes-
Gibby et al., 2008) Similarly, psychological stress episodes activate the hypothalamic-pituitary-
axis, which releases cortisol in order to regulate inflammation (Dantzer, 1997; Dantzer, Meagher, 
& Cleeland, 2012).  
 
1.2   Defining the Problem  
 
 An essential part of any cancer survivorship care plan is providing effective interventions 
to manage long-term CRS, such as pain, fatigue, sleep problems, depression, among others 
(Oeffinger et al., 2014). Even though researchers have begun to document the issues faced during 
the transition period - from active treatment to survivorship, many questions remain.  
The literature highlights many advantages in the use of integrative therapies, including 
massage therapy (MT) by BC patients. However, this link is virtually unexplored in BCS 
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(Barnes, Bloom, & Nahin, 2008; Billhult, Lindholm, Gunnarsson, & Stener-Victorin, 2009; 
Drackley et al., 2012; Kashani, Babaee, Bahrami, & Valiani, 2012; Krohn et al., 2011; Pruthi et 
al., 2009). Previous studies found that MT was effective in reducing fatigue, pain, anxiety, 
tension, and creating a general feeling of wellness in different groups of cancer patients, 
including breast cancer (Barnes et al., 2008; Billhult et al., 2009; Cassileth & Vickers, 2004; 
Drackley et al., 2012; Kashani et al., 2012; Krohn et al., 2011; Pruthi et al., 2009). Some studies, 
however, have presented controversial evidence, supporting the necessity for conducting more 
studies on this topic (Fernández-Lao et al., 2012; Jane, Wilkie, Gallucci, Beaton, & Huang, 2009; 
Sturgeon, Wetta-Hall, Hart, Good, & Dakhil, 2009).  
Although MT studies have been done before, these studies present a considered number 
of limitations (Billhult et al., 2009; Billhult, Stener-Victorin, et al., 2007; Drackley et al., 2012; 
Fernández-Lao et al., 2012; Field, Hernandez-Reif, Diego, Schanberg, & Kuhn, 2005; Hodgson 
& Lafferty, 2012; Krohn et al., 2011; Listing et al., 2009; Sturgeon et al., 2009). Certainly, all the 
gaps and limitations found in the current literature open wide possibilities for scientific 
exploration but are also preventing us to properly use these findings in clinical practice. Some of 
these limitations, are: (i) the massage protocols are not clearly detailed; (ii) the training of 
massage therapists is not usually indicated, which is an essential step to be taken since therapists 
must be all equally instructed to homogeneously deliver the study's massage protocol among the 
subjects; (iii) many studies have examined CRS during the treatment, but far less research has 
been conducted to examine persistent CRS in BCS shortly after the completion of treatment; (iv) 
the biological effects of MT in BCS remains a largely unanswered question (Chang, Mu, Jou, 
Wong, & Chen, 2013; Patterson, Wan, & Sidani, 2013), (v) the few studies that have explored the 
biological effects of massage have not taken into account the circadian rhythm of the biological 
markers investigated (Billhult et al., 2009; Billhult, Bergbom, et al., 2007; Drackley et al., 2012; 
Fernández-Lao et al., 2012; Field et al., 2005; Krohn et al., 2011; Listing et al., 2010, 2009; 
Sturgeon et al., 2009).  
In fact, a systematic review performed in 2017 concluded that there is high certainty of a 
net benefit of MT only in managing mood disturbance in BCS. There is not enough evidence up 
to date to conclude that the net benefit of MT is substantial to treat other persistent CRS 
(Greenlee et al., 2017). Overall, the quantity and quality of preliminary evidence is not sufficient 
to build trustworthy clinical practice guidelines for MT use. Additional research is needed to 
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unveil which type of MT is most effective for which specific purpose so that tailored 
recommendations can be made to target individual interests of the patients. There is an emerging 
need to establish optimal type-specific norms for integrative therapies use among different cancer 
survivors’ populations. 
Biobehavioral studies that encompass the interactions of the numerous biological 
pathways with patient-reported outcomes (PRO) have not been formally investigated in the 
context of MT. The justification for and validation of massage benefits to BCS population is in 
part dependent upon identification of the functional pathways governing the healing process 
during the transition period. In this context, novel and further studies become increasingly 
important and needed in moving forward the evidence-based medicine in the context of 
integrative oncology.   
 
1.3   Research Purpose  
 
 
The overall purpose of this study was to explore the effects of an 8-week Swedish massage 
program on QoL, fatigue, stress, sleep, cortisol, c-reactive protein (CRP), interleukin-1 beta (IL-
1β), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α) and interferon gama (IFN-!), heart 
rate, oximetry, blood pressure pre and post the intervention. 
 
1.4   Research Questions  
 
This study was specifically designed to answer the following research questions:  
i. Are there any changes in QoL, fatigue, stress and sleep parameters in BCS 
submitted to an 8-week Swedish massage program?  
ii. Are there any changes in inflammatory markers (cortisol, CRP, IL-1β, IL-6, tumor 
TNF-α and IFN-!) in BCS submitted to an 8-week Swedish massage program?  
iii. What are the immediate changes in blood pressure, heart rate and oximetry 
following Swedish MT in BCS? 
iv. Are there any correlations between the levels of inflammatory markers and stress, 
QoL, fatigue and sleep efficiency? 
 
 5 
1.5   Hypothesis  
 
Our hypothesis is that, compared to baseline, recently treated breast-cancer survivors 
undergoing an 8-week protocol of Swedish massage will experience:  
i. An improvement in QoL, stress, fatigue and sleep parameters. 
ii. Decreased levels of cortisol, CRP, IL-1β, IL-6, TNF-α and IFN-!. 
iii. Decreased levels of blood pressure and heart rate and increased levels of SpO2.  
iv. Positive correlations between fatigue, stress and the inflammatory markers and 
negative correlations between QoL, sleep efficiency and the inflammatory markers. 
 
1.6      Background  
 
1.6.1 Breast Cancer in Canada 
 
Lung and bronchus, colorectal, breast and prostate cancer are the most common types of 
cancer in Canada (Canadian Cancer Statistics, 2019; Brenner et al., 2020). According to the 
Canadian Cancer Statistics, a total of 220,400 new cancers are likely to be diagnosed in Canada 
in 2019. On average, about 1 in 2 Canadians will develop cancer in their lifetimes, and 1 in 8 
females are expected to be diagnosed with breast cancer in their lifetime  (Canadian Cancer 
Statistics, 2019). 
Compared to 2017 statistics, several new patterns have emerged in Canada’s cancer 
statistics. Notably, female breast cancer death rates have decreased an estimated 48% since they 
peaked in 1986  (Canadian Cancer Statistics, 2019). In 2020, pancreatic cancer is expected to be 
the third leading cause of cancer death in Canada surpassing breast cancer (Brenner et al., 2020). 
Breast cancer is expected to surpass colorectal cancer and become the second most commonly 
diagnosed type of cancer in 2019 (Brenner et al., 2020). 
Most women diagnosed with breast cancer in Canada (40%) are between 30 and 59 years 
old. (Canadian Cancer Statistics, 2019). According to a special report released in 2018 by the 
Canadian Cancer Society Statistics, most of female breast cancers (around 80%) are diagnosed at 
an early stage (stage I or II) (Canadian Cancer Statistics, 2019). 
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1.6.2 Breast Cancer in Saskatchewan  
 
BC rates have a similar trend between provinces and territories in Canada, ranging from 
117 per 100,000 in New Brunswick to 132 per 100,000 in Ontario. Among women, BC is the 
most diagnosed type of cancer with 740 cases estimated for 2020. Out of these 740 new cases, 
170 deaths are expected for the same period, yielding approximately 560 new BCS (Brenner et 
al., 2020). In Saskatchewan, most women diagnosed with BC were between the age of 55 to 59 
and 65 to 69 (Brenner et al., 2020). 
In Saskatchewan, most patients who develop the disease are diagnosed at stage I (47.4%), 
followed by stage II (34.1%) and Stage III (11.1%) (Canadian Cancer Statistics, 2019). Most 
patients diagnosed with stage I BC in Saskatchewan are between 60 and 69 years old  (Canadian 
Cancer Statistics, 2019). 
 
1.6.3 Survivorship and Persistent Cancer-Related Symptoms    
 
     After several decades of basic, epidemiologic and clinical research, we have learned much 
about the survivorship aspects of BC and are increasingly paying attention to the long-term and 
persistent effects of BC treatment (Ganz & Goodwin, 2015). 
 Although the benefits of current therapeutic strategies are well established, it is well 
known that many women who have received treatment for BC have a high risk of developing 
long-term side effects. These long-term disruptions are side effects that occur months or years 
after cancer treatment and are called persistent CRS (Bower, 2008; Bower et al., 2006, 2000; 
Dupont et al., 2014; Stanton et al., 2015). 
   Persistent CRS might lead to premature mortality and morbidity and compromise 
patient's QoL (Brem & Kumar, 2011). Indeed, the majority of women who experienced cancer do 
not return to their pre-treatment functional status and QoL (Donovan, Small, Andrykowski, 
Munster, & Jacobsen, 2007; Henselmans et al., 2010; Lyons, Svensborn, Kornblith, & Hegel, 
2015). Long-term CRS can be divided into two categories: (i) Psychophysiological: emotional 
difficulties, loss of self-esteem, fear of recurrence, fatigue, sleep problems, anxiety, cognitive 
impairment, psychological stress and depression and (ii) Physiological: long-term postoperative 
problems, heart problems (especially those in use of specific drugs such as trastuzumab), 
 7 
hypertension, lung problems, endocrine problems (affecting menopause and infertility, for 
instance), bone, joint, and soft tissue problems, hair loss, lymphedema, pain, numbness, weight 
gain, spontaneous menopause, peripheral neuropathy and reduced libido (Brem & Kumar, 2011; 
Penttinen et al., 2014; Stanton et al., 2005). 
The actual trajectory of CRS after treatment is not known – i.e. if they become weaker or 
stronger post-treatment. It is well known, however, that after completion of treatment, persistent 
CRS are reported by all-types of cancer population (Dupont et al., 2014; Kim, Barsevick, 
Tulman, & McDermott, 2008; Morrow, 2007). Evaluating and treating persistent CRS is an 
important part of survivorship care. However, there has been a paucity of studies identifying the 
occurrence of symptom clusters in breast cancer (BC) patients across different points in the post-
treatment trajectory (Bodai & Tuso, 2015; Eccles, Grimshaw, Campbell, & Ramsay, 2003; 
Mazor et al., 2018).   
 
1.6.4 Massage Therapy and Breast Cancer Survivors    
     
The literature highlights the value of several integrative therapies in improving CRS in 
BC patients (Bernstein & Grasso, 2001; Kang, McArdle, & Suh, 2014; Patterson et al., 2013).  
Particularly regarding MT, several studies found that this therapy exerts hypoalgesic effects, 
along with reduction of fatigue, anxiety and tension in different groups of cancer patients 
(Billhult et al., 2009; Cassileth & Vickers, 2004; Drackley et al., 2012; Fellowes, Barnes, & 
Wilkinson, 2004; Kashani et al., 2012; Krohn et al., 2011; Pruthi et al., 2009). MT has also 
shown positive effects within the immune system as changes on several biological markers has 
been identified, including Th1 molecules (IL-1, IFN- γ) (Cantarero-Villanueva et al., 2011), Th2 
(IL-4, IL-10) (Green et al., 2010), cortisol (Cantarero-Villanueva et al., 2011; Fernández-Lao et 
al., 2012) and CRP (Sheikhsaraf, Peeri, Azarbayjani, & Agha-Alinejad, 2016) in both cancer and 
non-cancer settings.   
It is important to highlight that even though some studies have postulated inconsistencies 
in their results regarding MT effects (Fernández-Lao et al., 2012; Jane et al., 2011, 2009; 
Sturgeon et al., 2009), MT has been notably chosen by cancer patients as a non-pharmacological 
option in reducing CRS. Cancer patients have been using MT in both hospital settings and private 
clinics, as well as during different phases of the condition and by those undergoing different 
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treatment types. For example, MT has been used to target not only the side effects of 
chemotherapy and radiotherapy, but also to help patients following mastectomy. A study that 
assessed the effect of having MT sessions incorporated into a breast surgical hospital practice 
after mastectomy, found that postoperative pain, stress, and muscle tension decreased, along with 
an increase in relaxation (Drackley et al., 2012). However, the definition of ‘dose’ or more 
precise recommendations has never been formally conceptualized for MT in the context of BCS 
population or cancer patients in treatment (Ali, Kahn, Rosenberger, & Perlman, 2012). 
As more BCS and care providers seek non-pharmacological modalities for CRS 
management, it is possible that MT and other myofascial techniques may relieve CRS, however, 
only a few studies have previously investigated this hypothesis in BCS. Practice guidelines are 
still needed to inform clinicians and patients about effective and efficient use of MT. 
 
1.7  Summary of Chapter One  
 
The mortality rate and the incidence rate for all cancers combined have been decreasing in 
Canada. Additionally, the survival rates have been also improving, which has implications for 
health policy and resource planning. Hence, efforts to support people living with and beyond 
cancer are of utmost importance.    
Fatigue, stress and sleep problem are among the most reported CRS by BCS. These 
symptoms can last up to 10 years after the treatment placing a great impact on patients’ QoL. The 
majority of BCS use at least one modality of integrative therapy to manage long-term CRS, 
prevent toxicities, and improve QoL. Women with BC are among the highest users of these 
therapies. 
  MT has been used by cancer patients during and beyond cancer treatment to mainly 
manage fatigue, pain, mood disturbances and to reduce stress and anxiety. However, like other 
IT, further rigorous trials investigation on MT are still required so this therapy can be 













 LITERATURE REVIEW 
 
2.1        General Scope of Literature Review  
 
The overall aim of this literature review is to describe the occurrence, correlates, and 
impact of fatigue, stress and sleep problems experienced by BCS on QoL. The biological and 
genetic mechanisms of these symptoms are also described. The definition of MT, its biological 
underpinnings, and the effects of MT in cancer patients and survivors were also reviewed. 
Literature providing explanations on the factors influencing the use of integrative oncology 
therapies by BCS are also summarized.  
  
2.2       An Overview on Breast Cancer    
 
BC is a result of an abnormal and malignant grow in the cells of the breast. The human 
breast is a modified, specialized apocrine gland that contains hormonally responsive and 
hormonally unresponsive tissue elements. Since BC is a hormone-dependent disease, post-
menopausal women have lower risk of developing the disease due to the decline in oestrogens 
production and particularly progestins after menopause (Hunt, 2008; Jacobs & Finlayson, 2011; 
Peters & Visscher, 1998). 
 Other risk factors for BC that are beyond patient’s control are family history (i.e. BRCA 
1, BRCA 2), race, gender (i.e. women have increased risk in comparison to men), and medical 
history. On the other hand, manageable risk factors related to the patient’s life-style are weight, 
diet, physical activity, exogenous hormones (i.e. oral contraceptives and post-menopausal 
hormone replacement therapy), smoking, stress levels and alcohol consumption (Hunt, 2008; 
Jacobs & Finlayson, 2011; Peters & Visscher, 1998). A few studies have also highlighted the 
socioeconomic disparities in BC incidence and mortality. Higher socioeconomic status has been 
linked to higher odds but inferior case fatality (Hu et al., 2019; Lundqvist, Andersson, Ahlberg, 
Nilbert, & Gerdtham, 2016).  
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  Treatment for BC include surgery, chemotherapy, hormonal therapy, and radiotherapy. 
Recently, phytochemicals have been also tested in BC therapy (Akhtar Siddiqui et al., 2015; 
Kapinova et al., 2019; Sun, Zhang, Zheng, & Feng, 2019). The choice of treatment depends on 
many factors including the type and stage of the disease (Hunt, 2008). 
Types of BC include ductal carcinoma in situ, invasive ductal carcinoma, inflammatory 
BC, and metastatic BC. Staging is a method of describing or categorizing a cancer based on how 
much the disease has spread in the body and where it is at the time of the diagnosis. This is also 
called extent of cancer. Accurate identification of the cancer stage can lead to appropriate 
interventions in therapy and during survivorship phase. Cancer staging helps us in understanding 
how the cancer will behave and ultimately, how patients will do during and after treatment (Hunt, 
2008). Figure 2.1 summarizes the stages according to the according to the Canadian Cancer Society 
(Canadian Cancer Statistics, 2019). 
 
Figure 2.1.  
 
Cancer stages. (Used with permission from Canadian Cancer Society, 2019 – Appendix A).  
 
A more sophisticated way of classifying breast tumors is the staging system proposed by 
the American Joint Committee on Cancer (AJCC) (Giuliano et al., 2017). This system is the most 
often used for BC tumors and utilizes in part the TNM scoring system: Tumor size, Lymph 
Nodes affected and presence of Metastases. The latest version of AJCC incorporated important 
changes in the staging system such as important biologic factors (i.e. tumor grade, proliferation 
rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) 
expression, and gene expression prognostic panels) (Giuliano et al., 2017). 
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2.3       Breast Cancer Survivorship  
 
Due to advances in detection and treatment, millions of cancer survivors are alive today, 
and the numbers are growing. Cancer survival has increased in Canada since 1990, when the five-
year net survival was only 55%, but the last Canadian Cancer Statistics released in 2019 
estimates a 63% of survival rate for all cancers combined. Cancer survival generally decreased 
with advancing age and females show higher net survival rates compared to males (Canadian 
Cancer Statistics, 2019).   
Particularly for breast cancer in Canada, predicted net survival is 97% 1 year after the 
diagnosis, which decreases to 92% 3 years after the diagnosis reaching the lowest survival rate of 
82% 10 years after diagnosis (Canadian Cancer Statistics, 2019). Although the prognosis and 
survival rates vary widely by the type and stage of cancer, breast cancers and blood-related 
cancers have the highest survival rates (Rubin, Constine, Marks, & Okunieff, 2008). 
Additionally, a literature review showed an association between race and BC survival. This same 
study revealed that a more efficient early detection approach needs to be developed for African-
American women and lower income women (Campbell, 2002).  
There are many definitions of cancer survivor, however, the most widely used is the one 
by the National Cancer Institutes from the United States that states that says:  
An individual is considered a cancer survivor from the time of diagnosis, through 
the balance of his or her life. Family members, friends, and caregivers are also 
impacted and are therefore included in this definition (National Cancer Institute, 
2019). 
 
Therefore, cancer survivorship is seen as a process that begins at the moment of diagnosis 
and continues through the balance of life (Marzorati, Riva, & Pravettoni, 2017). A clinical 
criterion used to classify cancer survivorship is based on cancer-specific survival rates, which 
refers to cancer patients who did not die from cancer during a certain period after the diagnosis. 
The most common used period of time is 5 years. Hence, when all signs and symptoms of cancer 
have disappeared, a patient can be classified in complete remission. If this patient remains in 
complete remission for 5 years or more, it may indicate that the patient is cured (Denlinger et al., 
2014). 
A widely used guideline created by the Institute of Medicine and the National Research 
Council helps patients and health professionals in understanding the essential components of 
 12 
survivorship care. In 2005, in a report entitled, “From Cancer Patient to Cancer Survivor: Lost in 
Transition” the following components of survivorship care were presented:  
(1) Prevention of new and recurrent cancers and other late effects; (2) 
Surveillance for cancer spread, recurrence, or second cancers; (3) Assessment 
of late psychosocial and medical effects; (4) Intervention for consequences of 
cancer and treatment (eg, medical problems, symptoms, psychologic distress, 
financial and social concerns); (5) Coordination of care between primary care 
providers and specialists to ensure that all of the survivor’s health needs are met 
(Hewitt, Greenfield, & Stovall, 2005). 
 
Cancer survivors experience significant morbidity associated with their disease and 
treatment regimens, which can be severe, debilitating, and sometimes permanent. A study found 
that cancer survivors who reported untreated stress showed a poorer performance in complying 
with surveillance screenings and are less likely to exercise and quit smoking (Carmack, Basen-
Engquist, & Gritz, 2011; Denlinger et al., 2014). Many CRS, both physical and/or psychosocial 
and can be improved through modifying behavioral and psychosocial risk factors. Cancer spread, 
recurrence, or second cancers are only a few aspects to be accounted in surveillance screenings.  
Accounting for psychosocial aspects in cancer survivorship care is essential to prevent adverse 
late outcomes such as psychological and behavioral CRS.  
 
2.4  Symptom Burden in Cancer Survivors  
 
Due to the high number of survivors, especially in North America, more attention has 
been paid to the persistent adverse effects associated with cancer treatment. Patients who have 
survived cancer are at risk of developing a range of CRS soon after treatment completion, which 
can last for short or long-term periods (Brem & Kumar, 2011). Findings from several studies 
suggest that symptom burden and residual symptoms remain high in cancer survivors, both at 
early and late cancer survivorship phases (Shi et al., 2011). In a study with 558 survivors (at 6 to 
8 months post- diagnosis) of breast, colorectal, gynecologic, lung, or prostate cancer reported an 
average of 9.2 symptoms (Deshields, Potter, Olsen, Liu, & Dye, 2011). 
The first 12 months after treatment had been identified to be the most stressful (Hewitt et 
al., 2005), however, symptom burden and the occurrence of CRS can vary throughout different 
phases of survivorship. According to the “seasons of survivorship” theory, once treatment is 
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completed, survivors go through four cancer survivorship phases: acute, transitional, extended, 
permanent, and chronic. Acute phase refers to the moment of diagnosis until the end of treatment. 
Transitional phase starts at the end of the treatment and goes until months after. Permanent 
phase refers to the period when months have passed since cancer treatment ended. Chronic phase 
refers to a period when there is very low chance that the cancer is going to reoccur. Therefore, the 
needs of BCS and CRS occurrence can change in each one of these phases (Miller, Merry, & 
Miller, 2008).  
Multiple persistent CRS impair patient’s function and QoL and its severity varies 
depending on the presence of physical and psychological co-morbidities (Gilbertson-White et al., 
2019; Shi et al., 2011). Several factors can predict the development of CRS and determine who 
will experience worse symptom burden. These factors include clinical factors (i.e. type of cancer 
and treatment (Deshields et al., 2011); social factors (i.e. socioeconomic status and social 
support) (Kroenke et al., 2013; Sullivan et al., 2016); psychosocial factors (i.e. optimism and 
psychological stress) (Ho, Fong, & Cheung, 2014); biological factors, (i.e. genetic and 
inflammatory markers activity) (Aouizerat et al., 2009; Fogelman et al., 2017; Koleck & Conley, 
2016; Miaskowski et al., 2017; Oliveira et al., 2014; Reyes-Gibby et al., 2008; Wang et al., 
2010). 
 
2.4.1 Symptoms Clustering 
 
Findings suggest that persistent CRS might occur together, influencing one another as a 
cluster of symptoms, in both patients and BCS (Cleeland, 2007; Cleeland et al., 2013; Dantzer et 
al., 2012; Dodd, Miaskowski, & Paul, 2001; Dodd, Miaskowski, & Lee, 2004). These symptoms 
are known to act additively and synergistically (Agasi-Idenburg, Thong, Punt, Stuiver, & 
Aaronson, 2017; Cleeland, 2007; Cleeland et al., 2013; Dantzer et al., 2012; Dodd et al., 2004; 
Dodd et al., 2001; Kim, Barsevick, Fang, & Miaskowski, 2012; Miaskowski, Dodd, & Lee, 2004; 
Nho, Kim, Park, & Kweon, 2018; Reich et al., 2017). It is believed that their co-occurrence is 
linked to a common underlying inflammatory, neuroendocrine and immunologic etiology 
(Cleeland, 2007; Dodd et al., 2004; Moreno-Smith et al., 2010). 
Fatigue, pain, psychological stress and sleep problems are among the most commonly 
reported CRS by BCS (Campos et al., 2011; Couzi et al., 1995; Davidson et al., 2002; Lindley et 
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al., 1998; Miaskowski et al., 2010), with co-occurring symptoms such as nausea/vomiting, 
peripheral neuropathy, dyspnoea, appetite loss, constipation, anxiety, depression, breast-area 
discomfort/symptoms and arm/axilla symptoms (Brem & Kumar, 2011; Kim, Lee, & Lee, 2012; 
Nho et al., 2018; Penttinen et al., 2014; Reich et al., 2017; Stanton et al., 2015). These symptoms 
group together creating different clusters, such as: psychological cluster, representing the inter-
relationships among anxiety and depression; general cluster, characterizing the inter-
relationships among appetite loss, fatigue, insomnia and dyspnoea; physical cluster, indicating 
the inter-relationships among arm symptom, breast symptom, pain and systemic therapy side 
effects; and gastrointestinal cluster, signifying the inter-relationships among nausea/vomiting 
and constipation symptoms (Nho et al., 2018).  
Either as a cluster or as an isolated complaint, CRS can significantly impair the patient’s 
QoL for many years after the treatment (Campos et al., 2011; Gordon & Siminoff, 2010a; M. C. 
Lee et al., 2013; Miaskowski et al., 2010; Penttinen et al., 2014). Therefore, in order to assist 
BCS to achieve the best outcomes post-treatment, screening for CRS and management need to be 
closely investigated (Brem & Kumar, 2011; Lopes-Junior et al., 2019; Lopez et al., 2015). 
Careful screening and observations of the emotional, social, and medical issues are essential to a 
favorable prognosis, remission and positive survivorship experience.   
 
2.4.2 Quality of Life  
 
Many aspects have been shown to affect cancer survivors’ QoL, including multiple 
persistent CRS (Campos et al., 2011; Deshields, Potter, Olsen, & Liu, 2014; Gordon & Siminoff, 
2010; Lee et al., 2013; Miaskowski et al., 2010; Penttinen et al., 2014). Results from several 
studies suggest that QoL negatively correlates with symptom burden and multiple persistent CRS 
after treatment (Campos et al., 2011; Deshields et al., 2014; Gordon & Siminoff, 2010a; M. C. 
Lee et al., 2013; Miaskowski et al., 2010; Penttinen et al., 2014). In metastatic breast cancer 
patients positive relationships were found between QoL and the survival duration of cancer 
patients and prognosis (Montazeri, 2008, 2009).    
The aspects influencing QoL in BCS are listed in the conceptual model created by Ferrel 
and colleagues (Ferrell et al., 1996) that encompasses four primary domains of well-being that 
influences QoL in BCS (Figure 2.2) (Chopra & Kamal, 2012). 
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Figure 2.2.  
 




The idea of psychological, social, physical, and spiritual domains affecting QoL proposed 
by the model described in Figure 2.2 is in agreement with recent studies being done. A literature 
review showed that psychological factors (i.e. stress, optimism, resilience) were found to predict 
QoL and overall survival in breast cancer patients (Montazeri, 2008; Zhang et al., 2017).  In 
addition, a large population-based study that aimed to determine the prognostic value of baseline 
health-related QoL for survival, found that in breast cancer patients, the following health-related 
QoL factors were predictive for survival: physical functioning, emotional functioning, global 
health status, and nausea and vomiting (Quinten et al., 2014).  
Additionally, studies have also shown negative correlations between QoL and persistent 
CRS, such as sleep problems, fatigue and stress in several types of cancer (Bower et al., 2000; 
Charalambous & Kouta, 2016; Dreidi & Hamdan-Mansour, 2016; Gedaly-Duff, Lee, Nail, 
Nicholson, & Johnson, 2006; Kim, Kim, Lim, & Kim, 2018; Li, Otomaru, & Taniguchi, 2017; 
Nunes et al., 2017). For instance, in children and adolescents with cancer, a study showed that 
general fatigue and relationship distress were significant predictors of QoL (Pan, Wu, & Wen, 
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2017). Similarly, sleep problems, fatigue and stress might result in poor QoL in adults with breast 
cancer and BCS (Bower et al., 2000; Huang et al., 2010; Tsai, Kuo, & Chung, 2017; Xu et al., 
2018).  
 
2.4.3 Fatigue  
 
Fatigue, psychological stress and sleep problems are one of the most prevalent CRS 
among oncology patients during and after treatment (Ahlberg, Ekman, & Gaston-Johansson, 
2005; Ahlberg, Ekman, Gaston-Johansson, & Mock, 2003; Sonia Ancoli-Israel et al., 2014; 
Cleeland et al., 2013; Curt, 2000; Morrow, Andrews, Hickok, Roscoe, & Matteson, 2002; Stasi, 
Abriani, Beccaglia, Terzoli, & Amadori, 2003). Fatigue is the prevailing symptom experienced 
by cancer patients in treatment, affecting from 50% to 90% of patients (Campos et al., 2011; 
Miaskowski et al., 2010; Penttinen et al., 2014). Furthermore, a few studies provide evidence for 
the prevalence and persistence of this problem in cancer survivors. For instance, one third of BCS 
report significant levels of fatigue up to 10 years following treatment (Bower et al., 2000; Lindley 
et al., 1998), and approximately 30% of BCS report fatigue more than five years after completion 
of treatment (Bower et al., 2006, 2000; Ganz & Goodwin, 2015; Lindley et al., 1998; Servaes, 
Verhagen, & Bleijenberg, 2002).  
 The fatigue associated with cancer or its treatment is usually referred to as cancer-related 
fatigue (CRF) and has a broad designation (Piper & Cella, 2010). The most commonly used 
definition is the one suggested by the National Comprehensive Cancer Network (NCCN) Fatigue 
Guidelines Committee. According to the NCCN, CRF can be defined as an unusual, persistent, 
subjective sense of tiredness related to cancer or cancer treatment that interferes with usual 
functioning (Sonia Ancoli-Israel et al., 2014). This sense of tiredness is not relieved by rest or 
sleep, and is considered a distinct phenomenon of the fatigue experienced after muscle exertion  
(Morrow, 2007). 
This symptom is widely recognized as the most distressing adverse effect experienced by 
breast cancer patients regardless of the therapy they underwent (Ahlberg et al., 2005, 2003; Sonia 
Ancoli-Israel et al., 2014; Bower et al., 2006; Cleeland et al., 2013; Curt, 2000; R. Morrow et al., 
2002; Otte, Carpenter, Russell, Bigatti, & Champion, 2010; Stasi et al., 2003), with a higher 
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severity reported by chemotherapy than radiation patients (Cleeland et al., 2013; G. R. Morrow, 
Shelke, Roscoe, Hickok, & Mustian, 2005; Yeh, Wang, Chiang, Lin, & Chien, 2009)  
 In a population-based study with of 314 women with breast cancer 1 year after diagnosis, 
fatigue was identified as the strongest predictor of QoL. This data confirms the large impact of 
fatigue on limiting function and on overall QoL in breast cancer patients after treatment (Arndt, 
Stegmaier, Ziegler, & Brenner, 2006).  
 The impact of fatigue on breast cancer survivorship is not yet fully understood. However, 
it is believed that somatic and psychosocial factors are related to fatigue persistence in BCS 
(Dupont et al., 2014; Reinertsen et al., 2017; Saligan & Kim, 2012; Servaes et al., 2002). Some of 
the psychosocial factors include stress (Reinertsen et al., 2010), discomfort around breast area 
(Reinertsen et al., 2010) and neuroticism, which is a personality trait associated with feelings of 
anxiety, worry, fear, anger and others (Orre et al., 2008).  
 
2.4.4 Stress  
 
Stress is considered a QoL domain and is defined as a state of physiological or 
psychological response to internal or external stressors (Radhakrishnan et al., 2019). There is a 
growing interest in the occurrence of psychological stress among cancer survivors (Armaiz-Pena, 
Cole, Lutgendorf, & Sood, 2013; Elenkov & Chrousos, 2002; Henselmans et al., 2010; Low, 
Stanton, Thompson, Kwan, & Ganz, 2006; McCorry et al., 2013; Miller et al., 2002). It is already 
known that episodes of stress, anxiety, and depression experienced by BCS can negatively affect 
patient’s QoL (Armaiz-Pena et al., 2013; Costanzo et al., 2007; Elenkov & Chrousos, 2002; 
Henselmans et al., 2010; Low et al., 2006; McCorry et al., 2013; Xiao et al., 2017), and that 
stressful life experiences are related to poorer quality of survivorship and to higher and premature 
mortality (Brem & Kumar, 2011; Chida, Hamer, Wardle, & Steptoe, 2008). 
 It is well documented that a cancer diagnosis can elicit a range of psychological 
symptoms and emotions, and that the stress associated with cancer can persist for a long time 
even after the treatment (Couzi et al., 1995; Hewitt et al., 2005). Fear of recurrence has been 
associated to both stress and anxiety post-treatment (Ziner et al., 2012). Other symptoms highly 
associated with this stress have been also reported by cancer survivors. For instance,  around 25% 
of cancer survivors report depression or anxiety five years or more after treatment (Maass, 
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Roorda, Berendsen, Verhaak, & De Bock, 2015; Saboonchi et al., 2014). In a sample of 90 BCS 
within 6 months post diagnosis, 34.7% reported anxiety and 15.3% reported depression 
(McCorry et al., 2013).  
Previous research suggests that besides the biological effects of stress, this symptom 
maintains a strong relationship with illness cognitions, which is defined as a range of cognitive 
process underlying psychological adjustment in response to an illness-related issue. i.e. attitudes 
and perceptions of illness and the ways to cope with it (Boltz et al., 2013). Two studies with BC 
patients demonstrated that even after controlling for disease-related variables, illness cognitions 
were correlated with a significant proportion of the variance in stress (Henselmans et al., 2010; 
Millar, Purushotham, McLatchie, George, & Murray, 2005).  
 In newly diagnosed BC patients, psychological stress along with fatigue have also been 
shown as predictors of the “length of time without recurrence”. Fatigue was identified as a 
significant predictor of recurrence-free survival, and emotional function was identified as a 
significant predictor of overall survival. It means that lower is psychological distress and fatigue 
levels, lower are the chances of cancer recurrence (Groenvold et al., 2007). 
 A study with 558 BCS evaluated whether intrusive thoughts could predict lingering 
symptoms in the year following treatment. Intrusive thoughts are an unwelcome and distressing 
involuntary thought that is difficult to manage or eliminate and according to the authors, they are 
a potentially important risk factor for persistent symptoms in survivorship. Women who 
participated in this study completed psychosocial questionnaires within 4 weeks of post-treatment 
and again 2, 6, and 12 months later. Authors found that women with higher levels of intrusive 
thoughts had higher levels of fatigue at baseline and stayed worse over the following year 
compared with women with low levels of intrusive thoughts at baseline (Dupont et al., 2014). 
This same study also found that during the first year of survivorship, all symptoms analyzed 
improved moderately except for sleep quality and pain, which remained constant (Dupont et al., 
2014). 
Another study with 171 BC subjects reported that throughout 12 months postdiagnosis, 
36.3% of women experienced no stress, 33.3% reported stress only in the active treatment phase, 
15.2% experienced stress in the survivorship phase, and 15.2% reported stress throughout all 
phases (Henselmans et al., 2010). A research examined psychological adjustment during  3 
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months following treatment among 89 women with BC stages 0-III and found that in general, 
BCS were at risk for sustained distress (Henselmans et al., 2010). 
 
2.4.5 Sleep problems  
 
 Sleep disorders can be defined as changes in sleeping patterns or habits. Signs and 
symptoms of sleep disorders include difficulty falling asleep, excessive daytime sleepiness, 
difficulty staying asleep, and/or nonrestorative sleep, and irregular breathing or increased 
movement during sleep  (Dement, Kryger, & Roth, 2017). 
The influence of sleep on BC development has been vastly investigated (Marinac et al., 
2017; Schernhammer, Kroenke, Laden, & Hankinson, 2006; Vgontzas et al., 2001). There is 
considerable evidence indicating that sleep deprivation is intimately linked to BC predisposition 
due to metabolic changes such as endocrine function and glucoregulation (K. Spiegel, Leproult, 
& Van Cauter, 1999), and increased inflammation (Vgontzas et al., 2004). Nonetheless, only a 
few studies have explored the role of sleep on BC survivorship and prognosis (Marinac et al., 
2017).  
Poor sleep quality is commonly reported by BCS and can persist for many years after the 
diagnosis and completion of treatment (Cleeland et al., 2013; Couzi et al., 1995; Lindley et al., 
1998).  Up to 65% BCS report sleep problems immediately after cancer treatment and up to 42% 
experience persistent insomnia (Bower et al., 2011). Sleep problems reported by BCS include 
delayed sleep onset, difficulty in maintaining sleep, and early morning waking (Alfano et al., 
2011; Bower, 2008). In cancer patients, sleep problems also have a high prevalence rate, which 
ranges from 24 to 95% (Graci, 2005). Similarly, sleep complaints among metastatic BC patients 
in treatment is up to 63% (Koopman et al., 2002).  
One of the most comprehensive insomnia prevalence studies in cancer population 
included 1904 cancer survivors with approximately 52% of the subjects with at least six years 
past their initial diagnosis. They found that nearly 30% reported insomnia symptoms, compared 
to 17% of healthy controls (Mao et al., 2007). 
 Additionally, abnormal sleep behaviors might result in daytime dysfunction and poor QoL 
(Dreidi & Hamdan-Mansour, 2016; N. Li et al., 2017). A survey with 300 BCS (median time 
since diagnosis of 49 months) found that 51% of the subjects reported insomnia symptoms, 19% 
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met diagnostic criteria for insomnia disorder, 33% reported that insomnia occurred after they 
were diagnosed with cancer (Savard, Ivers, Villa, Caplette-Gingras, & Morin, 2011). In this same 
study, although two thirds were already having insomnia before the cancer diagnosis, 58% 
reported that having cancer aggravated their sleep problem (Savard et al., 2011).  
Interestingly, studies have also shown an intrinsic relationship between sleep disorders 
and fatigue in cancer population. It has been hypothesised that fatigue may affect sleep and wake 
cycles, which in turn interferes in the intensity of the fatigue itself (Gedaly-Duff et al., 2006; 
Nishiura, Tamura, Nagai, & Matsushima, 2013). Nevertheless, although the relationship between 
fatigue and sleep in health and other illnesses has been widely studied, there is not a definite 
answer on how fatigue influences the quality or quantity of sleep or the biological circadian 
rhythmicity (Ancoli-Israel, Moore, & Jones, 2001). 
 
2.5   Biological and Genetic Mechanisms of Cancer-Related Symptoms   
 
The biological underpinning of CRS are yet to be fully understood. Although, several 
studies have explored the hypothesis of the immune system involvement in the genesis and 
etiology of CRS (Saligan & Kim, 2012; Saligan et al., 2015), more attention must be given to the 
contributions that basic science can make to CRS management and integrative oncology research. 
Some mechanisms have been investigated in adults with cancer to explain the relationship 
of the immune system and CRS. These mechanisms include cytokine level dysregulation, 
hypothalamic-pituitary-adrenal axis (HPA) activity, serotonin (5-HT) neurotransmitter action, 
circadian rhythm dysregulation, changes in adenosine triphosphate (ATP) levels, genetic 
polymorphisms, and muscle metabolism (Dantzer et al., 2012; Morrow et al., 2002)   
It is well known that the stress associated with cancer leads to disturbances in the HPA 
axis and defeats important aspects of the immune response. Particularly regarding fatigue, the 
following factors have been linked to the development of this symptom in cancer patients: the 
hypermetabolic state associated with tumor growth; the competition between the organism and 
the tumor for nutrients; the deleterious effects of chemotherapy and radiotherapy; inadequate 
nutritional intake associated with nausea and vomiting resulting from antineoplastic therapy; 
anemia; sleep disorders; uncertainty about the future; the fear of death and mutilation; and the 
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loss of family maintenance roles (Abrahão, Bomfim, Lopes-Júnior, & Pereira-da-Silva, 2019; De 
Jong, Candel, Schouten, Abu-Saad, & Courtens, 2006; Jean-Pierre et al., 2007). 
An increase in the concentrations of proinflammatory cytokines, such as IL-1, IL-6 and 
TNF-α has been found in several chronic degenerative and autoimmune diseases including 
cancer (Barsevick, Frost, Zwinderman, Hall, & Halyard, 2010; Malekzadeh et al., 2015; Paulsen 
et al., 2017; Seruga, Zhang, Bernstein, & Tannock, 2008). Stress and fatigue have shown 
important correlations with inflammatory markers such as cytokines, telomerase length, cortisol 
and CRP in cancer patients (Law et al., 2016; Matousek, Pruessner, & Dobkin, 2011; Reyes-
Gibby et al., 2013; Schubert, Hong, Natarajan, Mills, & Dimsdale, 2007; Xiao et al., 2017). The 
action of pro- and anti-inflammatory cytokines has been recognized as an important element in 
the pathophysiology and the genesis of CRS during and after the treatment (Condon, 2018; 
Dupont et al., 2014; Laine, Iyengar, & Pandita, 2013). 
Studies have shown a relationship between the levels of IL-6, TNF-α and fatigue severity 
in cancer patients (Condon, 2018; Saligan et al., 2015). Increased CRP levels were also found in 
association with fatigue in BC patients (Alexander, Minton, Andrews, & Stone, 2009; Alfano et 
al., 2012; Orre et al., 2011; Pertl et al., 2013; Wratten et al., 2004).   
The stress experienced as the disease evolves decreases immune response, such as the 
Natural Killer (NK) cells activity and T cells proliferation, (Abrahão et al., 2019; Antoni et al., 
2006; McDonald et al., 2005). These two cells play a vital role in the immune response against 
cancer, by fighting against tumor cells and monitoring their disordered growth (Abrahão et al., 
2019; Armaiz-Pena et al., 2013; Elenkov & Chrousos, 2002). A study with 111 stage 0-III BCS at 
1 year post-radiotherapy, found that depressive symptoms, CRP, IL-1β (antagonist receptor) and 
TNF- α (receptor 2) were risk factors of fatigue (Xiao et al., 2017). 
Similarly, sleep problems seem to share a common underlying biological mechanism with 
fatigue and stress. Studies with cancer patients and other non-cancer populations have found 
correlations between several biomarkers and sleep quality, such as TNF-α (Clinton, Davis, 
Zielinski, Jewett, & Krueger, 2011; Wright et al., 2015), IL-10 (Wright et al., 2015), IL-6 (L. Liu 
et al., 2012a), CPR (L. Liu et al., 2012a; Wright et al., 2015), cortisol (Chang & Lin, 2017; Hoyt, 
Bower, Irwin, Weierich, & Stanton, 2016), oxalic acid (Weljie et al., 2015), diacylglycerol 36:3 
(Seugnet, Boero, Gottschalk, Duntley, & Shaw, 2006), alpha-amylase (Sigurdardottir et al., 
2015), melatonin (Innominato et al., 2016), urinary 6-sulfatoxymelatonin (A. H. Wu et al., 2012) 
 22 
and serotonin (Payne, Held, Thorpe, & Shaw, 2008). Genetic variation in the IL-6 gene, as well 
as high serum concentrations of this cytokine, may contribute to differences in the severity of 
sleep disorders and fatigue experienced by cancer patients (Miaskowski et al., 2010). 
Advances in molecular genetics have allow scientists to identify the genes encoding the 
biomarkers related to CRS (A. Barsevick et al., 2010). Genetic variations of these biomarkers 
have been also investigated in different cancer populations in the development of CRS (Illi et al., 
2012; Lyon et al., 2011; Miaskowski et al., 2010; Reyes-Gibby et al., 2008).  
For instance, research has shown that several CRS are susceptible to the influence of the 
effects of several genetic single nucleotide polymorphisms (SNP) (Reyes-Gibby et al., 2008). 
SNPs are the most common type of genetic variation. They are variants of only one nucleotide 
representing a difference in a single DNA building block (Schaefer, 2014)(Schaefer, 2014). 
Therefore, SNP’s determine phenotypes that express in different amounts of the encoded proteins 
and are considered “functional polymorphisms”, alongside variants that lead to modifications of 
the protein itself (Schaefer, 2014). 
Fatigued BCS have shown SNPs in cytokines IL-1β and IL-6  (Reinertsen et al., 2011). 
Additionally, SNPs in the promoter region of IL-1β (--511) and IL-6 (--174) have been shown to 
control gene expression of cytokines associated with BC susceptibility and prognosis (Aouizerat 
et al., 2009; Illi et al., 2012). A study on functional SNP in the promoter region of TNF-α gene 
reported that individuals with common homozygous alleles reported higher levels of sleep 
disturbance when compared to those with heterozygous alleles. In a population of lung cancer 
survivors, a study found relationships between cytokines SNPs and the symptom of burden along 
with poor QoL (Rausch et al., 2010). 
 
2.6   Factors Influencing the Persistence and Severity of Cancer-Related Symptoms  
  
Although the exact physiopathology of CRS is unknown, the etiology and biological 
mechanisms that lead to some of these symptoms can be considered as part of a complex 
systemic and cellular feedback system. This system is characterized by pathophysiological, 
psychological, situational/environmental and genetic regulatory factors (Erickson, 2008; Saligan 
& Kim, 2012). 
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 As for the pathophysiological factors, they include cytokine balance disturbance, cancer 
stage, hormone therapy, hemoglobin and hematocrit levels, chronic pain, albumin levels, C-
reactive protein levels, prostaglandin levels, leukocyte count, monocyte count, the hydro-
electrolytic imbalance, acid-base imbalance, dehydration, hypoxia, presence of cardiac 
abnormalities and thyroid disorders. Other factors related to the pathophysiology of cancer may 
also be associated with the severity and persistence of CRS, such as the hypermetabolic state 
associated with tumor growth, the deleterious effects of chemotherapy and radiotherapy and the 
competition between the body and the tumor for nutrients, which can be aggravated by 
inadequate nutrition (Erickson, 2008; Jean-Pierre et al., 2007; Kim et al., 2012; Orre et al., 2011; 
Paddison, Temel, Fricchione, & Pirl, 2009; Wang et al., 2002). 
 Psychological factors impacting CRS include chronic depression, chronic stress, fear of 
recurrence and social isolation. Situational factors include the type of treatment and protocol 
used, phase of treatment, patient’s sleep and wakefulness pattern, infections, activity and rest 
pattern, among other environmental factors (Erickson, 2008). Genetic factors include cytokines 
genetic variations (i.e. SNPs) and epigenetic alterations (i.e. telomere length) (Kim et al., 2012; 
Okamoto & Seimiya, 2019; Reyes-Gibby et al., 2013; Saligan & Kim, 2012). 
The co-occurrence of some of these factors generates a cumulative load that creates 
burden to an already overloaded biological system (Erickson, 2008). Consistently exploring all 
the possible interferences between these factors means capturing the dynamic and continuous 
response of the immune system to cancer, which may be associated with the persistency and 
severity of CRS. 
 The side effects of chemotherapy are one of the major factors associated with the 
persistence of CRS, with some authors referring to these symptoms as chemotherapy-induced 
symptoms. Side effects are intrinsically related to the individual’s response to treatment, which 
seems to be related to the balance between pro and anti-inflammatory cytokines levels. For 
instance, in a study comparing cytokine levels with individuals’ response to the first three cycle 
of chemotherapy, serum IL10 levels were found to be elevated in patients with poor treatment 
response and were found to be in lower levels in patients with good or consistent treatment 
response (Bien et al., 2013b). 
  Similarly, CRS also change in response to treatment. In general, CRS are more severe 
among those who underwent chemotherapy when compared to those who underwent radiotherapy 
 24 
(Donovan et al., 2004). Fatigue in patients receiving chemotherapy usually follows a cyclic 
pattern, reflecting scheduled chemotherapy cycles; whereas fatigue in patients undergoing 
radiotherapy is cumulative and worsens after the end of treatment. For those patients under a 
multimodal therapy schedule the pattern of onset and severity of fatigue may overlap (Erickson, 
2008). 
 Evidence has also shown that in animal models (murine), the use of chemotherapy drugs 
such as cyclophosphamide and etoposide alter the levels of IL-1β, IL-6 and TNF-α, and are 
linked to the development of fatigue in these animals (Smith et al., 2014; Wood et al., 2006).   
The type and stage of cancer can also influence the severity and persistence of CRS. 
Severe fatigue was reported more frequently among patients with hematologic cancers when 
compared to those diagnosed with solid tumors (Wang et al., 2002). Likewise, in hematological 
malignancies, the prevalence of anemia, which is associated with fatigue and sleep problems, is 
approximately twice the frequency found in patients with solid tumors (Birgegård, Gascón, & 
Ludwig, 2006).  
Persistent CRS are related to survivors’ cancer stage. Often times, higher cancer stages 
experience more severe and frequent CRS. These changes are also seen in biological markers. 
For instance, in children with soft tissue sarcomas, stage I and  II patients showed lower levels of 
IL-10 in comparison to stage III and IV patients (Bien et al., 2013a). 
Different levels of CRS and cytokines have been identified at different time-points during 
treatment and after treatment. This shows that disease progression may have a relationship with 
the development of CRS (Bien et al., 2009, 2013a, 2013b). For instance, survivors of testicular 
cancer who are 1 year beyond diagnosis reported different severity and types of CRS in 
comparison to the same patient 20 years later (Miller, Pandey, Jain, & Mehta, 2015) 
 It is important to make progress in understanding the trajectory of each CRS and the 
mechanism that triggers changes in the severity of these symptoms at all levels (biological, social, 
psychological, physical, situational/environmental). Further steps need to be taken to identify the 
complex network of factors orchestrating the genesis and persistence of CRS. However, in 
oncology, defining a biological cause or mechanism is a complex task (A. Barsevick, Whitmer, 
Nail, Beck, & Dudley, 2006). A comprehensive and constant screening approach of CRS during 
and after treatment might help us in understanding the factors associated with its severity and 
persistence. 
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2.7 Cancer-Related Symptoms Management  
 
2.7.2  Allopathic Approach  
 
The allopathic approach to treat many CRS include a range of 
pharmacological interventions. For instance, some sleep problems can be treated with zolpidem, 
eszopiclone, ramelteon, trazodone among others (Dement et al., 2017; Pagel & Pandi-Perumal, 
2007).  Similarly, CRF can be treated with psychostimulants such as Ritalin and Modafinil have 
been also prescribed (Lyon et al., 2011). Clinical trials have also been testing new drug 
treatments for CRF such as hematopoietic growth factors, progestational steroids, 
methylphenidate, and paroxetine (Ollie Minton, Richardson, Sharpe, Hotopf, & Stone, 2008). 
Moreover, the prescription of anti-depressants, muscle relaxants and antiemetics have 
been also documented to treat other CRS. In addition to the variety of side effects that these 
medications can cause, several patients refrain in using a pharmacological approach due to the 
risk of dependence and/or interactions with other medications (Couzi et al., 1995; Dement et al., 
2017; Pagel & Pandi-Perumal, 2007). 
 
2.7.3  Integrative Medicine Approach  
 
According to the Academic Consortium Integrative Medicine and Health, integrative 
medicine (IM) can be defined as: 
The practice that affirms the importance of the relationship between the 
practitioner and the patient, focuses on the whole person, is informed by 
evidence and makes use of all appropriate therapeutic and lifestyle 
approaches, healthcare professionals and disciplines to achieve optimal 
health and well-being (Tick & Nielsen, 2019).  
 
Aiming to alleviate some of these symptoms, BC patients and survivors take advantage of 
several non-pharmacological treatments, including several modalities of integrative therapies 
(Antoni et al., 2006; Chandwani et al., 2012; Yates et al., 2005).  There are four categories of 
integrative therapies according to the National Center for Complementary and Integrative Health 
(National Center for Complementary and Integrative Health, 2019). These categories are mind-
body, energy-based, biologically based and whole medical system. Mind-body therapies include 
yoga, massage, art therapy, dance therapy, biofeedback, meditation. They focus on behavioral, 
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psychosocial and spiritual approaches. Energy-based therapies refer to diathermy, Reiki, healing 
touch, electroacupuncture etc. They involve the use of electromagnetic, ultrasonic, thermal or 
subtle energy. Biologically based practices include probiotics, orthomolecular medicine, 
botanical and herbal supplements, and diet. They refer to the use of natural or biologically 
sourced products that are internally or topically taken. The whole medical system therapies 
include chiropractic, osteopathy, homeopathy, Ayurvedic medicine, naturopathy, among others. 
They have an unifying theory of health-disease, healing, diagnosis and treatment options 
(National Center for Complementary and Integrative Health, 2019).  
IM emphasizes a more inclusive collaborative way of viewing healthcare and wellness. It 
takes into account a holistic, patient-focused understanding, often including mental, emotional, 
functional, spiritual, social, and community aspects. Therefore, the underlying premise of IM is 
that optimal human health and wellbeing require merging and balancing the body, mind, and 
spirit. 
The term IM is an emerging nomenclature that has been replacing the term 
complementary and alternative medicine (CAM), as more and more of these non-mainstream 
therapies are being used in an integrated approach to conventional medicine. According to the 
NCCIH, the terms “complementary,” “alternative,” and “integrative” are continually evolving 
(National Center for Complementary and Integrative Health, 2019). This shift to the term 
“integrative” communicates the importance of understanding the actual purpose of these therapies 
and how it should be used together with all appropriate therapeutic and lifestyle approaches in a 
coordinated way (National Center for Complementary and Integrative Health, 2019). 
Another term used to define IM practices in the context of cancer care is integrative 
oncology, and it refers to the use of integrative therapies in association with conventional 
oncology care (Greenlee et al., 2017). A more comprehensive definition is that: 
Integrative oncology is a patient-centered, evidence-informed field of cancer 
care that utilizes mind and body practices, natural products, and/or lifestyle 
modifications from different traditions alongside conventional cancer 
treatments. Integrative oncology aims to optimize health, quality of life, and 
clinical outcomes across the cancer care continuum and to empower people 
to prevent cancer and become active participants before, during, and beyond 
cancer treatment (Witt et al., 2017).  
 
The slow recovery of CRS in the initial year after treatment may indicate persistent 
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difficulties in the years to come (Billhult, Stener-Victorin, et al., 2007). Overall, the literature 
highlights the promising effects of several integrative therapies in treating CRS in BC patients 
and BCS (Bernstein & Grasso, 2001; Greenlee et al., 2017; Kang et al., 2014; Patterson et al., 
2013).  A systematic review of the literature showed that, based on the quality and quantity of 
available evidence, the net benefit of the following integrative therapies is reliable and substantial 
in treating CRS in BCS: music therapy, meditation, stress management and yoga can be 
recommended for anxiety/stress reduction; meditation, relaxation, yoga, massage and music 
therapy can be used to manage depression/mood disorders; meditation and yoga to improve 
quality of life; acupressure and acupuncture can be used for reducing chemotherapy-induced 
nausea and vomiting (Greenlee et al., 2017).  
The management of CRS during and after treatment is one of the top-ranked research 
priorities identified by the National Cancer Institute through a Clinical Trials Planning Meeting  
in 2010 (A. Barsevick et al., 2013). It is important for each cancer patient completing treatment to 
receive a comprehensive care plan particularly focused on the physical and psychological CRS 
being experienced following treatment. A few IM modalities have the potential of being safely 
incorporated into survivorship care, most of them, however, still need more scientific evidence to 
be generated (Brem & Kumar, 2011; Penttinen et al., 2014; Stanton et al., 2005). 
 
2.8   An Introduction to Massage Therapy     
 
MT is defined by the Academic Consortium Integrative Medicine and Health as: 
A practice that involves manipulation of soft tissue structures of the body to prevent 
or alleviate pain, spasm, tension, or stress and to promote health and well-being (Tick 
& Nielsen, 2019).  
 
The definition of MT by the College of Massage Therapists of Ontario is also referred to 
as the “Scope of Practice” stated under the Massage Therapy Act, 1991 – a provincial legislation 
for MT in Ontario. According to this document, MT is:  
The assessment of the soft tissue and joints of the body and the treatment and 
prevention of physical dysfunction and pain of the soft tissue and joints by 
manipulation to develop, maintain, rehabilitate or augment physical function, or 




In general, MT consists of manual manipulation of body’s soft tissue — skin, muscles, 
tendons, ligaments, and fascia for the purpose of establishing and maintaining good health and 
promoting wellness (Braun & Simonson, 2008; Salvo, 2015). 
MT is one type of integrative therapy that has been evolving for thousands of years in 
different cultures and regions around the world. Archeologist have found European cave 
paintings depicting what appears to be the use of MT in 15000s BC after battles. Later, around 
the sixth century AD, Chinese and Japanese people had well established MT practices. After that, 
massage gradually became popular as part of Hindu tradition (Braun & Simonson, 2008; Salvo, 
2015). 
Nowadays, there are more than 80 types of documented massage methods, a few 
examples are heated stone massage, lymphatic massage, reflexology, aromatherapy massage, 
scalp massage, light pressure effleurage massage, myofascial release, deep tissue and trigger 
point therapy and Swedish massage (Billhult et al., 2009; Braun & Simonson, 2008; Green et al., 
2010; Imanishi et al., 2009; Salvo, 2015). Understanding the differences between each of these 
types is essential in choosing the most effective technique to obtain the maximum results. Based 
on the differences and similarities among all types of MT, a massage therapist who was cross-
trained in several techniques may easily incorporate different massage techniques (Billhult et al., 
2009; Braun & Simonson, 2008; Green et al., 2010; Imanishi et al., 2009; Salvo, 2015). Among 
the many specialized massage techniques being used today, the most commonly practiced and 
adopted by cancer patients is Swedish massage therapy (Braun & Simonson, 2008; Mustafa, 
Furmanek, Knapik, Bacik, & Juras, 2015; Salvo, 2015). 
 
2.8.1 Swedish Massage    
 
  Swedish massage is a relaxation technique that focuses on improving blood flow to the 
skin and muscle and removing muscle tension (Cowen et al., 2006; Mustafa et al., 2015). The 
term Swedish massage is more recognized in English and Dutch speaking countries, and in 
Hungary. Elsewhere in Europe the style is referred to as classic massage (Calvert, 2002). Swedish 
massage was the first systematic method of therapeutic massage based on a physiological 
perspective (College of Massage Therapist of Ontatio, 2019). 
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Although Swedish massage techniques may vary from light to vigorous, it is considered a 
superficial massage technique, which is, for example, different from the Thai massage, which is 
classified as deep tissue massage (Cowen et al., 2006). This massage type is built around five 
basic strokes – effleurage (sliding or (gliding), petrissage (kneading), tapotement (rhythmic 
tapping), friction (steady pressure) and vibration or jostling (Mustafa et al., 2015; Salvo, 2015).  
 
2.8.2 Biological Underpinnings and Effects of Massage Therapy   
 
In general, MT has therapeutic effects on the body and improves health and well-being by 
acting on the muscular, nervous and circulatory system (College of Massage Therapist of 
Ontatio, 2019). Studies have shown that MT has a positive effect on stress, low back pain, muscle 
pain, sleep, physiological markers (i.e. blood pressure and heart rate), inflammatory biomarkers 
and mood in several cancer and non-cancer populations (Buttagat, Techakhot, Wiriya, Mueller, & 
Areeudomwong, 2019; Hodgson & Lafferty, 2012; Krohn et al., 2011; Liptan, Mist, Wright, 
Arzt, & Jones, 2013; Listing et al., 2010, 2009; Sritoomma, Moyle, Cooke, & O’Dwyer, 2014; 
Sturgeon et al., 2009; Supa’At, Zakaria, Maskon, Aminuddin, & Nordin, 2013). Particularly in 
BCS it has been used to promote relaxation, address muscle stiffness and pain, and resolve 
musculoskeletal complaints (Greenlee et al., 2017). Patient-oriented-report (PRO) research 
reported that MT was effective in reducing fatigue, pain, anxiety, tension, and creating a general 
feeling of wellness in different groups of cancer patients, including BC (Barnes et al., 2008; 
Billhult et al., 2009; Cassileth & Vickers, 2004; Drackley et al., 2012; Kashani et al., 2012; 
Krohn et al., 2011; Pruthi et al., 2009).  
 The growing body of molecular-based research on IM helped to increase the 
understanding biological underpinnings of MT and other integrative therapies. Many studies have 
showed positive biological effects of MT on IgA levels (Cantarero-Villanueva et al., 2011; 
Fernández-Lao et al., 2012), α-amylase (Cantarero-Villanueva et al., 2011; Fernández-Lao et al., 
2012; Tiffany Field et al., 2005), salivary cortisol (Cantarero-Villanueva et al., 2011; Fernández-
Lao et al., 2012; Tiffany Field et al., 2005), salivary flow rate (Hernandez-Reif et al., 2005), 
serum cortisol (Listing et al., 2010), serotonin (Field et al., 2005; Listing et al., 2010),  NK cells 
(Billhult et al., 2009; Hernandez-Reif et al., 2005), lymphocytes (Green et al., 2010; Hernandez-
Reif et al., 2005, 2004), catecholamines (Field et al., 2005; Hernandez-Reif et al., 2004), some 
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Th1 (Type 1 T helper) and Th2 (Type 2 T helper) molecules (Green et al., 2010), peripheral 
blood mononuclear cell (Billhult et al., 2009) and hemodynamic effects (Billhult et al., 2009). 
However, many studies conducted so far did not show that there is high certainty of the 
net benefit of MT in addressing many of the CRS analyzed. Some studies demonstrate 
inconclusive benefits, creating equivocal evidence and indicating that there is moderate certainty 
of the net benefits of MT in managing CRS in BCS (Greenlee et al., 2017). 
In May of 2017, the Society for Integrative Oncology through a systematic review of the 
literature released a clinical guideline making recommendations on the use of integrative 
therapies by BC patient and BCS (Greenlee et al., 2017). Conclusions were made based on the 
quality of studies, magnitude of effect, statistical significance, sample size, consistency of 
findings across trials, and if the outcomes were primary or secondary. Based on the analysis of 
the MT trials, there is high certainty of a net benefit of MT in depression/mood disorders only. 
They also concluded that there is no evidence up to date to assure that the net benefit of MT is 
substantial to treat other CRS, which is due to the fact that only a few rigorous trials have been 
conducted and the risk of bias in such trials is high (Greenlee et al., 2017).  
Although MT has been less tested in BCS (Hodgson & Lafferty, 2012; Krohn et al., 2011; 
Listing et al., 2010, 2009; Rubin  1927- editor et al., 2013; Sturgeon et al., 2009), the following 
modalities of MT has been tested in BC patients in treatment: aromatherapy massage  (Imanishi 
et al., 2009), light pressure effleurage massage (Billhult et al., 2009; Kashani et al., 2012), scalp 
massage and reflexology  (Green et al., 2010), and lymphatic drainage therapy (Martín, 
Hernández, Avendaño, Rodríguez, & Martínez, 2011). Other studies have also examined 
multimodal methods by combining Swedish massage and acupressure (Boguszewski, Krupiński, 
& Białoszewski, 2017) meditation and massage (Dion et al., 2016) and massage and exercise 
(Cantarero-Villanueva et al., 2011), aromatherapy and acupressure massage (Kao et al., 2017) in 
different population types. Noteworthy that some studies, although performed with cancer 
population, did not specify the type of massage applied (Billhult, Bergbom, et al., 2007; Billhult, 
Stener-Victorin, et al., 2007; Drackley et al., 2012; Hernandez-Reif et al., 2005). 
 
2.9 Bio-Behavioral Research in Integrative Oncology   
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Although some studies have investigated the biological effects of IT including MT in 
BCS, this still remains a largely unanswered question (Barnes et al., 2008; Bernstein & Grasso, 
2001; Billhult et al., 2009; Cassileth & Vickers, 2004; Listing et al., 2010). It is unclear to what 
extent the observed effects of IT interventions are based on physical and biological adaptations or 
rather on psychosocial factors. More attention must be given to the contributions that basic 
science and bio-behavioral research can make to advance evidence-based practice on integrative 
oncology.    
The bio-behavioral theory is a highly interdisciplinary philosophy and an emerging 
approach to analyzing the effectiveness of all types of IT. Fairly often, IT interventions can elicit 
positive PRO, without concomitant biological effects and vice and verse (i.e., dance increased 
cortisol levels, whereas yoga decreased them) (Matousek, Dobkin, & Pruessner, 2010), hence an 
approach such as the bio-behavioral framework that brings together the biological and behavioral 
factors and integrates them into a cohesive, holistic view, may be utilized to tackle IT research 
questions from a multifaceted view. Although several bio-behavioral concepts are suitable and 
applicable to IT research, such as the interactions between biological and behavioral aspects, 
rigorous and expanded studies in a multidisciplinary collaboration setting have been limited 
(Driscoll, Lyon, & McCain, 2011).  
 One of the most overlooked and used bio-behavioral framework is the 
psychoneuroimmunology (PNI), which proposes the existence of multidimensional interactions 
among psychosocial factors and physiological mechanisms of the neuroendocrine and immune 
systems (Kang, 2003). The PNI theory suggests a physiological relationship between stress, 
psychosocial-behavioral factors, and neuroendocrine-immune effects (Kiecolt-Glaser et al., 
2014).  
 
2.10 Barriers in the Use and Implementation of Integrative Medicine    
 
There is a critical need to address the quality of survival after cancer, and this cannot be 
done without an analysis of the factors influencing patients, institutions and professionals in 
putting IM into practice.  
The field of integrative oncology emerged as a result of cancer patients’ advocacy for 
holistic care, leading to the need of patient-centered research to assess the safety and 
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effectiveness of integrative therapies (Berretta et al., 2017; Evans et al., 2007; Yates et al., 2005). 
Although the science of IM has significantly progressed in the past years, there are several 
barriers in the use and implementations of these therapies in clinical practice. It is of paramount 
importance to discuss the key components of an effective policy on the use of integrative 
therapies by BCS.  
Legal, ideological and social obstacles in the implementation of IM practice in clinical 
oncology settings persist. Obstacles are found at professional, institutional and patient levels.  
Professional barriers often include lack of a shared knowledge base and awareness, 
personal ideological beliefs; fear of indirect or shared liability, lack of research-based evidence 
on the reliability, validity, cost-effectiveness and effects of integrative therapies; a scarce number 
of specialists in integrative oncology and a lack of competency-based training models in IM at 
undergrad level in all health professions (Cohen & Ruggie, 2004; Latte-Naor & Mao, 2019). 
Institutional barriers include lack of institutional evidence-informed policies and 
regulation in integrative care, fear of indirect or shared liability and lack of a personalized care 
policies (Cohen & Ruggie, 2004; Latte-Naor & Mao, 2019).  
Patient-level barriers include lack of awareness and knowledge, insurance coverage 
and/or financial issues, ideological barriers, demanding treatment schedules and symptom burden 
(Cohen & Ruggie, 2004; Latte-Naor & Mao, 2019; Yabroff, Lawrence, Clauser, Davis, & Brown, 
2004).  
Interestingly, studies have shown that certain groups of people are more likely to use 
integrative therapies than others. Integrative therapies users tend to be female, middle-aged, 
highly educated, with a higher income, an interest in health knowledge, and have a diagnosis of at 
least one chronic disease (Astin, 1998; Eisenberg et al., 1993; Furnham & Smith, 1988; Wister et 
al., 2002).  A study with 6016 noninstitutionalized adults found that higher odds of CAM use 
were associated with being young, female, living in the west, highly educated, employed, and 
with functional limitations (Rhee, Evans, McAlpine, & Johnson, 2016). 
 The information brought by these studies lead to an important reflection on the utilization 
of IM therapies among racial and ethnic minority populations and on health disparities in IM. 
Awareness, self-management, availability of services, accessibility, and affordability seems to be 
important factors influencing the use of integrative therapies (Saper, 2016). 
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Greater awareness at patient, professional and institutional levels will lead to greater 
demand among all. Particularly in historically low-income and minority groups, affordability 
seems to be a bigger issue (Saper, 2016).  It becomes clear that the delivery of IM services for 
cancer patients and survivors must address not only the clinical aspects of CRS, but also socio-
economic obstacles. Developing personalized survivorship care planning based on a more 
collaborative and multidisciplinary approach might lead us to offer an affordable, accessible 
integrative health care for all (Kamsu-Foguem & Foguem, 2014). Personalized cancer 
survivorship care model has been shown to help meet several patients’ specific needs (Alfaro et 
al., 2014; Haq et al., 2013; Kamsu-Foguem & Foguem, 2014; Loonen et al., 2018; Tevaarwerk et 
al., 2019). Additionally, mobile health, electronic health and innovative open-access digital tools 
for the management of CRS (i.e. stress-management apps), can help address the lack of 
accessibility issue (Saper, 2016).  
In the near future, multifaceted, personalized and multimodal care plans will be needed. 
Further steps include refinement of the different personalized cancer survivorship care models 
and its components, along with feasibility testing in all cancer types, and planning for more 
systemic implementation. 
 
2.11 Summary of Chapter Two 
 
The booming population of cancer survivors is the result of early cancer detection and 
improved cancer therapy. As a consequence of this increased number of survivors, one of the 
greatest challenges in oncology today is how to provide best care for these individuals after 
treatment. Many survivors have persistent CRS that can last for up to 10 years after treatment. 
Persistent CRS have been well studied in survivors of childhood cancers, but less is known about 
the survivorship experience for adult cancer survivors.  Fatigue, stress and sleep problems are 
major symptoms reported by BCS and can significantly affect their QoL.   
Interestingly, the biological mechanisms involved in the development of CRS has become 
progressively evident. The role of inflammatory markers has been associated with many CRS, 
and the current evidence supporting the relationships among proinflammatory cytokines, CRP, 
cortisol and CRS in individuals with cancer is very promising. This potential relationship 
between immune system, inflammation and CRS calls for a new approach on cancer survivorship 
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care that integrates biological, psychosocial, and behavioral determinants of CRS. Additionally, a 
few factors influencing the development, severity and persistence of CRS can be found at 
different levels, such as biological, social, psychological, physical and situational/environmental. 
Some examples of factors within these levels are type of cancer, markers of inflammatory and 
immune response, stage of the disease, hormonal therapy, type of cancer treatment and so on. 
Changes at any of these levels interferes in the severity of the symptoms at different stages of 
treatment and after treatment. 
In other to reduce the burden of these symptoms, many BCS use non-pharmacological 
interventions including MT. Many MT therapeutic effects have been reported by cancer patients 
such as reduced fatigue, pain, anxiety, tension, and creating a general feeling of wellness. 
However, based on the quality and quantity of available evidence, the net benefit of many 
integrative therapies including MT is not substantial to create definite clinical guidelines.  
Patients, caregivers, families and clinicians need clarification and guidance regarding dosage, 
frequency, and timing of several IT modalities.  
Due to its impact on patient's life, persistent CRS must be properly understood, prevented, 
and mitigated. Hence, continued symptom monitoring and management in early and late 
posttreatment survivorship is needed for BCS. It is suggested that novel survivorship care models 
include systematic symptom screening tools and management interventions.   
However, there are numerous barriers in implementing integrative medicine into practice. 
These barriers can be found at patient, professional and institutional levels and include legal, 
ideological and social obstacles. For instance, the lack of understanding of the biomechanism of 
integrative therapies, its efficacy, and cost-effectiveness in managing CRS are important barriers. 
Additionally, awareness, insurance coverage and health discrepancies related to the use and 
access of IM are also significative barriers in implementing IM into practice.  
To make informed decisions on the use of integrative therapies, clinicians and patients 
should understand the level of evidence of associated benefits and harms for each therapy. 
Information on IM must be accessible, available and trusted in order to positively change 
patients’ and physicians attitude. Future steps in this field include developing more rigorous trials 













3.1 Overview  
 
This chapter describes the design, general methodology, ethical aspects, procedures and 
data analysis for the study. Additionally, this section provides an overview of important models 
and frameworks that guided this research.  
 
3.2 Study Design  
 This is an interventional study, designed as a one-group longitudinal quasi-experiment.  
3.3 Justification of using pre/post-test quasi-experimental design 
  
An interventional study design was chosen as a prospective type of study since we were 
interested in evaluating the direct impact of an intervention.  
A pre/post-test design was chosen to estimate the impact of an intervention through direct 
comparison within-subjects. Pre/Post-test design provides the possibility of having a repeated-
measure evaluation plan around a proposed intervention with little control over the delivery of 
the intervention.   
A quasi-experimental design was chosen to test our hypothesis due to its logistically 
moderate level of difficulty. This was the appropriate choice of study design since there were 
practical (i.e. personnel, budgetary, duration) barriers to conduct a genuine randomised 
experiment. Quasi-experimental designs are useful where there are political, practical, or ethical 
barriers to conducting a randomized controlled trial (Eccles et al., 2003). Due to its complexity, 
genuine randomised trials should only be considered when there is genuine uncertainty about the 
effectiveness of an intervention. 
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3.4 Philosophical underpinnings  
 
In IM research, a philosophical foundation that can accommodate the complexity of 
assessing integrative therapies must prompt the inquirer to examine phenomena more holistically, 
researching it from multiple perspectives. In 1997, a British sociologist and philosopher 
introduced the idea of critical realism as an ontological and epistemological position from which 
it is possible to research subjects in a social/health context. Critical realism is, therefore, 
particularly apposite for IM research and has been chosen as part of the philosophical 
underpinnings for this study (Bryman, 2001). 
Sharpe and Bhaskar (1976) posited that there are three realms of ontology: the 
‘empirical’, the ‘actual’ and the ‘real’. The ‘empirical’ which is what can be observed or 
experienced. The ‘actual’ represents occurrences and what is known that may not be observed but 
which is regulating the empirical. The final realm is the ‘real’ which is hidden or  unobservable 
causal mechanisms but a necessary precondition for the ‘actual’ and ‘empirical’ (Sharpe & 
Bhaskar, 1976). 
The application of Bhaskar's ontological levels to this study would be thus: at the 
‘empirical level’ integrative therapies have been used by BCS to manage CRS. At the ‘actual 
level’ integrative therapies can ease CRS and inflammation. At the ‘real level’, inflammatory 
markers are related to the development of CRS. Thus, there are a series of mechanisms operating 
at the ‘real’ level that eventually impact on the benefits of integrative therapies in managing CRS 
at the ‘empirical’ level.  
By relying on the critical realism position described above, the methodology chosen for 
this research has been designed based on an objectivist ontology that enquires about reality. 
When deciding on how that reality should be studied, we adopted a positivist paradigm in order 
to uncover the effects of MT by carefully and objectively measuring mechanisms and responses.  
(Bonell, Moore, Warren, & Moore, 2018). Indeed, the characteristics of interventional clinical 
research (i.e. RCT and quasi-experiments) are said to firmly situate this type of research in a 
positivist epistemological paradigm (Bonell et al., 2018; Marchal et al., 2013; Pearce & Raman, 
2014; Rowe & Oltmann, 2016).   
By following a positivists paradigm that seeks predictions and generalizations and 
attempts to reduce the complex to the simple, data is reduced to numerical symbols or quantifiers; 
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thus, a quantitative approach was undertaken in designing this study’s methodology (Creswell, 
2009; Pring, 2000). In aiming to yield a basis for prediction and generalization, a deductive 
approach was undertaken in this study. Correlation and experimentation were used to reduce 
complex interactions between variable and measurable evidence sought via repeated assessments 
and observation.   
 
3.5 Theoretical Framework  
 
This study was designed considering two theoretical frameworks: (i) the Middle Range 
Theory of Unpleasant Symptoms and (ii) the Psychoneuroimmunology Framework. Both provide 
the lens through which our research problem is being examined. They helped us in establishing a 
sense of structure to guide this research and the rationale for conducting it.  
The Theory of Unpleasant Symptoms was developed and introduced in 1995 (Lenz, Pugh, 
Milligan, Gift, & Suppe, 1997). It provides a model for the experience of, and relationships 
between concurrent symptoms. The three major components of this theory are: the symptoms, the 
consequences of the symptom experience, and the influencing factors. These influencing factors 
give rise to or affect the nature of the symptom and are classified in three categories: 
physiological, psychological, and situational. They are responsible for the variability in the 
experience reported by different individuals with the same symptoms (Lenz & Pugh, 2018; Lenz 
et al., 1997; Nguyen et al., 2011). Each symptom is designed to be a multidimensional 
experience, which can be measured separately or in combination with others. Although 
symptoms differ from each other, there are common dimensions among them: intensity, time, 
degree of affliction and perceived quality.  
 The psychoneuroimmunology (PNI) framework, is a valuable framework to guide the 
investigation of possible associations between biobehavioural aspects and the development of 
immunologically mediated diseases (Green et al., 2013; Kang, 2003; McCain et al., 2005). 
According to PNI, inflammatory and other innate immune mediators can signal back into the 
central nervous system, stimulate the production of cytokines, change neuronal function, and 
cause sickness behaviors and unpleasant symptoms as an adaptive response (Dantzer, O’Connor, 
Freund, Johnson, & Kelley, 2008; Green, O’Connell, & Lutgendorf, 2013). In the context of our 
conceptual schema, the PNI supports the idea that immune-to-brain communication cascades 
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might be related to cancer development and treatment-related symptoms such as fatigue, 
depression, cognitive dysfunction, and sleep disturbances (Green et al., 2013).  
Combined, the PNI framework and the Theory of Unpleasant Symptoms constitute an 
effective way to comprehensively investigate the management of CRS in cancer patients since it 
unifies the core elements that are potentially modeling the genesis of CRS. These theories 
allowed us to comprehend the experience of CRS as a matter of multi-directional communication 
among psychological aspects, situational factors and neuroendocrine and immune systems. 
 
3.6 Research Location 
 
The study was conducted at the University of Saskatchewan in the province of 
Saskatchewan, Canada. BCS were recruited from Saskatoon Cancer Center (SCC) in Saskatoon 
(approximately population size of 273,000). The MT sessions occurred at the Massage Therapy 
Association of Saskatchewan and the McKay Career Training School. The venues for the MT 
sessions were chosen based on their location (easily accessible and favourable) and the 
availability of massage rooms that met the study specificities. Laboratory analysis were 
performed at Cancer Cluster Laboratory at the University of Saskatchewan, Health Sciences 
Building (4D40) under supervision of Dr. Franco Vizeacoumar. 
 
3.7 Research Ethics 
 
3.7.1 Behavioural and Biomedical Research Ethics Board Approval  
 
 Ethical approval was obtained from the Biomedical Research Ethics Board (Bio# 16-112) 
at the University of Saskatchewan - See Appendix B. In addition to this approval, a data access 
agreement was signed with the Saskatchewan Cancer Agency.  
 Prior to taking part in the study, all participants were asked to sign an informed consent to 
declare their willingness to participate in the study (Appendix C). This form was drafted in clear 
and objective language, through which the subjects were informed about the objectives of the 
study, data collection procedures, possible constraints. It was ensured that participants were not 
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exposed to unnecessary or avoidable risks and that, overall, the potential benefits would outweigh 
the foreseeable risks. 
 
3.8 Participants & Sample Size  
 






• Confirmed diagnosis of cancer of non-
metastatic BC - stages I to III.  
 
• Pregnant or breastfeeding. 
• BCS who have completed treatment in 
the last 6 months.  
• Patients who have been receiving 
regular (i.e. at least twice a month) 
bodywork or any kind of MT over the 
past 6 months. 
 
•  Females over 18 years.  • Participants with potential for blood 
leakage into saliva by assessing oral 
health (i.e. "Did you observe bleeding 
gums in the past three days?")  
 
• One treatment-related risk factor: 
chemotherapy/chemoprevention, surgery 
and/or breast radiation.  
 
• Patients in use of cytokine-based 
treatments (i.e. interferon) 
• Able to read, write and speak English. 
 
• Known salivary gland disease 
• Women on hormonal therapy, such as 
tamoxifen (Novaldex), raloxifene 
(Evista), anastrozole (Arimidex), 
exemestane (Aromasin), or letrozole 
(Femara). 
 
• Known systemic infection or consistent 
fever > 38.5 °C.  
• Ability to understand study procedures 
and to comply with them for the entire 
length of the study. 
 
• Known upper respiratory infection (i.e. 
nasal drainage) 
 • Known inflammation (i.e. sore throat, 
periodontitis)  
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3.8.2 Power Analysis 
 
 Similar studies in cancer population showed positive and statistically significant effects 
of MT by working with different sample sizes, ranging from 24 subjects (Keir, 2011) to 286 
participants (Wilkinson et al., 2007).  
 Several studies suggest different methods to calculate sample size for feasibility studies 
(Hertzog, 2008). A safe range would be a minimum of 10 patients and a maximum of 30, but the 
most used approach suggests that a pilot study sample should be 10% of the sample projected for 
the larger correspondent study (Connelly, 2008; Treece, 1982). Other authors suggested 10 to 30 
participants. In randomized clinical trials, authors suggest that a group of 12 participants per group 
is satisfactory (Julious, 2005; Moore, Carter, Nietert, & Stewart, 2011).  
 Hence, an initial sample size was projected for a larger correspondent study based on a 
previous work developed with similar design, same population and a similar intervention 
(Sturgeon et al., 2009).  This previous study demonstrated an effect of MT in QoL with a subset of 
50 subjects (Sturgeon et al., 2009). Our initial calculation was based on detecting a ten-point pre 
and post difference in the QoL score and an improvement of 15% on QoL pre and post 
intervention with an α level of .05, a desired power of 80%, and assuming a standard deviation of 
15 points. This generated a sample size of at least 100 participants, already considering a 30% 
dropout rate. Therefore, considering 20% of our initial calculation of 100 patients for the larger-
scale study, we fixed our sample in 20 patients for this feasibility study.  
 
3.8.3 Subjects  
 
       A total of 24 females over 18 years who were diagnosed with non-metastatic BC - 
stages I to III and have completed the treatment in the last six months participated in this study 
(Figure 3.1).  
     Convenience sampling – a non-probabilistic method was used to select participants; 
therefore, subjects were consecutively selected in order of appearance. Recruitment came to an 




3.8.4  Dropouts  
 
    One participant withdrew from the study due to personal reasons (city relocation). An 
intention-to-treat (ITT) analysis was employed, which included data of all participants with at 
least one timepoint and one outcome measured. This patient withdrew from the study at week 3 
(i.e. right before assessment 1), therefore, baseline data from this patient was included in the 
linear mixed methods analysis following the ITT approach (Figure 3.1).  
Figure 3.1.  






















Assessed for eligibility (n=31) 
Excluded (n=7):  
• Not meeting inclusion criteria  
- Additional other primary cancer 
diagnosis (n=1)  
- Surgeries scheduled during the study 
period (n=1) 
- More than 6 months after the end of the 
treatment (n=3) 
• Declined to participate (n=2)  
Pre-intervention measures (n=24) (Baseline) 
(n=24) 
Intervention  
Withdrew from the study (n=1)  
Post-intervention measures (n=24) (Endpoint) 
 
Intention-to-treat (ITT) analysis  
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3.8.5 Recruitment  
 
Participants were recruited from the SCC in Saskatoon. There were no study-specific 
costs to the patients if they decide to participate. As for recruitment strategies, brochures as flyers 
were used. Brochures were distributed: i) in the waiting rooms and elevator at the SCC; ii) during 
the sessions of the "Cancer Transitions Support Group" held at the SCC. This group is a six-week 
(once a week) program designed to help cancer survivors make the transition from active 
treatment to post-treatment life; and ii) at the cancer lodge center. (Appendix D) 
Prospective participants were also identified with the help of medical oncologists from the 
SCC. Once the patients demonstrated interest in participating in the study, they were given a 
study folder and advised by their oncologist to contact the principal investigator or the primary 
researcher involved in this research. Those who responded directly to posters and/or flyers 
contacted the principal investigator or the primary researcher. After being accessed for eligibility 
and agreed on participating in this study, all participants signed the consent form (Appendix C). 
A Tim Horton’s gift card of $10 was given to all participants at the end of the study in 
appreciation for their time. 
 
3.9 Methods and Outcome Measures  
 
QoL served as a primary outcome measure while stress, sleep and fatigue are considered 
secondary outcomes in this study. The biomarkers may not be considered as secondary outcomes 
as they are less critical than PRO in informing decisions, but they were taken into consideration 
in explaining the intervention effects at a biological level.  
 
3.9.1 Quality of Life 
 
 QoL was assessed through the Functional Assessment of Cancer Therapy Version B 
(FACT-B).  The FACT-B is an instrument that measures QoL among BC patients in five 
domains: Physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing 
and concerns specific to BC population. It has 38 items, 5-point Likert scale, self-
administered (Brady et al., 1997; Webster, Cella, & Yost, 2003) (Appendix E).  
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3.9.2    Fatigue 
 
Fatigue was assessed through the Functional Assessment of Cancer Therapy Fatigue 
(FACT-F) scale. The FACT-F is a short, 13-item, easy to administer tool that measures an 
individual’s level of fatigue during their usual daily activities. The level of fatigue is measured on 
a 4-point Likert scale (4 = not at all fatigued to 0 = very much fatigued) (Minton & Stone, 2009;  
Wang et al., 2015; Webster et al., 2003).  Both FACT-B and FACT-F were chosen due to its high 
reliability (α = .70-.80), feasibility and validity for the English language, and they also have been 
validated in several populations of cancer patients (Minton & Stone, 2009; Murray et al., 2013; 




Participants were asked to complete the Perceived Stress Scale (PSS-10), a 10-item 
questionnaire designed to assess individual’s response to stress (Appendix G). Each question is 
rated on a 5-point scale from 0 (never) to 4 (very often). Higher scores indicate higher levels of 
stress. The scale scores range from 0-40. Scoring is completed by reverse scoring of four 
positively worded items and summing all item scores. To be identified as “stressed” by perceived 
stress scale, the score must be ≥ 12.1 for women (Cohen, Kamarck, & Mermelstein, 1983; Cohen 
& Williamson, 1988). The PSS was chosen because has demonstrated a good reliability of .87 of 
Cronbach's in previous studies with cancer population and also in the context of MT as a 
therapeutic intervention (Brennan & DeBate, 2006; Keir, 2011; Moraska & Chandler, 2009). 
 
3.9.4    Sleep  
 
Individual rest/activity cycle was measured noninvasively with a small-size wrist-worn 
accelerometer called Actigraph - Figure 3.2 (Basic Motionlogger®, Ambulatory Monitoring 
Inc.). Participants were asked to wear the device for 5 days at each assessment (baseline, 
assessment 1, assessment 2 and endpoint). The sleep devices and software for analysis were 
provided by the Sleep Lab and Sleep Disorders Center located at the Saskatoon City Hospital, 
Saskatoon.  
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Figure 3.2.  
 









The Basic Motionlogger® (Ambulatory Monitoring, Inc, New York, USA), is similar to a 
watch and has an integrated piezoelectric accelerometer, which provides data related to daily 
activity and sleep pattern. This device infers sleep from the presence or absence of wrist 
movement. Based on previous literature, the sleep parameters assessed were sleep duration (SD), 
sleep efficiency (SE), sleep wake time after sleep onset (WASO) and sleep onset latency (SOL) 
(Sonia Ancoli-Israel et al., 2003; Landry, Falck, Beets, & Liu-Ambrose, 2015; Littner et al., 
2003; Sadeh & Acebo, 2002). SD is a measure of quantity of sleep and represents the measure of 
time in minutes during down interval. SE is a measure of quality of sleep and represents the 
percentage of time asleep while in bed. WASO was measured in minutes and represents the 
minutes awake between sleep onset and wake time. SOL represents the length of time taken to 
fall asleep. Approximately 2,760 hours of sleep were recorded. In addition to the actigraphy data, 
patients were also asked to complete a 5-day sleep diary that was subsequently used to validate 
information from the actigraphy. By comparing two sources of data (subjectively and objectively 
assessed) concordance between measures was assessed (Appendix H). 
The sleep scoring algorithm Cole-Kripke was used to score the sleep data, and the 
ActionW® and Action4® analysis software (Ambulatory Monitoring, Inc, New York, USA) were 
used to analyze data (Cole, Kripke, Gruen, Mullaney, & Gillin, 1992). The Cole-Kripke 
algorithm is the most used algorithm to analyse actigraphy data in BC population (Berger, Farr, 
Kuhn, Fischer, & Agrawal, 2007; Berger, Wielgus, Hertzog, Fischer, & Farr, 2010; Madsen, 
Huang, & Gögenur, 2015; Moore, Schmiege, & Matthews, 2015). 
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3.9.5  Biomarkers   
 
Saliva samples were collected using the passive drooling collection method. This method 
has been extensively used from previous studies and involves the collection of whole saliva by 
unstimulated passive drool (Ahlberg et al., 2005, 2003). The following biomarkers were analysed 
in this study: cortisol, CRP, IL-1β, IL-6, TNF-α, IFN-!. The reasons why these analytes were 
chosen is supported by previous studies that showed a correlation between them and several 
aspects of inflammation, disease progression, recurrence and prognosis in breast cancer patients 
as well as survivors (Abdollahpour, Khosravi, Eskandari, & Haghighat, 2017; Derry et al., 2015; 
Fancourt et al., 2016; Jones et al., 2013; Kaur et al., 2018; Ma et al., 2017; Sephton, 2000; K. 
Spiegel et al., 1999; Wan, Couture-Lalande, Narain, Lebel, & Bielajew, 2016). Particularly, a few 
studies analysed these biomarkers in breast cancer subjects undergoing yoga and aerobic exercise 
programs (Abdollahpour et al., 2017; Derry et al., 2015; Jones et al., 2013).  
• Cortisol: Salivary cortisol levels serve as a biomarker of chronic psychological stress 
(Debono et al., 2009; Stalder et al., 2016) and have been associated with sleep patterns and 
insomnia (Rodenbeck, Huether, Rüther, & Hajak, 2002; Vgontzas et al., 2001).  
• Cytokines and CRP: Salivary levels of CRP, IL-1β, IL-6, TNF-α, IFN-! were also 
measured in this study. Among other possibilities, cytokines and CRP can be sampled through 
human blood (serum, plasma) and saliva, which have been preferred by researchers for its non-
invasive advantage (Corwin, 2000; Janssen, Caniato, Verster, & Baune, 2010). These molecules 
are a group of proteins released by a variety of cells. They have a major role in the inflammatory 
response and in the immune system (Corwin, 2000; Janssen et al., 2010). 
Correlations between CRP, cytokines and the severity and development of CRS during 
treatment has been heavily investigated as detailed in the previous chapter. Most of these 
investigations report that high concentrations of IL-1β, IL-6, TNF-α, IL-13 and NF-kβ may 
contribute to the development of CRS and sleep problems in cancer patients in treatment and 
post-treatment (Alfaro et al., 2014; Bower, Ganz, Aziz, & Fahey, 2002; Illi et al., 2012; 
Miaskowski et al., 2010; Reyes-Gibby et al., 2008; Saligan & Kim, 2012). 
 
3.9.6  Physiological Parameters  
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Oxygen saturation (SpO2), heart rate (HR) and blood pressure (BP) were assessed by 
using an automated Vital Signs Monitor (Welch Allyn Vital Signs Monitor 6000 Series), as 
referred in previous studies (Muller et al. 2012; Wentworth et al. 2014).  
Physiological parameters were assessed right before and after the intervention by the 
therapists or the primary researcher involved in the research. These measurements were not taken 
while the participant was resting on the massage table. Right after the massage session, patients 
were asked to dress up and walk to the next door where measurements were performed.  
  
3.9.7 Clinical and Demographic Data   
 
Clinical and demographic data were collected by using a questionnaire divided in four 
sections: i) Demographic data; ii) Disease characteristics; iii) Treatment details and iv) Other 
clinical information (Appendix I). Data was collected by reviewing participant’s medical health 
record following authorization from SCA.  The information from this questionnaire provided a 
clinical profile of each participant in the context of cancer disease, which has biological and 
statistical importance in the interpretation of the results.  
 
3.10 Intervention Protocol 
 
  We aimed to create a reproducible, standardized and semi-structured Swedish MT 
protocol for BCS (Appendix J). Participants received the same one-hour, standardized MT upon 
each visit for 8 weeks (once a week). All the sessions were arranged in the afternoon from 
Mondays to Thursdays at the same time every week. Three participants missed a total of 5 
sessions. These were contacted to reschedule the missed session to that same week. The same 
massage therapist was allocated for each participant during the entire duration of the study. 
The MT protocol used in this study was designed by considering the advancements and 
limitations of previous studies with breast cancer patients (Billhult et al., 2009; Billhult, Stener-
Victorin, et al., 2007; Hernandez-Reif et al., 2005, 2004; Kashani & Kashani, 2014; Krohn et al., 
2011; Listing et al., 2010; Sturgeon et al., 2009). Limitations of previous studies included the 
massage being performed only in supine position (Kashani & Kashani, 2014) and by different 
therapists at each visit (Listing et al., 2009).  
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This protocol was developed in collaboration with Pam Fitchner, who is a registered 
massage therapist, and craniosacral and somatoemotional release therapist for over 12 years with 
a large experience MT for cancer patients. To assure consistency during protocol delivery, only 
standard Swedish strokes and massage techniques were used (i.e. effleurage, petrissage, little to 
no tapotement, vibration (gentling rocking), friction, and skin-rolling were used). The 
intervention protocol were as follows: a) prone position: the first phase encompassed a total of 32 
minutes and involved foot massage (5 minutes), lower limb massage (10 minutes), back massage 
(10 minutes) and upper limbs (7 minutes); and b) supine position: a total of 28 minutes involving 
lower limbs (7 minutes), torso/breast area (5 minutes), upper limbs (6 minutes), neck, head and 
face (5 minutes) and neck (5 minutes).  
The sessions took place in small, quiet and private rooms where lights were dimmed and 
soft. After checking for vital signs, participants were asked to undress (except for 
undergarments), and then make themselves comfortable on the MT table. Tables were properly 
sanitized before each session and draped with clean cotton sheets. Therapists were asked to 
refrain from talking during the sessions, except for asking about how the patient was feeling. All 
therapists used unscented fractioned coconut oil during the sessions. Therapists were also advised 
to do not treat muscles specifically or to do not deeper pressure as week progress. Some latitude 
was allowed if patient was unable to lie in prone or any area had lymphedema or swelling. Hence, 
if patient was unable to lie in prone, the sidelying position could be used; and if any area had 
lymphedema or swelling, the therapist was allowed to adapt by moving to another area. However, 
none of these adaptations were needed during the study. No music or aromatherapy was used in 
conjunction with the MT sessions. 
 A total of 5 registered massage therapists (RMT) and 10 senior massage therapy students 
participated in the study. All therapists were oriented and trained on how to perform the protocol 
by Pam Fitchner. Mock sessions were performed with each therapist and observed by the 
instructor in order to control for intra- and inter-therapist variability. Training included the 
theoretical aspects of the protocol (1hour) and hands-on practice (3 hours). Training sessions 
occurred at MTAS, for the RMT and at McKay school for the senior students. Each massage 
therapist received a certificate from the College of Medicine stating their participation in the 
study. The therapist remuneration rate per massage sessions was $35. In addition, MTAS offered 
3 continuing education unit (CEU) credits for training participation.  
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3.11 Data Collection     
 
Data was collected from September 2017 to May 2018. In this period, three rounds of data 
collection were performed. The first from September 2017 to November 2017 – total of 10 
participants. The second round was carried out from February 2018 to early April 2018 – total of 
8 participants. The third and final round was carried out from mid-March 2018 to May 2018 – 
total of 6 participants. 
 
3.11.1.    Piloting Saliva Collection Scheme 
 
In order to predict potential issues and analyze the feasibility of the saliva collection 
scheme, we asked three graduate students to volunteer their time and kindly go over the saliva 
collection scheme. They received the exact same kit that were used by the study participants and 
were asked to go through this experience by following the same instructions, same timing and 
number of samplings that would be used in this study. This was an important step since it allowed 
us to get some critical feedback on the saliva collection scheme. 
The participants judged their experience as very easy to perform, painless and handy. The 
drawbacks highlighted were the burden level due to the number of sampling and that it was easy 
to forget one or more collection samples. 
 
3.11.2     Saliva Collection 
 
All participants received a collection kit with all the material needed to collect and 
properly store the samples (Figure 3.3), along with instructions sheets (Appendix L and M). 
Approximately 1,152 saliva vials were collected to measure a total of six biomarkers, yielding a 
total of 6,912 readings using saliva specimens. 
Participants were asked to follow the same instructions at every saliva collection. The 
instructions include asking the patients to tilt the head forward, allowing the saliva to pool on the 
floor of the mouth, passing the saliva into a polypropylene tube using a collection aid provided in 
the kit. Usually 1 min is enough to collect unstimulated passive drooled saliva using this method. 
To avoid contamination, participants were oriented to refrain from mouth cleaning, drinking 
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caffeinated beverages, smoking, having meals, snacks, or medications at least 1 hour before 
proceeding with the collection.  
Figure 3.3.  













Several molecules in the human body are secreted in a circadian rhythmicity, hence 
careful consideration of sampling times was employed in this study. The kinetics and time-
release of several molecules in the saliva and blood specimens, as well as the reactivity (speed of 
change) of these molecules are still unclear (Bonz et al., 2003; Desborough, 2000; Pramanik et 
al., 2012; Smith, Kemp, Hemphill, & Vojir, 2002). For instance, cortisol, CRP, IL-1β, IL-6, 
TNF-α, IFN-! have distinct peak release after an intervention and, therefore, studies with MT 
and other IM therapies have employed different data collection schemes when measuring 
biological markers. The study’s research question (s) and the biomarkers of interest often 
determines the biological specimen (i.e. saliva, blood, urine) and the collection timepoints. 
Studies aiming to assess pre and post immediate changes tend to use blood specimens, while 
those aiming to assess late and/or long-term changes overtime employ saliva and urinary 
specimens. Likewise, studies have also employed a diverse scheme of collection timepoints. 
Previous studies have multiple collection points in the same day (Bernard, Hostinar, & Dozier, 
2015; Bonz et al., 2003; Jäger, Schmidt, Conzelmann, & Roebers, 2014; Leardi et al., 2007; 
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Nilsson, 2009; Pędziwiatr et al., 2015; J. J. Wu et al., 2014), while others have characterized the 
whole diurnal profile by considering a multiple-time and multiple-day collection approach 
(Malarkey, Jarjoura, & Klatt, 2013; Matousek et al., 2011). 
To reflect biomarkers’ circadian pattern, collecting saliva samples at multiple times 
throughout the day for more than one day is the ideal approach. The following summarizes the 
most relevant studies' recommendations in regards to salivary sampling of biomarkers: (i) in 
order to reliably characterize within-person changes across interventions, at least 3 days of data 
collection are needed for the whole diurnal profile through Area Under the Curve (AUC) 
calculation (Jens Pruessner, Kirschbaum, Meinlschmid, & Hellhammer, 2003; Segerstrom, 
Boggero, Smith, & Sephton, 2014); (ii) collecting less than four samples per patient in 24 hours 
would not yield accurate results of the diurnal pattern (Stalder et al., 2016); (iii) instead of having 
many samples per day over the course of a few days, it is recommended collecting fewer 
samples, per day over more days (Segerstrom et al., 2014); (iv) sampling times throughout the 
day must be as evenly spread out as possible (Stalder et al., 2016) and (v) if multiple collections 
cannot be done, afternoon collection is preferable for adults to avoid the influence of the 
awakening response of some markers (Lovallo, Farag, & Vincent, 2010).  
 While it is desirable to acquire multiple measurements over time for finding individual 
variations with regard to response time and duration, the amount of data gathered is enormous 
and can represent a problem for the statistical analysis (Fekedulegn et al., 2007; Khoury et al., 
2015; Jens Pruessner et al., 2003). When trying to identify possible relations between repeated 
measures and other outcomes, as well as to comprise biomarkers concentrations sampled in 
multiple measurements over time, the AUC has been routinely used to incorporate multiple time 
points (Fekedulegn et al., 2007; Khoury et al., 2015; Jens Pruessner et al., 2003). The exact 
number of measurements needed to create an accurate AUC depends on several factors such as 
the homogeneity of participants involved, the timing and interval of the measurements, and if 
clinically relevant cofounders are taken into account (Booij et al., 2015). For instance, in an 
attempt to estimate the exact number of measurements needed to create an accurate cortisol AUC, 
an author stipulated that 70 and 88 measurements would have been necessary to estimate 
between-individual differences with moderate reliability (Hruschka, Kohrt, & Worthman, 2005). 
However, up to date, only a few studies have sampled cortisol between 50 to 60 times (Peeters, 
Nicolson, & Berkhof, 2004; Van Eck, Berkhof, Nicolson, & Sulon, 1996). 
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For the purposes of this study, we were interested in the long-term effects of the 
intervention overtime (every two weeks). Immediate pre and post changes were not primarily 
intended to be captured in this study given that every biomarker of interest displays a different 
salivary reactivity and recovery pattern. Hence, based on these recommendations, three days of 
consecutive sampling were employed in this study, and the following time points were used for 
saliva collection: i) at day one: 5pm (roughly 1h after the MT session) and 8pm; ii) at day two: 
upon awake, 30 min. later, noon, 5pm and 8pm; and iii) at day three: upon awake, 30 min. later, 
noon, 5pm and 8pm (Appendix M). Awakening was either spontaneous or by alarm clock, since 
previous study has shown that the cortisol response is not affected by this factor (Pruessner et al., 
1997). 
 
3.11.3     Compliance  
 
As for the compliance with saliva collection, the importance of collecting samples at 
designated times was emphasized, however we cannot confirm that participants strictly adhered 
to the collection scheme. Although it has been shown that the consistency of salivary measures is 
directly dependent on subject compliance, it has also been revealed that patient compliance rate is 
superior to that of healthy controls or volunteers (Broderick, Arnold, Kudielka, & Kirschbaum, 
2004).  
In order to help participants in remembering to collect the samples we used a bulk SMS 
system (RedOxygenTM), which is able to send mass text messaging. The reasons for choosing this 
system were based on the fact that this tool allows to track message delivery, along with the cost-
effectiveness and the capability to send SMS to several types of mobile devices. SMS were 
standardized and scheduled at specified times and dates. By using this tool, we were able to reach 
each participant by SMS according to the saliva collection scheme and remind them within 
approximately 10 minutes before each time point (Appendix N). A daily log was automatically 
generated by the system reporting the status of each SMS and allowing the researchers to confirm 
that the SMS was promptly delivered.  
During the study, three participants opted out of receiving the SMS indicating that they 
had their own alerts/reminders set up in their personal mobile.  
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3.11.4.    Study Assessments   
 
As depicted in Figure 3.4, participants went through four assessments (i.e. baseline, 
assessment 1, assessment 2 and endpoint) over the course of 10 weeks. Participants received the 
intervention for 8 weeks, and the whole duration of the study was 10 weeks. The time points 
were selected based on results previously described in the literature and based on the most 
accurate methodologies to date applied (Bower et al., 2005; Carlson et al., 2013; Chan et al., 
2006; Hsiao et al., 2012; Lipschitz, Kuhn, Kinney, Donaldson, & Nakamura, 2013; Nater, 


















Pre and post every MT session, the physiological parameters SpO2, HR and BP were 
assessed, as well as at baseline and endpoint. QoL, fatigue, stress, fatigue and the biomarkers 
were assessed at all assessments. Hence, participants completed a battery of self-reported 
questionnaires (QoL, fatigue and stress), recorded sleep data for 5 days (actigraphy), and 
collected a 3-day cycle of saliva samples at: 
Figure 3.4. 
 Scheme summarizing the measurements according to the study phases. 
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o Baseline: the week prior to the first MT session.  
o Assessment 1: upon week 3. 
o Assessment 2: upon week 6. 
o Endpoint: the week after the last MT session. 
 
3.12 Laboratory Analysis  
 
3.12.1   Saliva Sample Preparation  
 
Saliva samples were labelled and stored at -80oC. Frozen samples were allowed to attain 
room temperature (RT) before analysis. Vortex followed by centrifugation at 10,000 × g for 5–10 
minutes was performed. Even though saliva collection instructions were reinforced with all 
participants to prevent sample contamination with food debris, inevitably a few samples showed 















In order to achieve good and standard quality sample, any collection that presented 
contaminants were centrifuged a second time to remove cellular and food debris.  
 
3.12.2    Saliva Sample Analysis   
 
Saliva samples were analysed using Luminex technology® along with 6-plex Magnetic 
Bead ProcartaPlex® kits by ThermoFisher (Thermo Fisher Scientific, Waltham, MA). The 
Luminex technology enables multiple analytes to be measured at the same time. Previous studies 
Figure 3.5.  
 
Saliva samples collected from study participants showing the differences in sample quality. 
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in cancer population have chosen this same technique to analyse saliva, serum, plasma and cell 
culture supernatant samples (Arellano-Garcia et al., 2008; Lee et al., 2018).  
A MAGPIX®, Luminex® 100/200™ (serial number MAGPX13355701) was used to 
read the samples and the xPONENT® 4.2 software package was used to data acquisition. 
(Thermo Fisher Scientific, Waltham, MA).   
Following the manufacture’s recommendations, the reagents were allowed to attain RT 
before analysis. The analysis protocol constituted of six steps. The first step was the antigen 
standard preparation. Initially, each different antigen standard vial was centrifuged at 2,000 × g 
for 10 seconds. Standards were reconstituted by adding 50 μL of Universal Assay Buffer (1X) 
into each standard vial. Vials were then gently vortex for 10 seconds and centrifuged at 2,000 × g 
for 10 seconds. Vials were then incubated on ice for 10 minutes to ensure complete 
reconstitution. After complete reconstitution, the second step was pooling of standards. The 
entire content of standards vials was pooled into one single vial (total volume after this step will 
be 150uL). Vials were filled up with 100uL of Universal Assay Buffer (1X). (the final volume 
after reconstitution and pooling should be 250 μL). After gently vertexing the vial for 10 seconds, 
they were centrifuged at 2000 × g for 10 seconds to collect contents at the bottom of the vial. 
The third step was the preparation of a 4-fold serial dilution. A provided PCR 8-tube strip 
was used to prepare the 4-fold serial dilution of the reconstituted standards.  Tubes were labeled 
Std1, Std2, Std3, Std4, Std5, Std6, and Std7. A total of 200 μL of the reconstituted antigen 
standards were added into the Std1 tube of the strip. A total of 150 μL of Universal Assay Buffer 
were added into Std tubes 2 to 7. A volume of 50 μL of the reconstituted antigen standards was 
transferred from Tube 1 into Tube 2. The same amount (50 μL) of the mixed standards was 
transferred from Tube 2 into Tube 3 – and so on until Tube 7. A volume of 200 μL of Universal 
Assay Buffer was added into Tube 8 which served as a blank. These were kept on ice until ready 
to use (See Appendix O for 96-well plate template).  
The fourth step was the preparation of the cortisol competitive conjugate solution (1X). A 
25 μL of Competitive Conjugate Solution (50X) was mixed with 1,225 μL Universal Asssay 
Buffer (1X). Fifth step was the preparation of the cortisol beads. Cortisol beads were provided as 
concentrated 50x beads. Therefore, dilution of concentrated cortisol beads was required. Each 
cortisol bead vial (50X) was vortexed for 30 seconds and 50uL of the bead vial (50X) were added 
to a mixing bottle (Eppendorf tube). This bottle was filled up with 2,450uL of wash buffer (1X) 
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to a final volume of 5mL.  
The sixth step of the protocol is the execution of the assay itself. The 6-plex Magnetic 
Bead vials was vortexed for 30 seconds. A volume of 50uL of the 6-plex Magnetic Bead solution 
was added into each well of the plate.  In addition, 50uL of the diluted 1X cortisol beads were 
added into the same plate. Beads were washed from the plate (1x wash). After wash, a total of 25 
μL of Universal Assay Buffer (1X) were added to each well, followed by 20 μL of the diluted 
Competitive Conjugate Solution (1X), and 25 μL of prepared standards and samples. After that, 
plate was sealed and covered with the black microplate lid and set to shake at 500 rpm for 60–
120 minutes at RT. After incubation, plate was washed (2x wash) followed by the addition of the 
25 μL of Detection Antibody Mixture (1X) to each well. A second incubation was performed 
with plate sealed and covered with the black microplate lid and set to shake for 30 minutes on a 
plate shaker at room temperature to 800 rpm for 1 min, back down to 600 rpm for remainder of 
time. After incubation, plate was washed (2x washes) followed by the addition of 50 μL of SAPE 
solution to each well. A third incubation was performed with plate sealed and covered with the 
black microplate lid and set to shake for 30 minutes on a plate shaker at room temperature to 800 
rpm for 1 min, back down to 600 rpm for remainder of time. After incubation, plate was washed 
(2x washes) followed by the addition of 120 μL of reading buffer into each well. A third and final 
incubation was performed for 5 minutes on a plate shaker at 800 rpm for 1 minute, back down to 
600 rpm for remainder of time. 
Data analysis was performed using the Bio-Plex Manager™ 6.11 software®. The 
standard curves were fit with the designated model using those standards that encompassed the 
values for each marker obtained from the samples in each assay. A good percentage recovery was 
set from 80 to 120%. To reflect intra-assay precision, %C.V. were aimed to be less than 20-25%. 
The r2 values for the linear fits were always between 0.80 and 0.95 and very often above 0.90. In 
each 96-well plate, the standards were run in duplicate, as well as the samples.  
 
3.13 Statistical Analysis 
 
3.13.1 Descriptive Statistics  
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Initial dataset was created in Microsoft Excel version 16.6 (Microsoft for MacBook Inc, 
Redmond, WA) and analyzed with Statistical Package for the Social Sciences (SPSS) version 
19.0 (IMB Inc, Chicago, IL).  Assumptions of independence, linearity and homoscedasticity were 
tested for all levels of independent variables. The Shapiro-Wilks test was used to assess the 
normality of the data. Measures of central tendency (e.g., mean and median) along with measures 
of dispersion (e.g., standard deviation and interquartile range) were calculated for continuous 
variables. Frequencies and percentages were used to present all categorical variables. Graphically 
displaying the data was considered as an additional aid in assessing patterns of dispersion in 
order to identify potential outlying values that may influence the results. 
  
3.13.2 Inferential Statistics   
 
 Since this study proposed a quasi-experimental design, each participant was assessed by 
the same instruments at different points in time, and the results obtained for each individual 
during different measurements were compared; thus the statistical analyses was performed using 
paired methods such that each participant serves as her own comparison (i.e. two paired - 
dependent - samples). 
For research question one (i.e. are there any changes in QoL, stress, fatigue and sleep in 
BCS submitted to an 8-week Swedish massage program?) a General Linear Model (GLM) and a 
Linear Mixed Model (LMM) were used.  
General Linear Model:  
Repeated-measures ANOVAs (RM-ANOVAs) were conducted to identify if there were 
significant changes in QoL, stress, fatigue and sleep data over the course of the program. For the 
RM-ANOVAs, measures at each of the four time points were entered as within-subject factors. 
Independent variables (i.e. age, cancer stage, sleep medications in use, months after treatment, 
type of treatment, presence of comorbidities, hormonal therapy) were entered as between-subject 
factors. If Mauchly’s test was statistically significant, the Greenhouse-Geisser and Huynh-Feldt 
values were used as alternative corrections to the sphericity assumption. If both of these values 
are greater than 0.75, Huynh-Feldt was used, if lesser than 0.75, the Greenhouse-Geisser was 
chosen (Field, 2009). Absolute values of skewness and kurtosis were also checked. The variables 
that were not normally distributed but had good values for skewness and kurtosis were treated as 
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normally distributed after outliers removed. Skewness and kurtosis were expected to not exceed 
0.8 and 2 respectively (George & Paul, 2010). The total sample size for the RM-ANOVAs was 
23 subjects.  
Linear Mixed Model:  
Given the exploratory nature of the present study, only the variables that showed statistical 
significance in the RM-ANOVAs and significant interactions with the covariates were included 
in the LMM analysis. LMM allows modeling of subject-specific trajectories over time, as well as 
modeling the correlation between measurements within subject. In the case of the present study, 
the Satterthwaite approximations to degrees of freedom were used when testing fixed effects. 
Satterthwaite has shown to be more accurate especially when sample size is small or moderate 
(Luke, 2017). Second, in LMM, random effects and error terms express correlated and 
nonconstant variability in their results. It provides a fully specified model of the distribution of 
the outcome. Third, it allowed the analyses to be pragmatic and based on the intention-to-treat 
(ITT) principle, which included data on all participants with at least one timepoint and outcome 
measured. This procedure prevented listwise deletion due to missing data given that LMM use all 
data available at each time point; thus, missing data imputation was not undertaken. A total of 
twenty-three participants had data collected at all timepoints, and one participant had only 
baseline data collected. Because we applied ITT principle, LMM presented as a powerful 
alternative given its flexibility and robustness in dealing with missing data. Final sample used in 
the LMM analysis was 24 subjects.  
For the LMM model, the response variables were the dependent variables (i.e. QoL, 
fatigue, sleep outcomes and the biomarkers) and the fixed effects were time and the predictor 
variables (i.e. age, type of treatment, cancer stage, hormone use, sleep aids in use, comorbidities,  
and months after treatment).  
Careful application of model building strategies was employed to yield the best possible 
model within the constraints of the available data. Clinically biologically or scientifically 
meaningful independent variables (IVs) were chosen based on supporting literature, the 
biological theory related to the study, as well as on the RM-ANOVAs results. Following the 
forward/step-up selection strategy to fit multivariable models, the analysis of each variable to be 
included in the model was verified as follows: (i) starting with an intercept-only model (empty 
model), a model was initially generated with no predictors (fixed effects) in the model. This was 
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the base model for comparison; (ii) One at a time, IVs (potential predictors) were added to the 
model; (iii) an examination of AIC and BIC was performed; (iv) and a comparison of each 
estimated coefficient with the model containing only that variable; (v) variables that showed no 
significant main effect were removed from the final model, unless significant differences between 
categories and/or interactions were found (Harrison et al., 2018).  
Additionally, variables with strong theoretical justification even if was statistically 
insignificant were retained, based on the assumption that explanatory power plays a major role in 
assessing predictive performance, whereas statistical significance does not. In fact, according to 
the literature, removing variables with small coefficients, even if they are statistically significant, 
results in improved prediction accuracy (Shmueli, 2010; Wu, Harris, & Mcauley, 2008). 
Finally, we compared Akaike’s Information Criterion (AIC) and Bayesian information 
Criterion (BIC) across each model. The difference in AIC and BIC values between models 
determines the strength of support for the model with the lowest AIC and BIC. AIC for model 
choice is commonplace in many scientific fields (Muth et al., 2016; Schober & Vetter, 2018; 
West, 2009). AIC measures predictive accuracy while BIC measures goodness of fit, and 
overall, lower values of these estimators mean that a model has a good fit (West, 2009). In 
addition to AIC and BIC values, the relationship between variables were also taken into account. 
Considering that the dependent variables (DVs) might be affected by the IVs, as well as by time, 
it is believed that the DVs will decrease or increase throughout the time. Any two distinct 
observations from the same patient have the same correlation coefficient (0 < r ≤ 1). We assumed 
that factors and predictor variables have a linear relationship to the dependent variables, 
justifying the use of compound symmetry covariance structure, since its structure assumes 
constant variance and constant covariance (Muth et al., 2016; Schober & Vetter, 2018; West, 
2009). Therefore, based on adherence values BIC and AIC, and on the assumption of relationship 
between variables, the compound symmetry covariance structure was used to adjust the LMM in 
this study. 
Once we have identified a model that had the essential variables, the inclusion of 
interaction terms was undertaken. Significant interactions were retained and represented 
graphically.  If not affecting the overall model goodness of fit, lower order effects were kept in 
the model when they were connected to higher order effects and vice versa.  
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For research question two (i.e. are there any changes in inflammatory markers in BCS 
submitted to an 8-week Swedish massage program?) the same procedure employed for research 
question one, were used to analyze the biomarkers data (GLM followed by LMM). Skewness and 
kurtosis were analyzed to detect whether biomarkers data was positively skewed (skewed to 
right, skew > 0) or negatively skewed (skewed to left, skew < 0). Because of a skewed non-
normal distribution of the biomarkers data, data were logarithmically transformed. Since saliva 
samples were collected at multiple time points, indices representing total biomarkers’ magnitude 
and production were calculated using AUC based on the log-trapezoidal method as described by 
previous studies (Fekedulegn et al., 2007; Khoury et al., 2015; Pruessner et al., 2003). Most of 
missing data was from the saliva collection (i.e. when a patient missed a collection, or the 
biological specimen did not meet the quality criteria). Missing values were handled by multiple 
imputation after missing patterns analysis. Littler’s MCAR test (p>0.05) failed to reject the null 
hypothesis, determining randomness of missing data. Values were estimated based on data 
patterns. Linear regression is used to create values that are appropriate and realistic (Haukoos & 
Newgard, 2007; McKnight, 2007; Newgard & Haukoos, 2007; Sterne et al., 2009). 
For research question three (i.e. what are the immediate changes in BP, HR and SpO2 in 
BCS submitted to an 8-week Swedish massage program?) bivariate association analysis was 
performed to identify if there was any changes in BP, SpO2 and HR using the nonparametric 
paired Wilcoxon for the variables not normally distributed and Paired T-test for the normally 
distributed. Mean Arterial Pressure (MAP) was calculated to analyse BP following previous 
studies methodology (Jane et al., 2009). MAP is defined as the average pressure in a patient’s 
arteries during one cardiac cycle. MAP is considered a better indicator of perfusion to vital 
organs than systolic blood pressure (SBP) (Furlanis et al., 2018; Tee et al., 2017). To calculate a 
MAP, the diastolic blood pressure (DBP) was doubled, and the result added to the SBP, and then 
divided by 3. 
For research question four (i.e. are there any correlations between the main variables in the 
study?) Spearman ρ (rho) bivariate correlation tests were carried out to examine putative 
correlations between inflammatory markers with QoL, fatigue, stress and sleep measures. 
Following similar studies, we adopted Spearman’s to examine correlation properties as a 
conservative measure, in order to avoid the effects of extreme values (Chowdhury, Chandra, Li, 
Ely, & Turner, 2019; Khosravi et al., 2018; Lopes-Junior et al., 2019; Nakamura et al., 2010) 
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All calculations were performed at a 95% confidence interval. Two-sided p values <0.05 
were considered statistically significant. Effect sizes (Cohen’s ") were also calculated as a 
measure of practical significance. For non-parametric data, log transformed data were used to 
calculate effect size based on previous studies recommendations (Rodríguez-Barranco, Tobías, 
Redondo, Molina-Portillo, & Sánchez, 2017). 
 
3.14 Quality Assurance  
 
A series of planned and systematic activities were conducted to ensure that this trial was 
performed in compliance with the study protocol. The following strategies were used to prevent, 
detect, and correct problems during the execution of the protocol, and to increase the quality of 
findings produced by this study:  
   
• Participants that best represented the research topic were chosen; 
• Student (primary researcher) received appropriate training to conduct the study (e.g. 
biosafety training, laboratory training, statistical training, ethics certification); 
• A sustainable community-academic partnership was developed with the community 
partners to ensure long-term engagement throughout the study;  
• The research processes were clearly generated, documented, and reported to the research 
supervisor and advisory committee;  
• The decisions made throughout the study were summarized in an audit trial. 
 
 3.15 Knowledge Translation  
 
 
The study results were presented to participants and key informants in a small gathering at 
MTAS on November 13th 2019. Medical oncologists, nurses, social workers and massage 
therapists who participated in the study were also invited, as well as the general public and 
anyone who were interested. Folders advertising the gathering were posted around the SCC and 
sent to our local partners which included: HOPE Cancer Help Centre 
(https://hopecancercare.com); McKay School Training  (www.mckaysk.ca), SCC 
(www.saskcancer.ca), Breast Cancer Support Saskatoon 
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(http://breastcancersupportsaskatoon.com); Too Tired Fatigue Education Group, the Cancer 
Transition Group at SCC, Cancer Connection Network (https://survivornet.ca); Massage 
Therapists Association of Saskatchewan  (MTAS) (https://www.saskmassagetherapy.com); Live 
Well program (www.saskatoonhealthregion.ca/locations_services/Services/cdm).  
During this gathering session, Ms. Bomfim acknowledged the participation of all patients 
and recognized any supporter institutions, such as Saskatchewan Health Research Foundation 
(SHRF) and MTAS. Participants received a brochure with a summary of the principal results in 
layman's terms, although copies of the final research report were also available. They were 
encouraged to ask questions they may have. For those that were unable to attend, they were 
contacted individually by email or phone call to be informed of the results of this study. Our 
findings were also disseminated to the agencies and support groups that we partnered with 
through e-mail.  
At an academic level, partial results have been presented at various international 
conferences (e.g. The Network: Towards Unit for Health in Darwin, Australia and CAPO/IPOS 
21st World Congress of Psycho-Oncology in Banff, Canada, both in September 2019). Final 
results will be also disseminated in academic conferences. In addition, articles on the research 
findings will be submitted to indexed and peer-reviewed journals. 
 
3.16 Summary of Chapter Three  
 
This study is a one-group, longitudinal quasi-experiment without a control group. The 
study was carried out in Saskatoon at the University of Saskatchewan, Massage Therapy 
Association of Saskatchewan, the McKay Career Training School. The study is framed and 
guided by the Middle Range Theory of Unpleasant Symptoms and the Psychoneuroimmunology 
Framework. 
Participants were females over 18 years who were diagnosed with breast cancer - stages I 
to III and have completed the treatment in the last month. The study involved the following 
methods and procedures: participants underwent 1 hour of Swedish relaxation massage over 8 
weeks. Participants were assessed at: Baseline (T1); Assessment 1 (T2), Assessment 2 (T3) and 
Endpoint (T4). At all these assessments, all outcomes were assessed: QoL, stress, sleep, fatigue, 
physiological parameters, cortisol, CRP and cytokines. The FACT-F and FACT-B were chosen 
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to measure fatigue and QoL, and the Perceived Stress Scale was used to measure stress. 
Individual Rest/Activity Cycle was measured noninvasively with a small-size wrist-worn device 
(Basic Motionlogger®, Ambulatory Monitoring Inc.®). This tool is similar to a watch and the 
patients used it for at least 5 days. Saliva was collected to detect cortisol, CRP and cytokines 
levels.  Also, physiological parameters (arterial oxygen saturation - SpO2, heart rate and blood 
pressure) were measured pre and post every massage session. 
The next chapter displays the results of this study. The results are presented in alignment 











































4.1 Overview  
 
In this chapter, the demographics of the participants and the results of the effects of the 8-
week MT intervention on QoL, sleep, stress, fatigue and inflammatory markers in recently treated 
BCS are presented. 
 
4.2 Characteristics of the Participants   
 
A total of 23 participants completed the study, however, since ITT was employed, a total 
of 24 subjects were included in the final sample. Table 4.1 shows the main variables of the 
clinical-demographic profile. The average age of participants was 56.9 (±9.3). Most participants 
(n=11) went through all three types of treatment (chemotherapy, radiotherapy and surgery). All 
participants were diagnosed with a primary cancer. Most participants (n=13) enrolled in the study 
within the first three months after completion of treatment. The majority of BCS in our study 
were diagnosed with a stage I cancer (n=10), and the majority was in hormonal therapy (n=16). A 
total of 13 participants were taking sleep aids during the course of the study.  
 
Table 4.1.  
 
Descriptive statistics of the clinical-demographic variables 
of a sample of BCS, Saskatoon (n=24). 
 
Variable M SD 
Age (years) 56.9 9.3 
   
Variable n % 
Age Classification   
30-40 3 12.5 
40-50 4 16.6 
50-60  10 41.7 
≥61 7 29.2 
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Table 4.1. (continued)   
Education Level n % 
    Finished high school 7 29.1 
    College or Bachelor’s degree 16 66.7 
    Post-degree education 1 4.2 
   
Marital Status   
    Married 19 79.1 
    Widowed 2 8.2 
    Not married 2 8.2 
    Divorced 1 4.5 
       
Birth Country   
    Canada 23 95.8 
    Out of canada 1 4.2 
   
Work Status   
    Not working 4 16.6 
    Part-time worker 4 16.6 
    Domestic worker 3 12.5 
    On medical leave 9 37.7 
    Pensioner 4 16.6 
   
 Disease Classification   
     New primary 24 100 
   
Months after treatment    
  < 3 months 13 54.2 
  ≥ 3 months 11 45.8 
   
Cancer Stage   
  I 10 41.6 
  II 7 29.2 
  III 7 29.2 
   
Treatment Classification   
      Unimodal therapy 3 12.5 
      Multimodal = 2 therapies  10 41.6 
Multimodal > 2 therapies 11 45.9 
   
Type of Treatment    
    Chemo, Radiation and Surgery 11 45.9 
    Radiation and Surgery  5 20.8 
    Only Chemotherapy  2 8.2 
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Table 4.1. (continued)   
    Chemotherapy and Radiation  1 4.2 
    Surgery only 1 4.2 
    Chemotherapy and Surgery  4 16.6 
   
Hormone Therapy   
  Yes 16 66.7 
  No 8 33.3 
   
Medications   
  On sleep aids 13 54.2 
  Off sleep aids 11 45.9 
   
Comorbidities    
  Yes 14 58.3 
  No 10 41.7 
   
   
 
 
4.3  Changes in QoL, Fatigue, Stress and Sleep 
 
 
This subsection will address the findings of research question one: are there any changes in 
QoL, stress, fatigue and sleep parameters in BCS submitted to an 8-week Swedish massage 
program? Below, a detailed description of the results is presented for each outcome.  
 
4.3.1  Quality of life  
 
 
The trajectory of QoL throughout the 8-week MT program is depicted in Figure 4.1 (below). 
QoL scores measured with FACT-B questionnaire ranges from 0-144. Interpretation assumes that 








Figure 4.1.  
 




According to Figure 4.1, patients improved their QoL at the end of the 8-week MT 
program. Participants showed the lowest QoL at baseline (mean=92) and showed improvement of 
this construct at endpoint (mean=103.8). Among the study covariates tested in the LMM, only 
two (i.e. Months After Treatment and Cancer Stage) yielded statistically significant main effects 
and/or significant interaction terms in the QoL models, which are described below.   
 
QoL and Months After Treatment  
 
Table 4.2 (below) shows that Time had a significant effect on QoL [F=(3, 66.000)=12. 
328, p<0.0001], but Months After Treatment did not significantly affect QoL [F=(1, 22)=.682, 
p=0.418]. However, the interaction of Time and Months After Treatment had a significant effect 








Table 4.2.  
 
Type II tests of Fixed Effects Results for QoL Model 1 (n=24). 
 Source Num df Den 
df 
F Sig. 
Intercept 1 22 1037.07 .000 
Time 3 66 12.32 .000 
Months After Treatment 1 22 .682 .418 
Interaction Time * Months After Treatment  3 66 3.05 .034 




Estimates of Fixed Effects Results for QoL Model 1 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 100.34 5.10 33.33 19.64 .000 89.95 110.72 
Time        
Baseline -9.66 3.68 66.00 -2.62 .011 -17.03 -2.30 
Assessment 1 -8.69 3.68 66.00 -2.35 .021 -16.06 -1.33 
Assessment 2 7.55 3.68 66.00 2.049 .044 .19 14.91 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Months After Treatment        
< 3 months  7.06 6.93 33.33 1.01 .316 -7.04 21.17 
≥ 3 months(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Interactions(b)         
      Assessment 2 *< 3 months -9.77 5.01 66.00 -1.95 .055 -19.77 0.23 
      Endpoint * < 3 months(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
        
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
 
Estimates of fixed effects results displayed in Table 4.3, shows an interaction term between 
Assessment 2 * < 3 months with a p value marginally significant (b=-9.77, t=-1.95, p=0.055, CI 
95%: -19.77, 0.23), indicating that those who finished treatment less than 3 months after study 
onset showed significantly lower QoL (9.77 points) when compared to those who finished 
treatment more or equal than 3 months after study onset at assessment 2 when compared to 
endpoint. This interaction is graphically displayed in Figure 4.2. 
To describe how this interaction term indicates that there are differences in QoL scores 
for each group of Months After Treatment between Timepoints, and that, similarly, QoL scores 
 68 
were different at each Timepoint for each level of the Months After Treatment variable, pairwise 
calculations were performed using the estimated means from the final LMM displayed in Table 
4.3. For instance, to find the difference between QoL1 [< than 3 months group at assessment 2] 
and QoL2 [≥ 3 months group at endpoint], the following values were used for pairwise 














Similarly, to find the difference between QoL3 [< than 3 months group at assessment 1] 












Results of all pairwise calculations are displayed in Tables 4.4 and 4.5. In addition to 
these calculations, a paired sample t-test was run to analyse if selected pairwise comparisons of 




• QoL1 [≥ than 3 group * assessment 2] = bintercept + bAssessment2  + b≥3 months + binteraction 
• QoL1 [≥ than 3 group * assessment 2] = 100.34 + 7.55 + 0 + 0 
• QoL1 [≥ than 3 group * assessment 2] =  107.89 
 
• QoL2 [≥ than 3 group * endpoint] = bintercept + bEndpoint  + b≥3 months + binteraction 
• QoL2 [≥ than 3 group * endpoint] = 100.34 + 0 + 0 + 0  
• QoL2 [≥ than 3 group * endpoint] =  100.34 
 
• QoL1-2 = 107.89 – 100.34 = 7.55, meaning that QoL scores for those who finished treatment ≥ 3 










• QoL3 [< than 3 group * assessment 1] = bintercept + bAssessment1  + b<3 months + binteraction 
• QoL3 [< than 3 group * assessment 1] = 100.34 - 8.69 + 7.06 + 5.04 
• QoL3 [< than 3 group * assessment 1] =  103.75 
 
• QoL4 [≥ than 3 group * assessment 1] = bintercept + bAssessment1 + b≥3 months + binteraction 
• QoL4 [≥ than 3 group * assessment 1] = 100.34 - 8.69 + 0 + 0  
• QoL4 [≥ than 3 group * assessment 1] =  91.65 
 
• QoL4-3 = 103.75 – 91.65 = -12.1, meaning that QoL scores at assessment 1 were 12.1 points lower 
for those who finished treatment ≥ 3 months before study onset when compared to those who 
finished treatment < 3 months before study onset.  
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Table 4.4.  
Mean Difference of QoL scores for each group of Months after Treatment between Timepoints  
(n=24).  
Moths After Treatment Mean 
Difference 
< 3 months  Baseline Assessment 1 -9.00 
Assessment 2 -10.43* 
Endpoint -12.65* 
Assessment 1 Baseline 9.00 
Assessment 2 -1.43 
Endpoint -3.65 
Assessment 2 Baseline 10.43 
Assessment 1 1.43 
Endpoint -2.21 
Endpoint Baseline 12.65* 
Assessment 1 3.65 
Assessment 2 2.21 
≥ 3 months Baseline Assessment 1 -0.97 
Assessment 2 -17.22* 
Endpoint -9.67 
Assessment 1 Baseline 0.97 
Assessment 2 -16.25* 
Endpoint -8.69 
Assessment 2 Baseline 17.22 
Assessment 1 16.25* 
Endpoint 7.55 
Endpoint  Baseline 9.67* 
Assessment 1 8.69 
Assessment 2 -7.55 
*. The mean difference is significant at the .05 level (paired t-test).  
 
Important differences in QoL scores for each group of Months after Treatment between 
Timepoints were found (Table 4.4 above). As shown in Table 4.4, for those who finished 
treatment < 3 months after study onset, QoL scores at baseline were significantly lower (12.65 
points) in comparison to endpoint (p=0.003), showing improvement of this construct. Similarly, 
for those who finished treatment ≥ 3 months after study onset, QoL scores at endpoint were 
significantly higher (9.67 points) in comparison to baseline (p=0.011) (Table 4.4). For this same 
group, QoL scores at baseline and assessment 1 were significantly lower (17.22 points and 16.25 
points, respectively) in comparison to assessment 2 (p<0.000) (Table 4.4).  
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Table 4.5.  
Mean Difference of QoL scores at each Timepoint for each level of Months After Treatment  
(n=24). 
Timepoints   
Mean 
Difference  
Baseline < 3 months ≥ 3 months 4.07 
 ≥ 3 months < 3 months -4.07 
Assessment 1 < 3 months ≥ 3 months 12.11 
 ≥ 3 months < 3 months -12.11 
Assessment 2 < 3 months ≥ 3 months -2.70 
 ≥ 3 months < 3 months 2.70 
Endpoint < 3 months ≥ 3 months 7.06 
 ≥ 3 months < 3 months -7.06 
   
 
Table 4.5 shows that, overall, those who finished treatment ≥ 3 months after study onset 
showed lower QoL (except at assessment 2), with no significant differences at timepoints. For 
instance, at assessment 1, a mean difference of 12.11 was found between groups, but this 
difference was not statistically significant (p=0.090) (Table 4.5).   
 
QoL and Cancer Stage 
 
Table 4.6 shows that Time had a significant effect on QoL [F=(3, 63.000)=11.337, 
p<0.0001], but main effect of Cancer Stage did not significantly affect QoL [F=(1, 21)=.242, 
p=0.787]. Main effect of the interaction Time * Cancer Stage was found to be not significant 
(Table 4.6), but the Estimates of Fixed Effects yielded significant interaction terms between these 
variables’ categories (Table 4.7).  
 
Table 4.6. 
Type II tests of Fixed Effects Results for QoL Model 2 (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 21 958.87 .000 
Time 3 63 11.33 .000 
Cancer Stage 2 21 .242 .787 
Interaction Time * Cancer Stage  6 63 1.53 .180 




Estimates of Fixed Effects Results for QoL Model 2 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 104.85 6.56 91.66 15.96 .000 9147 118.24 
Time        
Baseline -15.37 4.71 63.00 -3.26 .002 -24.79 -5.95 
Assessment 1 -2.91 4.71 63.00 -.618 .539 -12.33 6.50 
Assessment 2 -3.8 4.71 63.00 -.813 .419 -13.25 5.59 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Cancer Stage        
Stage I 2.73 8.56 31.66 .677 .751 -14.71 20.18 
Stage II -6.26 9.28 31.66 1.209 .505 -25.19 12.66 
Stage III(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Interactions (b)        
Assessment 2 * Stage II 14.35 6.66 63.00 2.15 .035 1.03 27.68 
Endpoint * Stage III -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
 
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
 
Estimates of fixed effects displayed in Table 4.7, shows a significant interaction term 
between Assessment 2 * Stage II (b=14.35, t=2.15, p=0.035, CI 95%: 1.03, 27.68) indicating that 
stage II patients showed significantly higher QoL (14.35 points) than stage III patients at 
assessment 2 in comparison to endpoint. This interaction term is graphically shown in Figure 4.9. 
To further assess this interaction, mean difference calculations (i.e. pairwise) were performed 
(Tables 4.8 and 4.9). Calculations were performed following the same procedures described on 
page 86. Table 4.8 presents the differences in QoL scores for each group of Cancer Stage 
between Timepoints. Similarly, Table 4.9 shows that QoL scores were different at each 
Timepoint for each level of the Cancer Stage variable. In addition to these calculations, a paired 








Table 4.8.  
Mean Difference of QoL scores for each group of Cancer Stage between Timepoints (n=24).  
Cancer Stage Mean 
Difference 
Stage I   Baseline Assessment 1 -3.17 
Assessment 2 -11.95* 
Endpoint -11.21* 
Assessment 1 Baseline 3.17 
Assessment 2 -8.78 
Endpoint -8.04 
Assessment 2 Baseline 11.95* 
Assessment 1 8.78 
Endpoint 0.74 
Endpoint Baseline 11.21 
Assessment 1 8.04 
Assessment 2 -0.74 
Stage II Baseline Assessment 1 -1.26 
Assessment 2 -17.83* 
Endpoint -7.31 
Assessment 1 Baseline 1.26 
Assessment 2 -16.57* 
Endpoint -6.05 
Assessment 2 Baseline 17.83* 
Assessment 1 16.57* 
Endpoint 10.52 
Endpoint  Baseline 7.31 
Assessment 1 6.05 
Assessment 2 -10.52 
Stage III Baseline Assessment 1 -12.46 
Assessment 2 -11.54* 
Endpoint -15.37* 
Assessment 1 Baseline 12.46 
Assessment 2 0.92 
Endpoint -2.91 
Assessment 2 Baseline 11.54* 
Assessment 1 -0.92 
Endpoint -3.83 
Endpoint  Baseline 15.37* 
Assessment 1 2.91 
Assessment 2 3.83 
*. The mean difference is significant at the .05 level (paired t-test).  
 
  Important differences in QoL scores for each group of Cancer Stage between Timepoints 
were found (Table 4.8 above). As shown in Table 4.8, for Stage I and II patients, QoL scores at 
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baseline were significantly lower (11.95 and 17.83 points, respectively) in comparison to 
assessment 2 (p<0.000, for both). Also, for Stage III patients, QoL scores at baseline were 
significantly lower (15.37 points) in comparison to endpoint (p=0.006). 
 
Table 4.9.  
Mean Difference of QoL at each Timepoint for each level of Cancer Stage (n=24). 
Timepoints   
Mean 
Difference  
Baseline Stage I Stage II  5.10 
  Stage III  6.90 
 Stage II Stage I  -5.10 
  Stage III  1.80 
 Stage III Stage I  -6.90 
  Stage II -1.80 
Assessment 1 Stage I Stage II  7.00 
  Stage III  -2.39 
 Stage II Stage I  -7.00 
  Stage III  -9.40 
 Stage III Stage I  2.39 
  Stage II  9.40 
Assessment 2 Stage I Stage II -0.78 
  Stage III  7.31 
 Stage II Stage I  0.78 
  Stage III  8.10 
 Stage III Stage I  -7.31 
  Stage II -8.10 
Endpoint Stage I Stage II  9.00 
  Stage III 2.74 
 Stage II Stage I  -9.00 
  Stage III  -6.26 
 Stage III Stage I  -2.74 
  Stage II  6.26 
   
 
As shown in Table 4.9, overall, Stage III patients showed the lowest levels of QoL 
throughout the study (except at assessment 1), with no significant differences between stage 
groups at timepoints.   
 
QoL and other covariates  
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The inclusion of the other covariates (i.e. age of the participants, hormone use, presence 
of comorbidity, sleep aids use and treatment type) did not yield any statistically significant results 
in any of linear models tested. The trajectory of the QoL scores according to each independent 
variable throughout the 8-week MT program can be found in Figure 4.2 and in Appendix P, 
Table A.1 with descriptive statistics of QoL mean scores by each covariate at all timepoints. 
 
Summary of QoL results 
 
In summary, QoL increased after the 8-week MT program, with Time showing a 
significant effect on QoL. From all the covariates tested, only Cancer Stage and Months After 
Treatment showed significant interactions with Time. These interactions were broken down by 
conducting separate pairwise calculations for each level of Cancer Stage and Months After 
Treatment categories. Pairwise comparisons of interest were followed up with a paired-sample t-
test. Results showed that QoL scores changed significantly between study timepoints for each 
category of Cancer Stage independently. In addition, Stage III patients showed the lowest levels 
of QoL throughout the study (except at assessment 1), with no significant differences at 
timepoints. Similarly, QoL scores changed significantly between study timepoints for each 
category of Months After Treatment independently. In addition, those who finished treatment ≥ 3 
months before study onset showed lower QoL (except at assessment 2), with no significant 
differences at timepoints. In conclusion, QoL significantly improved after the 8-week MT 
program, regardless of the age of the participants, hormone use, presence of comorbidity, sleep 












Changes in QoL scores by each independent variable (n=24).  
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4.3.2  Fatigue  
 
 
The trajectory of fatigue scores throughout the 8-week MT program is depicted in Figure 
4.3. Fatigue scores measured with FACT-F questionnaire ranges from 0-52. Interpretation assumes 








According to Figure 4.3, patients improved their fatigue at the end of the 8-week MT 
program. Participants were more fatigued at baseline (mean=28) and progressively showed 
improvement of this construct over time, reaching the lowest levels of fatigue assessment 2 
(mean=35.8) and endpoint (mean=35.7). Among the study covariates tested in the LMM, only 
two covariates (i.e. Sleep Aids and Comorbidities) yielded statistically significant (or marginal 







Fatigue and Sleep Aids     
 
Table 4.10. 
Type II tests of Fixed Effects Results for fatigue Model 1 (n=24). 
 Source Num df Den 
df 
F Sig. 
Intercept 1 22 361.41 .000 
Time 3 66.00 15.65 .000 
Sleep Aids 1 22 .249 .623 
Interaction Time * Sleep Aids  3 66.00 2.96 .038 
AIC:591.69; BIC: 596.56 
 
Table 4.10 shows that Time had a significant effect on fatigue levels [F=(3, 
66.000)=15.605, p<0.0001], but main effect of Sleep Aids did not significantly affect fatigue 
[F=(1, 22)=0.246, p=0.623]. However, an interaction was found between Time and Sleep Aids in 
use [F=(3, 66.000)=2.961, p=0.038]. 
 
Table 4.11. 
Estimates of Fixed Effects Results for fatigue Model 1 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 29.44 2.85 30.36 10.29 .000 23.61 35.28 
Time        
Baseline 5.40 1.82 66.00 2.95 .004 1.74 9.05 
Assessment 1 3.54 1.82 66.00 1.93 .057 -.10 7.19 
Assessment 2 5.59 1.82 66.00 3.06 .003 1.94 9.25 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Sleep Aids        
on meds -1.29 3.88 30.36 -.33 .742 -9.22 6.63 
off meds (a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Interactions(b)         
      Assessment 2 * on sleep aids 7.14 2.48 66.00 .767 .005 2.18 12.10 
      Endpoint * on sleep aids (a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
        
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
Estimates of fixed effects results displayed in Table 4.11, shows a significant interaction 
term between Assessment 2 * Sleep Aids/On (b=7.14, t=2.87, p=0.005, CI 95%: 2.18, 12.10), 
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indicating that those on meds showed significantly higher fatigue scores (less fatigue) (7.14 
points) when compared to those who were off meds at assessment 2 when compared to endpoint. 
This interaction is graphically displayed in Figure 4.4. To further assess the interaction term, 
pairwise calculations based on estimated means were performed following the same procedures 
described on page 86. 
Tables 4.12 and 4.13 show all pairwise calculations based on estimated means. Table 4.12 
presents the differences in fatigue scores for each group of Sleep Aids between Timepoints. 
Similarly, Table 4.13 shows that fatigue scores were different at each Timepoint for each level of 
the Sleep Aids variable. In addition to these calculations, a paired sample t-test was run to 
analyse if selected pairwise comparisons of interest were statistically significant.  
 
Table 4.12.  
Mean Difference of fatigue scores for each group of Sleep Aids between Timepoints (n=24).  
Sleep Aids Mean 
Difference 
On Sleep Aids Baseline Assessment 1 -7.30 
Assessment 2 -10.69* 
Endpoint -8.84* 
Assessment 1 Baseline 7.30 
Assessment 2 -3.38 
Endpoint -1.54 
Assessment 2 Baseline 10.69* 
Assessment 1 3.38 
Endpoint 1.85 
Endpoint Baseline 8.84* 
Assessment 1 1.54 
Assessment 2 -1.85 
Off Sleep Aids Baseline Assessment 1 -5.40 
Assessment 2 -3.55 
Endpoint -5.59* 
Assessment 1 Baseline 5.40 
Assessment 2 1.86 
Endpoint -0.20 
Assessment 2 Baseline 3.55 
Assessment 1 -1.86 
Endpoint -2.05 
Endpoint  Baseline 5.59* 
Assessment 1 0.20 
Assessment 2 2.05 
*. The mean difference is significant at the .05 level (paired t-test).  
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             As shown in Table 4.12, fatigue scores for those on sleep aids were higher at assessment 
2 and endpoint (10.69 and 8.84 points, respectively) in comparison to baseline (p<0.0001, for 
both). Additionally, fatigue scores for those off sleep aids, were significantly higher at endpoint 
(less fatigue) in comparison to baseline (5.59 points) (p=0.003). 
 
Table 4.13.  
Mean Difference of fatigue scores at each Timepoint for each level of Sleep Aids (n=24). 
Timepoints   
Mean 
Difference  
Baseline On Sleep Aids Off Sleep Aids -1.29 
 Off Sleep Aids On Sleep Aids 1.29 
Assessment 1 On Sleep Aids Off Sleep Aids 0.61 
 Off Sleep Aids On Sleep Aids -0.61 
Assessment 2 On Sleep Aids Off Sleep Aids 5.85 
 Off Sleep Aids On Sleep Aids -5.85 
Endpoint On Sleep Aids Off Sleep Aids 1.95 
 Off Sleep Aids On Sleep Aids -1.95 
   
 
As shown in Table 4.13, overall, patients on sleep aids showed higher fatigue scores (less 
fatigue) in comparison to patients off sleep aids. For instance, at assessment 2, there was a non-
significant difference of 5.85 points in fatigue scores between patients who were on and off sleep 
aids, with those on sleep aids showing higher fatigue scores (less fatigue).  
 
 Fatigue and Comorbidity  
 
Table 4.14. 
Type II tests of Fixed Effects Results for fatigue Model 2 (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 22.00 350.90 .000 
Time 3 66.00 16.59 .000 
Comorbidities 1 22.00 .013 .911 
Interaction Time * Comorbidities  3 66.00 2.39 .076 
  AIC:593.26; BIC: 598.22 
 
Table 4.14 shows that Time had a significant effect on Fatigue levels [F=(3, 
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66.000)=16.697, p<0.0001], but main effect of Comorbidity did not significantly affect fatigue 
[F=(1, 22)=.013, p=0.911]. In addition, a marginal statistically significant main interaction was 
found between Time and Comorbidity [F=(3, 66.000)=2.397, p=0.076] (Table 4.14). 
 
Table 4.15. 
Estimates of Fixed Effects Results for fatigue Model 2 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 36.43 3.01 30.47 12.07 .000 30.27 42.59 
Time         
Baseline -9.04 1.94 66.00 -4.66 .000 -12.91 -5.16 
Assessment 1(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Assessment 2 -2.17 1.94 66.00 11.12 .266 -6.04 1.69 
Endpoint .71 1.94 66.00 .369 .713 -3.15 4.59 
Comorbidity        
Yes -2.14 3.95 30.47 1.76 .591 -10.21 5.91 
No(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Interactions (b)        
Assessment 2 * Yes 5.41 2.54 66.00 2.13 .037 0.34 10.48 
Assessment 1 * No -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
 
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
Estimates of fixed effects results displayed in Table 4.15, shows a significant interaction 
term between Assessment 2 * Comorbidity/Yes (b=5.41, t=2.13, p=0.037, CI 95%: 0.34, 10.48), 
indicating that those who had a comorbidity showed significantly higher fatigue scores (less 
fatigue) (5.41 points) when compared to those who did not have a comorbidity at assessment 2 
when compared to assessment 1. This interaction is graphically displayed in Figure 4.4. To 
further assess the interaction term, pairwise calculations based on estimated means were 
performed following the same procedures described on page 86. 
Tables 4.16 and 4.17 (next page) show all pairwise calculations based on estimated 
means. Hence, Table 4.16 presents the differences in fatigue scores for each group of 
Comorbidities between Timepoints. Similarly, Table 4.17 shows that fatigue scores were 
different at each Timepoint for each level of the Comorbidities variable. In addition to these 
calculations, a paired sample t-test was run to analyse if selected pairwise comparisons of interest 
were statistically significant.  
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Table 4.16.  
Mean Difference of fatigue scores for each group of Comorbidities between Timepoints (n=24).  
Comorbidities Mean Difference 
Yes  Baseline Assessment 1 -4.57 
Assessment 2 -7.81* 
Endpoint -5.64* 
Assessment 1 Baseline 4.57 
Assessment 2 -3.24 
Endpoint -1.07 
Assessment 2 Baseline 7.81* 
Assessment 1 3.24 
Endpoint 2.17 
Endpoint Baseline 5.64* 
Assessment 1 1.07 
Assessment 2 -2.17 
No Baseline Assessment 1 -9.04* 
Assessment 2 -6.86* 
Endpoint -9.75* 
Assessment 1 Baseline 9.04* 
Assessment 2 2.18 
Endpoint -0.72 
Assessment 2 Baseline 6.86* 
Assessment 1 -2.18 
Endpoint -2.89 
Endpoint  Baseline 9.75* 
Assessment 1 0.72 
Assessment 2 2.89 
*. The mean difference is significant at the .05 level (paired t-test).  
 
As shown in Table 4.16, for both comorbidity groups (Yes and No), a significant increase 
in fatigue score (less fatigue) was detected at endpoint in comparison to baseline (5.64 and 9.75, 
respectively). For instance, for both groups of commodities, a significant difference in fatigue 
was found between baseline and assessment 2, with both groups (Yes and No) reporting 
significant higher fatigue scores (better fatigue) at assessment 2 in comparison to baseline (7.81 
and 6.86 points higher, respectively) (p<0.0001, for both). Similarly, at endpoint, both groups 
(Yes and No) reported significant higher fatigue scores (less fatigue) in comparison to baseline 




Table 4.17.  
Mean Difference of fatigue scores at each Timepoint for each level of Comorbidities (n=24). 
Timepoints   
Mean 
Difference  
Baseline yes no 2.32 
 no yes -2.32 
Assessment 1 yes no -2.15 
 no yes 2.15 
Assessment 2 yes no 3.27 
 no yes -3.27 
Endpoint yes no -1.79 
 no yes 1.79 
   
 As shown in Table 4.17, overall, those who presented comorbidities showed slightly 
higher fatigue scores (less fatigue) in comparison to those who did not present any comorbidities. 
However, no statistically significant differences were found.  
 
Fatigue and other covariates  
 
The inclusion of the other covariates (i.e. age of the participants, hormone use, months 
after treatment, cancer stage and treatment type) did not yield any statistically significant results 
in any of linear models tested. The trajectory of the fatigue scores according to each independent 
variable throughout the 8-week MT program can be found in Figure 4.4 and in Appendix P Table 
A.2 with descriptive statistics of fatigue mean scores by each covariate at all timepoints.  
 
Summary of fatigue results  
 
In summary, fatigue improved after the 8-week MT program, with Time showing a 
significant effect on fatigue. From all the covariates tested, only Comorbidity and Sleep Aids 
showed significant interactions with Time. These interactions were broken down by conducting 
separate pairwise calculations for each level of Comorbidity and Sleep Aids use categories. 
Pairwise comparisons of interest were followed up with a paired-sample t-test. Results showed 
that fatigue scores changed significantly between study timepoints for each category of Sleep 
Aids independently. In addition, patients on sleep aids showed higher scores (less fatigue) in 
comparison to patients off sleep aids. However, no statistically significant differences were found. 
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Similarly, fatigue scores changed significantly between study timepoints for each category of 
Comorbidity independently. In addition, those who presented comorbidities showed slightly 
higher fatigue scores (less fatigue) in comparison to those who did not present any comorbidities. 
However, no statistically significant differences were found. In conclusion, fatigue significantly 
improved after the 8-week MT program, regardless of the age of the participants, hormone use, 
cancer stage, months after treatment, and treatment type.  
 
Figure 4.4. 












4.3.3  Stress  
 
 
The trajectory of stress scores throughout the 8-week MT program is depicted in Figure 4.5 
(next page). Stress scores measured with PSS questionnaire ranges from 0-40. Interpretation 









Figure 4.5.  
Changes in stress scores at each timepoint (n=24). 
 
 
 According to Figure 4.5, patients were more stressed at baseline (mean=20.9) and 
progressively showed improvement of this construct over time, reaching the lowest levels of stress 
at endpoint (mean=17.4). Among the study covariates tested in the LMM, only one (i.e. Cancer 
Treatment Type) yielded a statistically significant estimates of fixed effect in the stress models, 
with no significant interaction terms, as described below.  
 
Stress and Treatment Type 
 
Table 4.18.  
Type II tests of Fixed Effects Results for stress (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 21.00 157.90 .000 
Time 3 69.00 3.58 .018 
Cancer Treatment Type   2  21.00 2.39 .116 
AIC:569.98; BIC: 574.98 
 
Based on Table 4.18, Time had a significant effect on stress levels [F=(3, 69.000)=3.584, 
p=0.018], but main effect of Cancer Treatment did not  [F=(2, 21.000)=2.392, p=0.116]. 
However, the variable Cancer Treatment was kept in the model since it showed significant 
estimates of fixed effects (Table 4.19). 
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Table 4.19.  
Estimates of Fixed Effects Results for stress (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 25.38 4.03 22.35 6.29 .000 17.02 33.74 
Time        
Baseline 3.33 1.15 69.00 2.87 .005 1.02 5.64 
Assessment 1 .33 1.15 69.00 .28 .775 -1.97 2.64 
Assessment 2 .41 1.15 69.00 .35 .720 -1.89 2.72 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Treatment Classification        
      Unimodal therapy -7.75 3.61 21.00 -2.14 .044 -15.25 -0.24 
      Multimodal = 2 therapies  -6.90 3.57 21.00 1.93 .067 -14.33 0.52 
Multimodal > 2 therapies(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
 
According to Table 4.19, Stress improved by 3.33 points at endpoint, a significant 
difference (b=-3.33, t=2.87, p=0.005, CI 95%: 1.02, 5.64). 
In addition, those who went through unimodal treatment reported less stress (7.75 points) 
than those who underwent multimodal treatment with only two therapies, a significant difference 
(b=-7.75, t=-2.14, p=0.044, CI 95%: -15.24, -0.24) (Table 4.19). Figure 4.6 (next page) depicts 
this difference in stress level reported by those who went through multimodal treatment and those 
who went through unimodal treatment. Similarly, those who went through unimodal treatment 
reported less stress (6.9 points) than those who went through multimodal treatment with more 
than two therapies, reaching only a marginal significant difference (b=-6.90, t=-1.93, p=0.067, CI 
95%: -14.33, 0.52). 
 
Stress and other covariates 
  
The inclusion of the other covariates (i.e. age of the participants, hormone use, cancer 
stage, comorbidity, months after treatment, and sleep aids in use) did not yield any statistically 
significant results in any of linear models tested. The trajectory of the stress scores according to 
each independent variable throughout the 8-week MT program can be found in Figure 4.6 and in 
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Appendix P, Table A.3 with descriptive statistics of stress mean scores by each covariate at all 
timepoints. 
 
Summary of stress results 
 
In summary, stress significantly improved after the 8-week MT program, regardless of the 
age of the participants, hormone use, cancer stage, comorbidity, months after treatment, and sleep 
aids in use. Treatment type had an effect on stress, with those who went through unimodal 
treatment reporting significant less stress than those who underwent multimodal treatment with 













4.3.4  Sleep Duration  
 
 
The trajectory of SD throughout the 8-week MT program is depicted in Figure 4.7. SD 
was measured with Actigraphy and are represented in minutes. Interpretation assumes that higher 
numbers indicate longer SD.  
According to Figure 4.7, SD did not improve over time, with patients showing the 
shortest SD at assessment 1 (mean=255.5 min.) and reaching the longest SD at assessment 2 
(mean=357.2 min.). Among the study covariates tested in the LMM, none yielded statistically 
significant main effects and/or interaction terms in the SD models. The final model for SD is 




Figure 4.7.  
 





Sleep Duration and Time   
 
Table 4.20. 
Type II tests of Fixed Effects Results for SD (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 22.77 327.01 .000 
Time  3 66.59 7.75 .000 
AIC: 1079.48; BIC: 1074.46 
 
 











Estimates of Fixed Effects Results for SD model (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 275.45 22.03 57.95 12.50 .000 231.35 319.56 
Time        
Baseline 46.55 23.23 67.05 2.00 .049 .17 92.92 
Assessment 1 -22.52 23.37 66.13 -.964 .339 -69.18 24.13 
Assessment 2 79.74 23.37 66.13 3.41 .001 33.08 126.40 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
 
No significant improvement of sleep duration was detected after the 8-week MT program. 
Table 4.21 shows that, on average, patients at baseline showed higher sleep duration (46.5 
minutes) in comparison to endpoint (b=46.55, t=2.00, p=0.0049, CI 95%: 0.17, 92.92). 
Additionally, patients at assessment 2 reported higher sleep duration (79.7 minutes) in 
comparison to endpoint, a statistically significant difference (b=79.74, t=3.41, p=0.0001, CI 95%: 
33.08, 126.40) (Table 4.21). After changing reference category, it was also revealed that at 
assessment 1, patients reported significant lower sleep duration in comparison to baseline (b=-
69.07, t=-2.97, p=0.004, CI 95%:-115.45, -22.70), and in comparison to assessment 2 (b=-
102.28, t=-4.37, p<0.001, CI 95%: -148.92, 55.61) (Table 4.21, Figure 4.7). 
 
SD and other covariates  
 
The inclusion of the other covariates (i.e. age of the participants, hormone use, presence 
of comorbidities, sleep aids use, months after treatment, cancer stage and treatment type) did not 
yield any statistically significant results in any of linear models tested. The trajectory of the SD 
according to each independent variable throughout the 8-week MT program can be found in 
Figure 4.8 and in Appendix P, Table A.4 with descriptive statistics of mean SD by each covariate 





Summary of SD results  
 
In summary, SD did not improve after the 8-week MT program. From all the covariates 
tested (i.e. age of the participants, hormone use, comorbidities, sleep aids use, months after 
treatment, cancer stage and treatment type), none showed any significant effects on SD or 
interactions.   
 
Figure 4.8. 











4.3.5  Sleep Efficiency 
 
 
The trajectory of SE throughout the 8-week MT program is depicted in Figure 4.9. SE 
results measured with Actigraphy are represented in percentages and varies from 0-100%. 















As depicted in Figure 4.9, SE slightly improved after the 8-week MT program. A RM-
ANOVA showed that changes in SE did not reach statistical significance [F (1.85, 57) = 2.832, 
p=0.076]), therefore, the main effect of Time did not show any significant difference in SE at the 
different timepoints. Patients showed the lowest SE at assessment 2 (mean=91.2), reaching the 
highest SE at assessment 1 (mean=93.9).  
 
SE and other covariates  
 
No statistically significant interactions were found between SE and the between-subject 
factors age, sleep aids use, stage, cancer treatment, presence of comorbidity, months after 
treatment and hormone therapy. The trajectory of the SE according to each independent variable 
throughout the 8-week MT program can be found in Figure 4.10 and in Appendix P, Table A.5 
with descriptive statistics of mean SE by each covariate at all timepoints. 
 
Summary of SE results  
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In conclusion, our findings suggest an improvement trend in SE during the MT program. 
SE improved regardless of the age of participant, cancer stage, treatment type, months after 
treatment, hormone use, sleep aids in use, and presence of comorbidities.  
 
Figure 4.10. 



















4.3.6  Sleep Onset Latency  
 
The trajectory of the SOL throughout the 8-week MT program is depicted in Figure 4.11. 
SOL was measured with actigraphy and is denoted in minutes. SOL represents how long it takes 
to fall asleep. It is the length of time that it takes to accomplish the transition from full 
wakefulness to sleep. Along with WASO, SOL is the most used parameter in the assessment of 
insomnia, however, there is a lack of quantitative criteria and cut-off points for sleep quality 
assessment using actigraphy in several population types (Natale, Plazzi, & Martoni, 2009). 
Hence, the interpretation of SOL has to take into consideration a range of factors. For example, if 
it takes too fast for someone to fall asleep it can indicate a sleep debt, whereas, if it takes too long 
for someone to fall asleep it can indicate insomnia. Based on published literature (Blytt, Bjorvatn, 
Husebo, & Flo, 2017; Carskadon, 1986), the following SOL cut-off points were used in this 
study:   
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SOL (in min.) INTERPRETATION 
0 to 5 minutes severe sleep deprivation 
5 to 10 minutes is troublesome 
10 to 15 minutes mild but manageable degree 
of sleep debt 
15 to 30 minutes little or no sleep debt 
≥ 30 might indicate insomnia 
 
 
Figure 4.11.  
 





According to Figure 4.11 (previous page), patients showed the lowest SOL values at 
assessment 1 (mean=2.0), reaching the highest values at assessment 2 (mean=4.6 minutes). The 
trajectory of this measure shows that there was a slight trend towards SOL improvement over 
time, however, based on the overall mean (mean=3.6 minutes), patients in our study showed low 
SOL values, which is suggestive of sleep debt. Among the study covariates included in the LMM, 
only one (i.e. Cancer Stage) yielded statistically significant main effects and/or interaction terms 








Type II tests of Fixed Effects Results for SOL (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 20.565 464.81 .000 
Time 3 61.044 4.60 .006 
Cancer Stage 2 20.583 .130 .879 
Interaction Time * Cancer Stage  6 61.068 2.86 .016 
AIC: 336.71; BIC: 341.50 
 
Table 4.22 shows that Time had a significant effect on SOL [F=(3, 57.891)=5.398, 
p=0.002], but no significant effect of cancer stage on SOL was found. The interaction term 
Time*Cancer Stage was also found to be significant [F=(3, 61.068)=2.861, p=.0016] (Table 
4.23), indicating that there are significant differences in SOL duration between stage groups at 
one or more levels of time point. 
 
Table 4.23.  
Estimates of Fixed Effects Results for SOL (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 4.76 61.32 80.95 7.7 .000 3.54 5.98 
Time         
Baseline -2.40 .86 60.82 -2.79 .007 -4.13 -.68 
Assessment 1 -1.33 .86 60.82 -1.54 .128 -3.05 .39 
Assessment 2 -.19 .86 60.82 -.22 .826 -1.91 1.53 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Cancer Stage        
Stage I -.73 .81 80.96 -.89 .372 -2.36 .89 
Stage II -.77 .81 80.95 .70 .373 -2.50 .94 
Stage III(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Interactions (b)        
Baseline x Stage I 3.15 1.13 61.51 2.77 .007 0.88 5.42 
Endpoint x Stage III -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
 
a. Reference category. 




Estimates of fixed effects results displayed in Table 4.23, shows a significant interaction 
term between Baseline x Stage I (b=3.15, t=2.77, p=0.007, CI 95%: 0.88, 5.42), meaning that, at 
baseline, stage I patients showed significantly higher SOL duration (3.15 minutes) when 
compared to stage III patients at endpoint. This interaction is graphically displayed in Figure 
4.12. 
To further assess the interaction term, mean difference calculations based on estimated 
means were performed (as shown on page 86). Hence, Table 4.24 (next page) presents the 
differences in SOL for each group of Cancer Stage between Timepoints. Similarly, Table 4.25 
(page 118) differences in SOL at each Timepoint for each level of the Cancer Stage. In addition 
to these calculations, a paired sample t-test was run to analyse if selected pairwise comparisons of 
interest were significant.  
  Table 4.24 (next page) shows that for Stage I patients, SOL at assessment 1 was 
significantly higher (2.08 minutes) in comparison to baseline (p=0.007). For Stage III patients, 
SOL at endpoint was significantly higher (2.40 minutes) in comparison to baseline (p=0.007) 
(Table 4.24). 
In addition, according to Table 4.25 (nex page), only at baseline significant differences 
between stages were found. At baseline, stage I patients showed significantly higher SOL in 
comparison to Stage II (2.34 minutes; p=0.004) and Stage III (2.42 minutes; p=0.003). All these 














Table 4.24.  
Mean Difference of SOL for each group of Cancer Stage between Timepoints (n=24).  
Cancer Stage Mean 
Difference 
Stage I   Baseline Assessment 1 2.08* 
Assessment 2 1.07 
Endpoint 0.75 
Assessment 1 Baseline -2.08* 
Assessment 2 -1.01 
Endpoint -1.33 
Assessment 2 Baseline -1.07 
Assessment 1 1.01 
Endpoint -0.32 
Endpoint Baseline -0.75 
Assessment 1 1.33 
Assessment 2 0.32 
Stage II Baseline Assessment 1 -0.52 
Assessment 2 -2.61 
Endpoint -1.55 
Assessment 1 Baseline 0.52 
Assessment 2 -2.09 
Endpoint -1.03 
Assessment 2 Baseline 2.61 
Assessment 1 2.09 
Endpoint 1.06 
Endpoint  Baseline 1.55 
Assessment 1 1.03 
Assessment 2 -1.06 
Stage III Baseline Assessment 1 -1.08 
Assessment 2 -2.21 
Endpoint -2.40* 
Assessment 1 Baseline 1.08 
Assessment 2 -1.14 
Endpoint -1.33 
Assessment 2 Baseline 2.21 
Assessment 1 1.14 
Endpoint -0.19 
Endpoint  Baseline 2.40* 
Assessment 1 1.33 
Assessment 2 0.19 





Table 4.25.  
Mean Difference of SOL at each Timepoint for each level of Cancer Stage (n=24). 
Timepoints   
Mean 
Difference  
Baseline Stage I Stage II  2.34* 
  Stage III  2.42* 
 Stage II Stage I  -2.34* 
  Stage III  0.07 
 Stage III Stage I  -2.42* 
  Stage II -0.07 
Assessment 1 Stage I Stage II  -0.25 
  Stage III  -0.73 
 Stage II Stage I  0.25 
  Stage III  -0.48 
 Stage III Stage I  0.73 
  Stage II  0.48 
Assessment 2 Stage I Stage II -1.33 
  Stage III  -0.86 
 Stage II Stage I  1.33 
  Stage III  0.47 
 Stage III Stage I  0.86 
  Stage II -0.47 
Endpoint Stage I Stage II  0.04 
  Stage III -0.73 
 Stage II Stage I  -0.04 
  Stage III  -0.77 
 Stage III Stage I  0.73 
  Stage II  0.77 
  *. The mean difference is significant at the .05 level (paired t-test).  
 
SOL and other covariates  
 
The inclusion of the other covariates (i.e. age of the participants, hormone use, 
comorbidities, sleep aids use, months after treatment and treatment type) did not yield any 
statistically significant results in any of linear models tested. The trajectory of the SOL according 
to each independent variable throughout the 8-week MT program can be found in Figure 4.12 and 





Summary of SOL results 
 
 In summary, SOL improved after the 8-week MT program, with Time showing a 
significant effect on SOL values. From all the covariates tested, only Cancer Stage showed 
significant interactions with Time. These interactions were broken down by conducting separate 
pairwise calculations for each level of Cancer Stage variable. Pairwise comparisons of interest 
were followed up with a paired-sample t-test. Results showed that SOL significantly changed 
between study timepoints for each category of Cancer Stage independently, with only Stage III 
patients showing significantly improved SOL at endpoint. In addition, only at baseline, Stage I 
patients showed significantly higher SOL in comparison to Stage II and Stage III. In conclusion, 
SOL statistically significantly improved after the 8-week MT program, regardless of the age of 
the participants, hormone use, sleep medications in use, months after treatment, comorbidities 
and treatment type.     
 
 Figure 4.12. 










Figure 4.12. (continued) 
 
 
4.3.7  WASO 
 
 
The trajectory of WASO readings throughout the 8-week MT program is depicted in 
Figure 4.13. WASO values measured with actigraphy are represented in minutes. WASO 
represents the minutes awake during the sleep period after sleep onset. Interpretation assumes 
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that higher numbers indicate worse sleep quality. Some authors state that a standard cut-off point 
for WASO measured with actigraphy is >30 minutes, which is suggestive of poor sleep quality 
(Blytt et al., 2017). 
 
Figure 4.13.  
 




According to Figure 4.13, patients showed the lowest WASO values at assessment 1 
(mean=20.7 minutes), reaching the highest values at assessment 2 (mean=39.8 minutes). Among 
the study covariates tested in the LMM, none yielded statistically significant main effects and/or 
interaction terms in the WASO models. The final LMM for WASO is described below. 
 
WASO and Time  
     
Table 4.26. 
Type II tests of Fixed Effects Results for QoL Model 2 (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 22.40 99.26 .000 
Time  3 66.29 7.06 .000 
AIC: 793.87; BIC: 798.84   
 
Table 4.26 shows that Time had a significant effect on sleep duration [F=(3, 
66.298)=7.064, p=.000].  
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Table 4.27.  
Estimates of Fixed Effects Results for WASO (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 27.42 4.33 61.79 6.32 .000 18.75 30.09 
Time        
Baseline 10.53 4.74 66.77 2.21 .030 1.05 20.01 
Assessment 1 -6.21 4.77 65.82 -1.30 .198 -15.75 3.32 
Assessment 2 12.85 4.77 65.82 2.68 .000 3.31 22.39 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
A significant improvement of WASO was detected after the 8-week MT program. Table 
4.27 shows that, on average, patients at baseline showed significantly higher WASO (10.53 
minutes) in comparison to endpoint (b=10.53, t=2.21, p=0.030, CI 95%: 1.05, 20.01). 
Additionally, patients at assessment 2 reported higher WASO (12.8 minutes) in comparison to 
endpoint, a statistically significant difference (b=12.85, t=2.69, p<0.0001, CI 95%: 3.31, 22.39) 
(Table 4. 27). After changing reference category, it was also revealed that at assessment 1, 
patients reported significant lower WASO in comparison to baseline (b=-16.74, t=-3.52, p=0.001, 
CI 95%: 7.26, 26.22), and in comparison to assessment 2 (b=-19.06, t=-1.30, p<0.0001, CI 95%: 
-28.61, -9.52) (Figure 4.14). 
 
WASO and other covariates  
 
The inclusion of the other covariates (i.e. age of the participants, hormone use, 
comorbidities, sleep aids, months after treatment, cancer stage and treatment type) did not yield 
any statistically significant results in any of linear models tested. The trajectory of WASO 
readings according to each independent variable throughout the 8-week MT program can be 
found in Figure 4.14 (next page) and in Appendix P, Table A.7 with descriptive statistics of 
WASO by each covariate at all timepoints. 
 
Summary of WASO results 
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In summary, WASO significantly improved after the 8-week MT program, with Time 
showing a significant effect on WASO values. Improvement was detected regardless of the age of 
the participants, hormone use, comorbidities, sleep aids use, months after treatment, cancer stage 
and treatment type.   
 
Figure 4.14.  














4.3.8 Summary of Findings from Research Question One  
 
 
• QoL, fatigue, stress, SOL and WASO showed improvements after the 8-week MT 
program.   
• QoL improvements were significantly associated with time after cancer treatment 
completion and cancer stage.  
• Changes in fatigue scores were significantly associated with sleep aids in use and 
comorbidities.  
• Stress levels significantly improved at endpoint in comparison to baseline, regardless of 
any covariates tested.  
• WASO significantly improved at endpoint in comparison to baseline, regardless of age, 
hormone use, comorbidities, sleep aids, months after treatment, cancer stage and 
treatment type. 
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• SOL changes were significantly associated with cancer stage.  
• SD did not improve after the 8-week MT program. 
• SE improved after the program, however, differences did not reach statistical 
significance.  
 
  4.4 Changes in Inflammatory Markers  
 
This subsection will address the findings of research question two: are there any changes 
in inflammatory markers in BCS submitted to an 8-week Swedish massage program? Below, a 
detailed description of the results is presented for each outcome.  
 
4.4.1  Cortisol 
 
 
Figure 4.15 shows the trajectory of cortisol levels at each timepoint during the MT 
program.  
 
Figure 4.15.  
 




Figure 4.15 shows that there was a drop in cortisol levels from baseline to assessment 1, 
followed by an increase at assessment 2. Overall, cortisol levels decreased from baseline to 
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endpoint, showing an improvement. Among the study covariates tested in the LMM, none 
yielded significant main effects and/or significant interaction terms in the cortisol models. The 
final model for cortisol is presented next.   
 
Cortisol and Time      
 
Table 4.28. 
Type II tests of Fixed Effects Results for cortisol (n=24). 
 Source Num df Den df F Sig. 
Intercept 1 22.063 625.197 .000 
Time  3 66.711 5.458 .002 
AIC:  2734.55; BIC: 2739.53   
 




Estimates of Fixed Effects Results for cortisol (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 2350956.98 217585.37 86.77 10.805 .000 1918466.71 2783447.24 
Time        
Baseline 48359.49 318273.74 66.99 1.519 .133 -151818.89 1118737.89 
Assessment 1 -780051.26 321965.23 66.42 -2.42 .018 -1422798.50 -137304.02 
Assessment 2 72710.12 321965.23 66.42 .226 .822 -570037.11 715457.36 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
 
Cortisol levels decreased after the 8-week MT program. Table 4.29 shows that, on 
average, patients at assessment 1 showed significant lower cortisol in comparison to endpoint 
(b=-780051.26, t=-2.42, p=0.018, CI 95%: -1422798.50, -137304.02). Noteworthy that tables 
with a change in the reference category of Time are not shown, however all the significant results 
are described next. Patients at assessment 1 reported lower cortisol levels in comparison to 
baseline (b=-12635.76, t=-3.96, p<0.0001, CI 95%: -1232778.70, -123354.05) and in comparison 
 109 
to assessment 2 (b=-852761.38, t=-2.64, p=0.010, CI 95%: -1782228.50, -130478.55). 
 
Cortisol and other covariates 
 
The inclusion of the other covariates (i.e. age of the participants, hormone use, 
comorbidities, sleep aids use, cancer stage, months after treatment and treatment type) did not 
yield any statistically significant results in any of linear models tested.  
 
Summary of cortisol results 
 
In summary, there was an overall improvement in cortisol levels after the 8-week MT 
program, however, cortisol changes from baseline to endpoint did not attain statistical 
significance. Significant improvements were seen in cortisol levels only in the middle of the MT 
program in comparison to endpoint. From all the covariates tested, none significantly affected 
cortisol levels or showed any interactions with Time. 
 
  
4.4.2   CRP 
 
 
 Figure 4.16 (next page) shows the trajectory of CRP levels at each timepoint during the MT 
program.  
As depicted in Figure 4.16 (next page), CRP slightly improved after the 8-week MT 
program. A RM-ANOVA showed, however, that changes in CRP did not reach statistical 
significance [F (3, 66) = 1.268, p=0.293]. Overall, patients at assessment 2 (mean=34362.63 








Figure 4.16.  
 




CRP and other covariates 
 
No statistically significant interactions were found between timepoints and the following 
variables: sleep aids, months after treatment, cancer stages, hormone therapy, treatment type, and 
age, and presence of comorbidities.     
 
Summary of CRP results 
 
In summary, CRP levels decreased at endpoint, however, no statistically significant 
differences were found between timepoints. CRP levels varied regardless of the age of participant, 
cancer stage, treatment type, months after treatment, hormone use, sleep aids in use, and presence 
of comorbidities.  
 
 
4.4.3  IL-1β 
 
  
Figure 4.17 (next page) shows the trajectory of IL-1β levels at each timepoint during the 
MT program. According to Figure 4.24, IL-1β levels decreased at the end of the MT program in 
 111 
comparison to baseline. Patients at endpoint (mean=32959.31 pg/mL) followed by patient at 
baseline (mean=35285.26 pg/mL) showed the lowest IL-1β levels. 
 
Figure 4.17.  
 
Changes in IL-1β levels at each timepoint (n=24). 
 
 
 Among the study covariates tested in the LMM, only two covariates (i.e. Cancer Stage and 
Hormone Therapy) yielded statistically significant main effects and/or significant interaction terms 
in the IL-1β models, which are described below.   
 





Type II tests of Fixed Effects Results for IL1-b (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 21.02 46.49 .000 
Time 3 60.41 2.16 .102 
Cancer Stage 2 21.04 .064 .938 
Interaction Time * Cancer Stage  6 60.42 2.35 .042 
 AIC: 1869.00; BIC: 1873.78  
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Table 4.30 shows that Time did not have a significant effect on IL1-b [F=(3, 
60.412)=2.162, p=0.102], neither had Cancer Stage [F=(1, 21.045)=0.64, p=0.938]. However, the 
interaction of Time and Stage had a significant effect on IL1-b [F=(6, 60.429)=2.353, p=0.042]. 
 
Table 4.31. 
Estimates of Fixed Effects Results for IL1-b  Model 1 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 23937.09 11089.75 31.91 2.15 .039 1345.72 4628.45 
Time        
Baseline(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Assessment 1 25614.28 8118.13 60.23 3.15 .003 9376.89 4185.67 
Assessment 2 24023.75 8118.13 60.23 2.95 .004 7786.36 40261.14 
Endpoint 4813.21 8118.13 60.23 .593 .555 -11424.17 21050.61 
Cancer Stage        
Stage I 15903.66 14459.27 31.91 1.10 .280 -13551.87 45359.20 
Stage II 14312.29 15683.28 31.91 .913 .368 -17636.72 46261.31 
Stage III -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Interactions (b)        
Assessment 1 x Stage I -33239.86 10792.40 60.79 -3.08 .003 -54822.05 11657.66 
Endpoint x Stage I -28546.78 10792.40 60.79 -2.64 .010 -50128.98 6964.59 
Endpoint x Stage II -27214.47 11480.76 60.23 -2.37 .021 -50177.61 4251.33 
Baseline x Stage III(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
        
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
 
Estimates of fixed effects results displayed in Table 4.31, show several significant 
interaction terms between Time and Cancer Stage (b=-33239.86, t=-3.08, p=0.003, CI 95%: -
54822.05, 11657.66; b=-28546.78, t=-2.64, p=0.010, CI 95%: -50128.98, 6964.59, and b=-
28546.78, t=-2.370, p=0.021, CI 95%: -50177.61, 4251.33), indicating that QoL varied 
differently at the different levels of Time and Cancer Stage. These interactions are graphically 







Changes in IL1-b levels by Cancer Stage (n=24). 
 
 
To further assess these interaction terms, pairwise calculations based on estimated means 
were performed following the same procedures described on page 86. Hence, Table 4.32 (next 
page) presents the differences in IL1-b for each group of Cancer Stage between Timepoints. 
Similarly, Table 4.33 (page 132) shows that IL1-b levels were different at each Timepoint for 
each level of the Cancer Stage variable. In addition to these calculations, a paired sample t-test 
was run to analyze if selected pairwise comparisons of interest were statistically significant. 
According to Table 4.32 (next page), only Stage III patients showed significant changes 
between timepoints. Hence, Stage III patients showed significantly lower IL1-b at endpoint in 
comparison to assessment 1 (mean=20801.06 pg/mL) and assessment 2 (mean=19210.53 pg/mL) 
(p=0.013). In comparison to baseline, this same stage group showed significantly higher levels of 
IL1-b at assessment 1 (25614.28 pg/dL higher), and assessment 2 (24023.75 pg/mL higher) 
(p=0.003 and p=0.004, respectively). No significant changes between baseline and endpoint were 
found for Stage III patients. In addition, no significant changes in Stage I and Stage II groups 







Table 4.32.  
Mean Difference of IL1-b levels for each group of Cancer Stage between Timepoints (n=24).  
Cancer Stage Mean 
Difference 
Stage I   Baseline Assessment 1 7625.58 
Assessment 2 4523.03 
Endpoint 8582.06 
Assessment 1 Baseline -7625.58 
Assessment 2 -3102.54 
Endpoint 956.49 
Assessment 2 Baseline -4523.03 
Assessment 1 3102.54 
Endpoint 4059.03 
Endpoint Baseline -8582.06 
Assessment 1 -956.49 
Assessment 2 -4059.03 
Stage II Baseline Assessment 1 -7640.61 
Assessment 2 3190.72 
Endpoint 744.44 
Assessment 1 Baseline 7640.61 
Assessment 2 10831.32 
Endpoint 8385.04 
Assessment 2 Baseline -3190.72 
Assessment 1 -10831.32 
Endpoint -2446.28 
Endpoint  Baseline -744.44 
Assessment 1 -8385.04 
Assessment 2 2446.28 
Stage III Baseline Assessment 1 -25614.28* 
Assessment 2 -24023.76 
Endpoint -4813.22 
Assessment 1 Baseline 25614.28* 
Assessment 2 1590.53 
Endpoint 20801.06* 
Assessment 2 Baseline 24023.76 
Assessment 1 -1590.53 
Endpoint 19210.53* 
Endpoint  Baseline 4813.22 
Assessment 1 -20801.06* 
Assessment 2 -19210.53* 





Table 4.33.  
Mean Difference of IL-b levels at each Timepoint for each level of Cancer Stage (n=24). 
Timepoints   
Mean 
Difference  
Baseline Stage I Stage II  1591.36 
  Stage III  15903.66 
 Stage II Stage I  -1591.36 
  Stage III  14312.30 
 Stage III Stage I  -15903.66 
  Stage II -14312.30 
Assessment 1 Stage I Stage II  -13674.82 
  Stage III  -17336.20 
 Stage II Stage I  13674.82 
  Stage III  -3661.38 
 Stage III Stage I  17336.20 
  Stage II  3661.38 
Assessment 2 Stage I Stage II 259.05 
  Stage III  -12643.13 
 Stage II Stage I  -259.05 
  Stage III  -12902.18 
 Stage III Stage I  12643.13 
  Stage II 12902.18 
Endpoint Stage I Stage II  -6246.26 
  Stage III 2508.38 
 Stage II Stage I  6246.26 
  Stage III  8754.64 
 Stage III Stage I  -2508.38 
  Stage II  -8754.64 
 
According to Table 4.33, no significant differences in IL1-b levels at each Timepoint for 
each level of Cancer Stage were found.   
 




Type II tests of Fixed Effects Results for IL-b Model 2 (n=24). 





Intercept 1 22.66 42.99 .000 
Time 3 64.01 2.34 .081 
Hormone Therapy 1 22.66 .56 .459 
Interaction Time * Hormone Therapy  3 64.01 2.83 .045 
  AIC: 1954.95; BIC: 1959.84 
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Table 4.34 (previous page) shows that Time did not have a significant effect on IL1-b 
[F=(3, 64.015)=2.347, p=0.081], neither had Hormone Therapy use [F=(1, 22.660)=0.568, 
p=0.459]. However, the interaction of Time and Hormone Therapy use had a significant effect on 
IL-b [F=(3, 60.015)=2.839, p=0.045]. 
 
Table 4.35. 
Estimates of Fixed Effects Results for IL-b Model 2 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 30979.98 10427.08 38.79 2.97 .005 9885.17 52074.78 
Time        
Baseline -13188.61 8197.68 65.22 -1.60 .112 -29559.46 3182.22 
Assessment 1 7542.8 8274.40 63.38 .912 .365 -8990.33 24075.90 
Assessment 2 9361.86 8274.40 63.38 1.13 .262 -7171.25 25894.99 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Hormone Therapy        
Yes 3037.35 12626.91 37.57 .24 .811 -22533.89 28608.59 
No(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Interactions (b)        
Baseline x Yes 22382.66 9856.76 64.65 2.27 .026 -2695.36 42069.96 
Endpoint x No -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
 
a. Reference category. 
b. Only statistically significant or marginally significant interactions are displayed. 
 
 
Estimates of fixed effects results displayed in Table 4.35, shows a significant interaction 
term between Baseline x Hormone Therapy/Yes (b=22382.66, t=2.271, p=0.026, CI 95%: -
2695.36, 42069.96), indicating that those who were on hormone therapy showed significantly 
higher IL1-b (mean=22382.66 pf/mL) when compared to those who were not taking any 
hormones at baseline when compared to endpoint. This interaction is graphically displayed in 
Figure 4.19. 
To further assess the interaction term, pairwise calculations based on estimated means 
were performed following the same procedures described on page 86. Hence, Table 4.36 (page 
135) presents the differences in IL1-b for each group of Hormone Therapy between Timepoints. 
Similarly, Table 4.37 (page 135) shows that IL1-b levels were different at each Timepoint for 
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each level of the Hormone Therapy variable. In addition to these calculations, a paired sample t-
test was run to analyse if selected pairwise comparisons of interest were statistically significant.  
 
Figure 4.19. 




In Table 4.36, noteworthy mentioning that, IL1-b levels for those off hormone therapy, 
were significantly higher at assessment 1 (20731.40 pg/mL) and assessment 2 (22550.48 pg/mL), 
respectively) in comparison to baseline (p=0.014, p=0.008, respectively). No significant changes 













Table 4.36.  
Mean Difference of IL1-b levels for each group of Hormone Therapy between Timepoints (n=24). 
 
 Comorbidities Mean 
Difference 
Yes  Baseline Assessment 1 -812.93 
Assessment 2 3672.30 
Endpoint 9194.05 
Assessment 1 Baseline 812.93 
Assessment 2 4485.23 
Endpoint 10006.98 
Assessment 2 Baseline -3672.30 
Assessment 1 -4485.23 
Endpoint 5521.75 
Endpoint Baseline -9194.05 
Assessment 1 -10006.98 
Assessment 2 -5521.75 
No Baseline Assessment 1 -20731.40* 
Assessment 2 -22550.48* 
Endpoint -13188.62 
Assessment 1 Baseline 20731.40* 
Assessment 2 -1819.08 
Endpoint 7542.78 
Assessment 2 Baseline 22550.48* 
Assessment 1 1819.08 
Endpoint 9361.87 
Endpoint  Baseline 13188.62 
Assessment 1 -7542.78 
Assessment 2 -9361.87 
*. The mean difference is significant at the .05 level (paired t-test).  
 
Table 4.37.  
Mean Difference of IL1-b levels at each Timepoint for each level of Hormone Therapy (n=24). 
 
Timepoints   
Mean 
Difference  
Baseline yes no 25420.01* 
 no yes -25420.01* 
Assessment 1 yes no 5501.55 
 no yes -5501.55 
Assessment 2 yes no -802.77 
 no yes 802.77 
Endpoint yes no 3037.35 
 no yes -3037.35 
  *. The mean difference is significant at the .05 level (paired t-test).  
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As shown in Table 4.37, overall, throughout the MT program, patients on hormone 
therapy showed higher IL1-b levels in comparison to patients off hormone therapy. For instance, 
at baseline patients who were on hormone therapy, showed significantly higher IL1-b levels 
(25420.01 pg/mL) in comparison to those who were not (p=0.047).  
 
IL1-b and other covariates  
 
The inclusion of the other covariates (i.e. age of the participants, comorbidities, sleep aids 
use, months after treatment and treatment type) did not yield any statistically significant results in 
any of linear models tested.   
 
Summary of IL1-b results 
 
 In summary, IL1-b improved after the 8-week MT program, with only Hormone Therapy 
and Cancer Stage showing significant interactions with Time. These interactions were broken 
down by conducting separate pairwise calculations for each level of Cancer Stage and Hormone 
Therapy categories. Pairwise comparisons of interest were followed up with a paired-sample t-
test. Results showed that IL1-b levels changed significantly between study timepoints for stage 
III group only. In addition, IL1-b levels between Cancer Stage groups were not significantly 
different at each timepoint. Similarly, IL1-b levels changed significantly between study 
timepoints for those who were not in hormone therapy. In addition, patients on hormone therapy 
showed significantly higher IL1-b levels in comparison to patients off hormone therapy at 
baseline. In conclusion, a slight non-statistical improvement in IL1-b levels were detected after 
the 8-week MT program, regardless of the age of the participants, months after treatment, sleep 
aids use, comorbidities and treatment type. 
 
4.4.4  IL-6 
 
Figure 4.20 shows the trajectory of IL-6 levels at each timepoint during the MT program. 
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Figure 4.20.  
 
Changes in IL-6 levels at each timepoint (n=24). 
 
 
A RM-ANOVA revealed that there was not a statistically significant change in IL-6 
during the MT program [F (3, 66)=0.785, p=.507]. According to Figure 4.20, IL-6 levels 
decreased over time reaching its lowest levels at endpoint. Patients at endpoint (mean=30,969.85 
pg/mL) followed by patient at assessment 2 (mean=32,256.64 pg/mL) showed the lowest IL-6 
concentrations.   
 
IL-6 and other covariates 
 
No statistically significant interactions were found between timepoints and the following 
variables: sleep aids, months after treatment, cancer stages, hormone therapy, treatment type, 
presence of comorbidity, and age.    
 
Summary of IL-6 results 
 
In conclusion, there were improvement trends in IL-6 levels during the MT program, 
however, these failed to reach statistical significance. IL-6 levels slightly improved regardless of 
the age of participant, cancer stage, treatment type, months after treatment, hormone use, sleep 
aids in use, and presence of comorbidities.  
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4.4.5  TNF-α 
 
 
Figure 4.21 shows the trajectory of TNF-α levels at each timepoint during the MT program.  
 
Figure 4.21.  
 




According to Figure 4.21, TNF-α levels decreased at the end of the MT program in 
comparison to baseline, and in comparison to all other time-points. Overall, patients at endpoint 
showed the lowest TNF-a levels (mean=1013.12 pg/mL). Among the study covariates tested in 
the LMM, only three (i.e. Age, Treatment Classification, and Cancer Stage) yielded statistically 
significant main effects in the TNF-α models, which are described below.   
 
TNF-α and Age 
 
 
Table 4.38 shows that Time had a significant effect on TNF-α levels [F=(3, 
66.537)=6.835, p=0.000], when Age was in the model. The same table shows that Age also had a 








Type II tests of Fixed Effects Results for TNF-α Model 1 (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 18.92 06.60 .000 
Time 3 66.53 6.83 .000 
Age 3 18.98 4.12 .021 




Estimates of Fixed Effects Results for TNF-α Model 1 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 660.54 229.15 54.15 2.88 .006 201.16 1119.93 
Time        
Baseline 857.91 247.05 66.91 3.47 .001 364.77 1351.04 
Assessment 1 1062.89 249.59 66.15 4.25 .000 564.58 1561.20 
Assessment 2 610.94 249.59 66.15 2.44 .017 112.63 1109.25 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Age        
Between 30-40 346.39 296.95 19.07 1.17 .258 -274.97 967.74 
Between 41-50 950.28 270.72 19.15 3.51 .002 383.96 1516.60 
Between 51-60 326.99 215.61 19.41 1.52 .146 -123.66 777.63 
     > 60 -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
 
According to Table 4.39, TNF-α levels improved by the end of the 8-week MT program. 
In comparison to endpoint, TNF-α levels were increased at baseline (b=857.91, t=3.47, p=0.001, 
CI 95%: 364,78, 1351.04), assessment 1 (b=1062.90, t=4.26, p<0.0001, CI 95%: 564.59, 
1561.21), and assessment 2(b=610.95, t=2.45, p=0.017, CI 95%:112.64, 1109.25) (Figure 4.21).  
In regard to age, in comparison to patients >60 years old, those between 41-50 years old 
showed significant higher levels of TNF-α (b=950.27, t=3.510, p=0.002, CI 95%: 383.96, 
1516.60) (Table 4.39). Noteworthy that tables with a change in the reference category of Time 
and Age are not shown, however all the significant results are described next. Additionally, those 
between 30-40 years old showed marginally significant lower TNF-α levels in comparison to 
patients between 41-50 years old (b=-603.89, t=-1.871, p=0.077, CI 95%: -1280.29, 75.50). The 
trajectory of TNF-α by Age groups is showed in Figure 4.22 (below). 
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Figure 4.22. 









Type II tests of Fixed Effects Results for TNF-α Model 2 (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 19.93 337.69 .000 
Time 3 66.53 6.83 .000 
Cancer Stage 2 19.95 4.74 .021 
  AIC: 1443.39; BIC: 1448.32 
 
 
Table 4.40 shows that Time [F=(3, 66.535)=6.836, p=0.000] had a significant effect on 
TNF-α levels when cancer stage was in the model. The same table shows that Cancer Stage also 










Estimates of Fixed Effects Results for TNF-α Model 2 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 1145.15 224.69 56.33 5.10 .000 695.10 1595.20 
Time        
Baseline 858.06 247.05 66.91 3.47 .001 364.93 1351.19 
Assessment 1 1062.89 249.58 66.15 4.25 .000 564.61 1561.18 
Assessment 2 610.94 249.58 66.15 2.44 .017 112.65 1109.23 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Cancer Stage        
Stage I -469.77 218.60 20.06 -2.15 .044 -925.66 -13.88 
Stage II 167.66 233.26 19.71 0.72 .481 -319.37 654.69 
Stage III(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
a. Reference category. 
 
According to Table 4.41, TNF-α levels decreased after the 8-week MT program. On 
average, in comparison to endpoint, patients showed significant higher TNF-α at baseline 
(b=858.06, t=3.47, p=0.001, CI 95%: 364.93, 1351.20), at assessment 1 (b=1032.89, t=4.259, 
p<0.0001, CI 95%: 112.66, 1109.23), and at assessment 2 (b=610.94, t=2.44, p=0.017, CI 95%: 
695.10, 1595.20) (Table 4.41, Figure 4.21). Table 4.41 also shows that those diagnosed with 
stage I showed significant lower TNF-α levels in comparison to stage III patients (b=-469.77, t=-
2.156, p=0.044, CI 95%: -925.66, -13.88). Noteworthy that tables with a change in the reference 
category of Time and Cancer Stage are not shown, however all the significant results are 
described next. Those diagnosed with stage I showed significant lower TNF-α levels in 
comparison to stage II patients (b=-637.43, t=-2.916, p=0.009, CI 95%: -1093.32, -181.53). The 




















Type II tests of Fixed Effects Results for TNF-α Model 3 (n=24). 
 Source Num 
df 
Den df F Sig. 
Intercept 1 19.76 203.03 .000 
Time 3 66.40 6.80 .000 
Treatment Classification 2 19.85 3.54 .048 
  AIC: 1444.78; BIC: 1449.72 
 
Table 4.42 shows that Time had a significant effect on TNF-α levels [F=(3, 
66.400)=6.804, p<0.0001], when Treatment Classification was in the model. The same table also 
shows that Treatment Classification also had a significant effect on TNF-α levels [F=(2, 








Estimates of Fixed Effects Results for TNF-α Model 3 (n=24). 
Parameter Estimate SE df t Sig. 95% CI 
      Lower Upper 
Intercept 1273.13 205.16 68.79 6.21 .000 863.83 1682.44 
Time        
Baseline 855.34 247.43 66.80 3.46 .001 361.44 1349.24 
Assessment 1   1062.90 249.91 66.00 4.25 .000 563.94 1561.86 
Assessment 2 610.95 249.91 66.00 2.44 .017 111.99 1109.90 
Endpoint(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
Treatment Classification        
      Unimodal therapy -490.05 295.79 19.60 -1.66 .131 -1107.87 127.75 
      Multimodal = 2 therapies  -506.00 202.48 20.06 -2.50 .021 -928.29 -83.72 
Multimodal > 2 therapies(a) -(a) -(a) -(a) -(a) -(a) -(a) -(a) 
a. Reference category. 
 
According to Table 4.43, TNF-α levels decreased after the 8-week MT program. On 
average, in comparison to endpoint, patients showed significant higher TNF-α at baseline 
(b=855.34, t=3.46, p=0.001, CI 95%: 361.44, 1349.24), at assessment 1 (b=1062.90, t=4.25, 
p<0.0001, CI 95%: 563.94, 1561.86), and at assessment 2 (b=610.95, t=2.44, p=0.017, CI 95%: 
111.99, 1109.90) (Table 4.43, Figure 4.21). Table 4.43 also shows that those who went through 
multimodal therapies with only two therapies showed significant lower TNF-α levels in 
comparison to those who went through multimodal therapies with more than two therapies (b=-
506.00, t=-2.50, p=0.021, CI 95%: -928.29, -83.72). The trajectory of TNF-α by Treatment 













Changes in TNF-α by Treatment Classification (n=24). 
 
 
Summary of TNF-α 
 
Overall, TNF-α levels significantly decreased at the end of the MT program in 
comparison to baseline, and in comparison to all other time-points. Only Age, Treatment 
Classification, and Cancer Stage yielded statistically significant main effects in the TNF-α 
models. Therefore, during the MT program, TNF-α levels significantly varied between Age, 
Treatment Classification, and Cancer Stage groups.   
 
4.4.6  IFN-! 
 
 
Figure 4.25 (next page) shows the trajectory of IFN-! levels at each timepoint during the 
MT program.  
A RM-ANOVA revealed that there was not a statistically significant change in IFN-! 
during the MT program [F (3, 66)= 2.518, p=0.066]. According to Figure 4.25, IFN-! levels 
progressively decreased throughout the MT program reaching its lowest level at the end of the 
MT program. Overall, patients at endpoint (mean=46526.59 pg/mL) followed by patient at 





Figure 4.25.  
 




IFN-! and other covariates  
 
No statistically significant interactions were found between IFN-! and the between-
subject factors age, sleep aids use, stage, cancer treatment, presence of comorbidity, months after 
treatment and hormone therapy. 
 
Summary of IFN-! results 
 
In conclusion, there were improvement trends in IFN-! levels during the MT program, 
however, these failed to attain statistical significance. IFN-! levels varied regardless of the age of 
participant, cancer stage, treatment type, months after treatment, hormone use, sleep aids in use, 
and presence of comorbidities. 
 
4.4.7 Summary of Findings from Research Question Two  
 
• Significant changes in inflammatory markers in BCS submitted to an 8-week MT 
program were found.  
• Overall, all the biomarkers decreased at endpoint in comparison to baseline. Statistically 
significant results were found in the cortisol, IL1-β and TNF-α models.  
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• Although there was an overall improvement in cortisol levels after the 8-week MT 
program, significant improvements were seen in cortisol levels only in the middle of the 
MT program in comparison to endpoint.   
• IL1-β levels improved after the 8-week MT program, with Hormone Therapy and 
Cancer Stage showing important interactions.  
• Overall, TNF-α levels significantly decreased at the end of the MT program in 
comparison to baseline and in comparison to all other timepoints. In addition, TNF-α 
levels significantly varied between Age, Treatment Classification, and Cancer Stage 
groups.   
• Improvement trends in the IFN-!, IL-6 and CRP levels were found throughout the MT 
program, however, these failed to reach statistical significance.   
  
4.5 Changes in Physiological Parameters  
 
This subsection will address the findings form research question three: what are the 
immediate changes in BP, HR and SpO2 in BCS submitted to an 8-week Swedish massage 
program? Below, a detailed description of the results is presented for each outcome.  
 
4.5.1  Blood Pressure Changes Following MT Session 
 
 
Tables 4.44 and 4.45 (next page) show the results of SBP and DBP at each week of the 
study. Contrary to our hypothesis, SBP and DBP increased right after the MT sessions at all 
weeks. Tables 4.44 and 4.45 also show that SBP increased right after the MT sessions at all 
weeks. The increase in SBP, however, was only statistically significant at week 1 (p=0.003), 
week 2 (p=0.003), week 4 (p=0.006) and week 7 (p=0.022). Similarly, DBP increased right after 
the MT sessions at most all weeks. Pre and post differences on DBP were statistically significant 
at week 3 (p=0.007). There was a decrease in the SBP from baseline to endpoint, whereas DBP 
increased from baseline to endpoint. However, these differences failed to reach significance for 




Table 4.44.  
 
Median SBP pre and post MT sessions (n=24). 
 
Variable Median (IQR) Median (IQR)  Difference p value 
     
Systolic Blood 
Pressure (mmHg) 
Baseline (n=23) Endpoint (n=23) 
  
 133.5 (121.2-142.7) 129.0 (114.2-138.7) 4.5 .112 
Systolic Blood 
Pressure (mmHg) Pre (n=23) Post (n=23)   
Week 1 130.0 (116.2-146.0) 143.5 (120.5-152.25) -13.5 .003* 
Week 2 132.5 (118.0-144.0) 138.0 (128.0-150.5) -5.5 .003* 
Week 3  128.5 (117.0-143.7) 134.0 (124.2-145.5) -5.5 .063 
Week 4 128.0 (116.0-125.2) 137.5 (125.2-147.0) -9.5 .006* 
Week 5 132.0 (118.5-141.1) 138.0 (127.0-148.5) -6 .113 
Week 6 134.5 (122.0-143.5) 135.5 (126.0-148.5) -1 .249 
Week 7 130.0 (124.2-136.5) 136.5 (122.0-145.2) -6.5 .022* 
Week 8 130.5 (114.2-139.0) 133.5 (133.0-140.5) -3 .133 
  *p-values reflect Wilcoxon test <0.05. 
 
Table 4.45.  
 
Median DBP pre and post MT sessions (n=24). 
 
Variable  Median (IQR) Median (IQR)  Difference p value 
     
Diastolic Blood 
Pressure (mmHg) 
Baseline (n=23) Endpoint (n=23) 
  
 80.0 (73.5-86.5) 85.0 (75.0-89.0) -5 .247 
Diastolic Blood 
Pressure (mmHg) Pre (n=23) Post (n=23)   
Week 1 77.5 (72.0-90.75) 80.5 (74.2-91.5) -3 .108 
Week 2 83.0 (71.2-76.2) 83.5 (76.2-90.0) -.5 .116 
Week 3 79.0 (70.2-83.7) 83.5 (74.2-89.7) -4.5 .007* 
Week 4 77.0 (74.0-88.5) 83.5 (72.2-89.0) -6.5 .209 
Week 5 81.0 (70.2-91.7) 80.0 (72.2-86.0) 1 .951 
Week 6 82.5 (74.5-87.5) 81.5 (75.2-91.2) 1 .831 
Week 7 79.5 (70.2-92.7) 80.0 (75.2-90.0) -.5 .474 
Week 8 76.5 (67.7-89.0) 81.5 (78.2-89.5) -5 .777 





4.5.2  Oximetry Changes Following MT Session 
 
Oximetry values increased right after MT sessions at each week of the program, 
validating our hypothesis. This increase was only statistically significant at week 2 (p=.008), 
week 4 (p=.040), week 7 (p=.014), and week 8 (p=.033). 
 
4.5.3  Heart Rate Changes Following MT Session 
 
HR values decreased right after MT sessions at each week of the program, validating our 
hypothesis. This decrease was statistically significant between baseline and endpoint (p=.001). 
Immediate pre and post changes were also statistically significant at week 2 (p=.000), week 3 
(p=.000), week 5 (p=.000), week 6 (p=.000), week 7 (p=.001), and week 8 (p=.000). No 
statistical significance was found at week 1 and week 4. 
 
4.5.4  Summary of Findings from Research Question Three  
 
 
There were immediate changes in BP, HR and SpO2 in BCS submitted to an 8-week 
Swedish massage program. Overall, HR and oximetry values improved right after MT sessions, 
validating our hypothesis. On the other hand, contrary to our hypothesis, SBP and DBP increased 
right after the MT sessions at all weeks. 
 
 
4.6 Correlations Between Inflammatory Markers and PRO  
 
This subsection will address the findings form research question four: are there any 
correlations between the levels of inflammatory markers and QoL, stress, fatigue and sleep 
efficiency? Below, a detailed description of the results is presented for each outcome.  
 
4.6.1  Inflammatory Markers, Sleep and Patient-Reported Outcomes  
 
Our results demonstrate associations between inflammatory markers, PROs and sleep 
parameters. These confirm our hypothesis that these outcomes are symbiotically correlated and 
can potentially influence one another.    
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   There were statistically significant relationships between sleep parameters and 
inflammatory markers. Overall, the higher the levels of inflammatory markers, the poorer the 
sleep quality. Table 4.46 (next page) summarizes the statistically significant correlations between 
inflammatory markers and sleep parameters. On the other hand, QoL, stress and fatigue did not 
show any statistically significant association with inflammatory markers. However, there was a 
negative correlation between IL-6, TNF-α and IFN-! and the QoL subscale “additional 
concerns” at different time-points (r=-.474, p=.022; r=-.463, p=.026; r=-.421, p=.046, 
respectively). The “QoL additional concerns” is a subscale of FACT-B provides a disease-
specific QoL assessment for breast cancer (e.g., cancer-specific questions). It evaluates concerns 
such as shortness of breath, swollen arms, hair loss, weight change and so on. Higher scores 
mean less additional concerns. Hence, the negative correlations found between IL-6, TNF-α and 
IFN-! and this construct mean that the higher the additional concerns score (denotating less 
concerns), the lower the levels of inflammatory markers.  
 Additionally, there was a statistically significant relationship between CRP and the QoL 
subscale emotional well-being at baseline (r=-.565, p=.005). The QoL emotional well-being is a 
subscale of FACT-B that covers aspects such as feeling of sadness, fear of death, hope and so on. 
Higher scores mean a better sense of wellbeing. Hence, the negative correlation found between 
CRP and this construct means that the higher the well-being score, the lower the levels of CRP.   
No statistically significant correlations between inflammatory markers and patient-reported 
outcomes were found at endpoint. However, noteworthy that TNF-α and IFN-! negatively 
correlated to sleep duration and almost attained statistical significance at endpoint (r=-0.393, 











Table 4.46.  
Statistically significant correlations between inflammatory markers and sleep parameters using 
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Additional concerns A2 -.474 
 
.022 
IL-1β Sleep duration 
 
A1 -.544 .007 
TNF-α Additional concerns 
 
A2 -.463 .026 
IFN-! Additional concerns A2 -.421 .046 
     
 
 
4.6.2  Sleep and Patient-Reported Outcomes 
 
 
Our results demonstrate associations between PROs and sleep parameters. These confirm 
our hypothesis that QoL, fatigue and stress are correlated and can potentially play a role in the 
development and severity of each other.    
Hence, important statistically significant relationships between sleep parameters and PROs 
were found. Generally, the better the QoL, the better the fatigue and stress. Table 4.47 (below) 
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Wake after sleep onset 
 
 
B .452 .031 
 
Table 4.47 shows that there was a strong statistically significant relationship between QoL 
and stress and fatigue at all time points. A negative correlation between QoL and stress means 
that the higher the levels of stress, the lower the QoL (p<.000). In addition, QoL showed 
positively strong correlations with fatigue at all time-points. That means that the higher the 
fatigue score (denotating less fatigue), the better the QoL (p<.000).  
 Of particular relevance are the significant associations between sleep parameters found at 
all time points. Strong statistically significant relationships between the WASO and SD show that 
the lower the WASO, the higher the sleep duration (r=-0.969, p=0.000 at baseline; r=-
0.807, p=0.000 at assessment 1; r=-0.949, p=0.000 at assessment 2 and r=-0.734, p=0.000 at 
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endpoint). Similarly, WASO was associated to SOL meaning that the longer patients took to fall 
asleep, more awakening episodes they had after sleep onset (r=0.452, p=0.031 at baseline).  
 
4.6.3   Inflammatory Markers 
 
Our results demonstrate associations between several cytokines with each other. These 
confirm our hypothesis that cytokines follow an orchestrated mechanism of expression, 
suppression and production, and are correlated to each other, influencing one another.    
There were important statistically significant relationships between all pro-inflammatory 
cytokines as well as between the cytokines and CRP levels. No correlations were found between 
cortisol and cytokines or CRP. Overall, the higher the cytokine levels, the higher the CRP levels. 
Table 4.48 summarizes the statistically significant correlations between these outcomes.   
 
Table 4.48.  
 

















































































     
 136 
Table 48. (continued) 
IL-1β TNF-α A2 .59 .003 
 TNF-α E .530 .009 





















   
            Of particular relevance are the strong significant associations between IL-6 and TNF-α 




4.6.4  Summary of Findings from Research Question Four  
 
  
Our results demonstrate associations between several inflammatory markers, PROs and 
sleep parameters. Overall, the higher the levels of inflammatory markers, the poorer the sleep 
quality. Associations between QoL (“additional concerns” subscale) and cytokines were also 
found. Findings also showed associations between PROs and sleep parameters. In general, the 
better the QoL, the better fatigue and the stress. Our results also demonstrate associations 
between several cytokines with each other. For instance, there were important statistically 
significant relationships between all pro-inflammatory cytokines as well as between the cytokines 
and CRP levels. No correlations were found between cortisol and cytokines or CRP.   
 
4.7  Effect Sizes  
 
 
The effect sizes of the MT intervention were also calculated as a measure of practical 
significance. This measure can be understood as the difference that is clinically meaningful 
(Tran, 1997). It is determined by calculating the mean difference between two groups (i.e. 
baseline and endpoint), and then dividing the result by the pooled standard deviation (Hinton, 
2014). Interpretation of Cohen’s d suggests that a d≈0.2 is considered a 'small' effect size, d≈0.5 
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represents a 'moderate' effect size and d≈0.8 is considered a 'large' effect size (Cohen, 2013). 
Effect sizes results can be found in Table 4.49 (below). 
Table 4.49. 
 
 Effect sizes from the 8-week MT intervention (n=24). 
 
Outcome Cohen’s d Effect 
Sizea 
Magnitude of Effect 
Size 
QoL 0.70 Moderate to large 
Fatigue 0.80 Large 
Stress 0.50 Moderate  
SD 0.45 Small to moderate 
SE 1.12 Very large 
SOL 0.05 Very small 
WASO 0.46 Small to moderate 
Cortisol 0.59 Moderate 
CRP 0.08 Very small 
IL-6 0.28 Small 
IL-1β 0.02 Very small 
TNF-α 0.82 Large 
IFN-! 0.75 Moderate to large 
a Effect size calculated using Cohen’s d [d= mean1 – mean2 / √((SD12 + SD22) ⁄ 2] 
 
 
4.8  Summary of Results  
 
Overall, QoL, fatigue and stress improved at the end of the MT program. QoL 
improvements were significantly associated with time after treatment completion and cancer stage. 
Changes in fatigue scores were significantly associated with sleep aids in use and comorbidities. 
Stress levels significantly improved at endpoint in comparison to baseline, regardless of any 
covariates tested. Wake after sleep onset was the only sleep variable that significantly improved at 
endpoint. Changes in sleep onset latency (SOL) were significantly associated with cancer stage. 
Sleep duration did not show any significant improvement. Sleep efficiency improved after the MT 
program, however, it did not reach statistical significance. Overall, all the biomarkers decreased at 
endpoint in comparison to baseline; however, only cortisol, IL-1β and TNF-α reached significant 
changes, with IL-1β showing important associations with cancer stage and hormone therapy. Only 
improvement trends were detected in CRP, IL-6 and IFN-! levels. Heart rate and oxygen levels 








 DISCUSSION AND CONLCUSION 
 
5.1 Discussion of the results   
  
In this final chapter, the study results are discussed in light of what is known from the 
literature and aligned with the study’s philosophical underpinnings and theoretical framework. 
The results are discussed under the four major research questions. In addition, this chapter also 
presents the limitations and strengths of the research along with the clinical implications and 
recommendations for future research. A final section presents the study’s conclusion.  
The Middle Range Theory of Unpleasant Symptoms (Lenz & Pugh, 2018; Lenz et al., 
1997) and the PNI (Green et al., 2013; Kang, 2003; McCain et al., 2005) frameworks provided 
the lens through which the results of this study were discussed. They Middle Range Theory of 
Unpleasant Symptoms framework assisted in establishing a sense of structure to guide the 
discussion around the changes in QoL, fatigue, stress and sleep. Similarly, the PNI framework 
provided the lens to comprehensively investigate the multi-directional synchronicity among 
patient-oriented reports, sleep measures and neuroendocrine and immune systems markers. 
Together, these frameworks allowed us to better comprehend how MT can assist in the 
management of CRS in BCS since it unifies the core elements that are potentially modeling the 
genesis of CRS.  
 
5.1.1 Changes in QoL, Fatigue, Stress and Sleep  
 
5.1.1.1     QoL 
 
In the present study, QoL improved after the 8-week MT program. Participants 
experienced a statistically significant improvement in QoL after only 3 weeks in the MT program 
(i.e. assessment 1) and at the end of the program (i.e. endpoint). Our findings on QoL 
improvement are in accordance with other studies that found an increase in QoL after MT in 
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breast cancer patients in treatment (Listing et al., 2010; Ovayolu, Seviğ, Ovayolu, & Sevinç, 
2014; Sturgeon et al., 2009), and other populations such as gynecologic cancer survivors  
(Donoyama, Satoh, Hamano, Ohkoshi, & Onuki, 2018), patients with brain tumor (Keir, 2011) 
and advanced cancer (Kutner et al., 2008).   
Although only some of the independent variables explored in our study showed a statistically 
significant influence on QoL, it is well known that several aspects might affect QoL in breast 
cancer survivorship (e.g. demographic, medical and psychosocial variables). Interestingly, 
psychosocial aspects (i.e. family support, financial concerns) seems to play a greater influence on 
QoL in comparison to medical and demographic variables (Carver, Smith, Petronis, & Antoni, 
2006). 
 
QoL and cancer stage 
 
As a result of a significant interaction between Cancer Stage and Timepoints found in this 
study, important differences in QoL scores for each group of cancer stage between timepoints 
were revealed. These differences can be explained by the fact that different cancer stages will 
have a different impact on BCS’ QoL after treatment (Caan et al., 2005; Carver et al., 2006; 
Lidgren, Wilking, Jönsson, & Rehnberg, 2007). 
In this study, we found that Stage III patients showed the lowest levels of QoL throughout 
the study (except at assessment 1), with no significant differences at timepoints. This is in 
accordance to previous findings that show that patients who were diagnosed with higher cancer 
stages showed poorer QoL right after treatment (Caan et al., 2005; Carver et al., 2006; Lidgren et 
al., 2007).  
 
QoL and Months After Treatment  
 
A significant interaction between the variables Months After Treatment and Timepoints 
was found in this study. This interaction revealed that those who finished treatment ≥ 3 months 
after treatment showed lower QoL (except at assessment 2), with no significant differences at 
timepoints. This is not in accordance with previous studies, as it is expected that BCS and other 
cancer patients will recover their QoL as more time elapses after the end of treatment (Gordon & 
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Siminoff, 2010b; Imran, Al-Wassia, Alkhayyat, Baig, & Al-Saati, 2019; van Leeuwen et al., 
2018).  
Important differences in QoL scores for each group of Months after Treatment between 
Timepoints were also found, which can be explained by the fact that patients at different 
survivorship stages, will report different QoL after treatment (Gordon & Siminoff, 2010b; Imran 
et al., 2019; van Leeuwen et al., 2018). 
 
QoL and Hormonal Therapy  
 
The use of hormonal therapy can also influence QoL as endocrine treatments can elicit 
varying side effects (e.g. increased tumor or bone pain, hot flashes, nausea) (Fallowfield, Leaity, 
Howell, Benson, & Cella, 1999). Interestingly, our study showed that women taking hormonal 
therapy reported better QoL. This result is in accordance with a previous study, which indicates 
that despite the side-effects associated with adjuvant treatments, women taking endocrine 
treatments reported significantly higher QoL after breast cancer treatment (Fallowfield et al., 
1999). On the other side, a second study contradicts this finding by reporting an association 
between endocrine treatments and decreased overall QoL (Browall et al., 2008). Finally, some 
studies reported that side effects of tamoxifen and aromatase inhibitors did not lead to significant 
differences in perceived QoL in breast cancer patients (Buijs, de Vries, Mourits, & Willemse, 
2008; Fan et al., 2005).  
 
QoL and sleep aids 
 
 Another interesting finding in our study was that patients on sleep aids (17.4%) reported lower 
QoL. Sleep medications are expected to ultimately lead to a better QoL by improving sleep–wake 
disturbances, however, a previous study has shown that sleep aids are valuable to improve mental 
and cognitive QoL, but it might reduce the physical and functional QoL, due to adverse effects 
(Sasai et al., 2010). In addition, a study with 124 breast cancer patients found that those patients 
prescribed sleep medications during treatment were significantly more likely to be taking 
psychiatric medications (Costantini, Ale-Ali, & Helsten, 2011).  
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QoL and MT 
 
Given the limited number of interventional studies testing MT in BCS, our findings 
provide new evidence on how MT can improve BCS’ QoL in the transition period. It contributes 
to the understanding of how QoL can be managed after cancer treatment by the incorporation of a 
popular IM therapy. QoL is an indispensable outcome measure in clinical trials and patient-
oriented research. The full therapeutic potential of MT and other IM therapies are in part 
dependent of its effects on self-reported QoL. Therefore, it is an essential part of MT research to 
assess QoL and additional outcomes encompassing the whole person health—physical, mental, 
social, and spiritual.   
 
5.1.1.2    Fatigue 
 
The current study revealed that fatigue improved after the 8-week MT program, with 
significant interactions between the variable sleep aids and timepoints, as well as the variable 
comorbidities and timepoints. Similar studies also found beneficial effects of full-body MT 
programs on fatigue  in different types of cancer patients and survivors (Donoyama et al., 2018; 
Fernández-Lao et al., 2012; Kinkead et al., 2018; Listing et al., 2010, 2009). A study with 63 
breast cancer patients reported that a one to two sessions of 20 minutes of neck and shoulder 
massage and relaxing background music decreased fatigue (Pruthi et al., 2009). Additionally, a 
significantly great reduction of fatigue has been reported in a systematic review on MT in cancer 
palliation (Ernst, 2009) and a lessening in fatigue according to a metanalysis on MT interventions 
and treatment-related side effects of breast cancer (Pan, Yang, Wang, Zhang, & Liang, 2014). 
 
Fatigue and sleep aids 
 
In our study, a statistically significant interaction between sleep aids and timepoints 
revealed significant differences in fatigue scores for each group of Sleep Aids between 
Timepoints. More interesting is that, overall, patients on sleep aids showed non-significantly 
higher fatigue scores (less fatigue) in comparison to patients off sleep aids. Similarly, other 
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studies have reported how sleep medications affect fatigue in cancer patients (Clanton et al., 
2011; Liu et al., 2012b). 
Another interesting finding of our study was that patients on medications for sleep started 
the study more fatigued, and throughout the program showed superior improvement of this 
symptom in comparison to patients off meds. Patients on meds also seemed to sustain the effects 
of massage, since this group did not show a worsening of fatigue at assessment 2, in comparison 
to the group of patients off meds. These results indicate that, in our sample, a combined approach 
(massage plus medication) showed greater impact on fatigue. However, our outcome validity is 
limited due to a small study population.  
 
Fatigue and Comorbidities  
 
 In our study, a statistically significant interaction between sleep aids and timepoints 
revealed significant differences in fatigue scores for each group of Comorbidities between 
Timepoints. Overall, those who presented comorbidities showed slightly higher fatigue scores 
(less fatigue) in comparison to those who did not present any comorbidities. The relationship 
between fatigue and other diseases has been studied in previous studies, which have pointed out 
to the role of comorbidities as a predictor or an effect modifier of fatigue levels in several types 
of cancer (Hoffman, Given, Von Eye, Gift, & Given, 2007; Kozachik & Bandeen-Roche, 2008; 
Rao & Cohen, 2004).  
 
Fatigue and hormonal therapy  
 
There is little published work with respect to hormonal therapy and severity of fatigue in 
cancer patients. Our findings pointed that patients who were under hormonal therapy (i.e. 
Tamoxifen or Aromatase Inhibitors) showed less fatigue (non-significant difference). It is 
possible that adjuvant hormonal treatment for breast cancer, which lowers serum estradiol levels, 
may have a significant influence on fatigue levels (Fan et al., 2005). Contrary to our results, 
previous studies found that different types of cancer patients, including breast cancer, who were 
taking adjuvant hormonal therapy showed higher levels of fatigue and cognitive function 
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problems (Castellon et al., 2004; Fan et al., 2005; P. Stone, Hardy, Huddart, A’Hern, & Richards, 
2000; Tannock, Mar Far, Houédé-Tchen, Qi-Long, & Vardy, 2005).  
 
Fatigue and treatment type  
 
Treatment type is a well-researched aspect and potential predictor of fatigue severity 
during and after treatment. Overall, the severity of the fatigue is worse in patients who underwent 
chemotherapy in comparison to radiotherapy (Donovan et al., 2004; Karthikeyan, Jumnani, 
Prabhu, Manoor, & Supe, 2012). Additionally, cancer patients who went through combined 
therapy (i.e. chemotherapy and radiotherapy) have reported higher levels of fatigue compared to 
those who went through single therapy (Irvine, Vincent, Graydon, Bubela, & Thompson, 1994; 
Mendoza et al., 1999; Woo, Dibble, Piper, Keating, & Weiss, 1998). In this study, we observed 
differences in fatigue severity in our subgroup analyses, however, our findings are not 
generalizable as the study sample is small. 
 
Fatigue and MT 
 
In summary, our study shed some light on how BCS can benefit from MT in the transition 
period after treatment. Fatigue is the most common symptom reported by cancer patients in 
treatment - of any kind, and can linger well past treatment’s completion, however, as of yet, no 
single cause or the mechanisms behind fatigue persistence in BCS had been discovered. 
Similarly, how MT actually affects BCS is also not well described, but it is believed that MT 
increases blood circulation and oxygen flow throughout the body, decreasing muscle tension. The 
mechanical pressure employed during MT results in important biomechanical mechanisms that 
could explain fatigue improvement after MT in BCS, such as increased recovery of joint motion, 
joint fluid collection and diminished joint stiffness. Pressure might also change muscle tissue 
temperature from rubbing, and it might have a role in how MT helps with fatigue (Field, 1998; 
Waters-Banker, Dupont-Versteegden, Kitzman, & Butterfield, 2014). 
We argue that the Swedish gliding strokes and broad muscle compression techniques in 
our study protocol led to an increase in blood flow, neurological excitability, thereby speeding 
the tissues’ recovery and the overall physical performance, and therefore decreasing fatigue in 
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our participants. Although allopathic treatments are available to treat fatigue in BCS (i.e. 
psychostimulants), IM therapies have the potential to ease persistent fatigue in BCS, therefore, 
further studies are merited in this arena.  
 
5.1.1.3    Stress 
 
 
In the present study, stress improved after the 8-week MT program. Participants 
experienced a statistically significant improvement in stress after the MT program (i.e. 
assessment 1) and at the end of the program (i.e. endpoint). MT has been nominated as an 
established therapy in reducing perceived immediate stress in healthy individuals (Moyer, 
Dryden, & Shipwright, 2009). Although our study did not assess any immediate effect on 
perceived stress, we showed a sustained and significant reduction of stress over the course of our 
MT program. Our findings correspond to studies that also found a reduction in stress levels over 
time in cancer patients undergoing MT programs (Billhult, Bergbom, et al., 2007; Hernandez-
Reif et al., 2004; Listing et al., 2010; Pan et al., 2014) and aromatherapy massage programs 
(Wilkinson et al., 2007). However, a few previous studies in patients with cancer found 
contradictory results concerning reduction of stress by showing that perceived stress did not show 
significant changes after four sessions of MT twice-week  (Wilkie et al., 2000) and after an 8-
week course of massage, with or without the addition of a blend of essential oils (Corner, 
Cawley, & Hildebrand, 1995). The inconsistency of existing results may be caused by variations 
on the measuring instrument applied to assess stress, as well as sample heterogeneity.   
 Moyer and colleagues (2009) argue that MT reduces stress by being able to reduce the 
perceived effect of negative stressors (Moyer et al., 2009). The stress buffering effect of MT is 
also explained by considering MT as a direct positive stimuli to recipient’s affective state (Moyer, 
2008) and as a form of emotion-focused coping practice (Folkman & et al, 1986). 
 
Stress and MT  
 
 In light of the increased number of BCS using MT to decrease stress, our study brings 
important contributions to this arena by providing evidence of an improvement in stress levels 
after the MT program, which was sustained until the end of the program. Although there is no 
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evidence indicating a causal relationship between stress and cancer recurrence in BCS, there has 
been a link between fear of recurrence or progression as a mechanism underlying stress states in 
cancer survivors. Therefore, managing stress and other somatic symptoms can improve QoL and 
emotional well-being in BC survivorship ((Hall, Lennes, Pirl, Friedman, & Park, 2017; Todd, 
Moskowitz, Ottati, & Feuerstein, 2014). Gauging BCS’s risk of severe levels of stress or cancer-
related Post-Traumatic Stress (PTS) are crucial in clinical care. Recommendations are that cancer 
patients must be screened for stress early in the course of treatment and at critical points along the 
course of care and survivorship period.   
It is possible to speculate that stress improvement could be related to a relaxation 
response following MT sessions. An overarching potential reason for this relaxation reaction after 
MT is related to decreased muscle tension, along with diminished activity of the sympathetic 
nervous system (SNS), increased parasympathetic activity and vagal outflow (Field, 1998; 
Waters-Banker et al., 2014). Noteworthy that some of these effects are dependent on the pressure 
massage (i.e. moderate pressure or a light pressure massage) (Diego & Field, 2009; Porges, 
2001), as it will be discussed further in this chapter.  
 
5.1.1.4    Sleep  
  
 Slight improvements in sleep quality were found in our study. All measures, except for 
SD, showed a trend to improvement at endpoint in comparison to baseline, however baseline-to-
endpoint improvements failed to reach statistical significance. On the other hand, SD, WASO and 
SOL showed statistically significant improvements in the middle of the MT program. Previous 
studies indicated the effectiveness of MT in the management of sleep disorders in cancer patients. 
In this regard, the study by Kashani et al. (2004) showed an improvement in the mean scores of 
quality of sleep before and after a 4-week (20 min.) MT program (effleurage and petrissage) in 
breast cancer patients  (Kashani & Kashani, 2014). Neck and shoulder massage on a chair for 20 
minutes has been also reported to increase the sense of well-being, and improve sleep quality in 
breast cancer patients (Pruthi et al., 2009).  
In non-breast cancer patients, a study that tested a Swedish massage protocol for 1 week 
(15-30 min.) also found it effective in reducing pain, stress, and sleep disorders in hospitalized 
cancer patients (Smith et al., 2002). In another investigation with patients with bone metastasis, 
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MT (45-minute full-body massage) was shown to have beneficial effects on sleep quality (Jane et 
al., 2011). In non-cancer population, 30 min. of superficial and deep MT showed decrease in pain 
and sleep disorder on 14 patients with back pain and sleep disorder (Field, Hernandez-Reif, 
Diego, & Fraser, 2007). Back massage once a week for 4 weeks (30 min.), significantly improved 
sleep in hospice patients (Soden, Vincent, Craske, Lucas, & Asley, 2004). 
 In all of the mentioned studies, to assess the patients’ quality of sleep, no actigraphy was 
recorded, but the following scales were used instead: Pittsburgh Sleep Quality Index (Kashani et 
al., 2014), Verran and Snyder-Halpern (VSH) sleep scale (Solden et al., 2004; Smith et al. 2002; 
Field et al., 2007), Richards-Campbell Sleep Questionnaire (Jane et al. 2011) and Pruthi and 
colleagues (2009) did not mention if any instrument was used to assess sleep, indicating that 
sleep was assessed by just directly asking participants about their sleep quality.   
 
Sleep Duration  
 
In our study, the SD mean was 326.6 minutes at baseline, and 277.5 minutes at endpoint. 
Healthy adults usually sleep from 420–540 minutes per night (American Academy of Sleep 
Medicine, 2005). This suggests that sleep was already disturbed when participants started the 
study. Similar to our study, SD ranged from 386–480 minutes in BCS who went through 
chemotherapy and an average of 420 minutes in BCS who went through radiotherapy (Berger et 
al., 2003). Berger et al. measured actigraphy for only 48 hours. Another study that assessed sleep 
for 3 consecutive nights in a sample of metastatic breast cancer patients reported a SD of 478.5 
minutes (Palesh et al., 2008). With actigraphy measured during seven nights, SD in BCS was less 
than 360 minutes (Otte, Payne, & Carpenter, 2011) and 314.21 minutes (Alexander et al., 2009). 
Similar results were found in breast cancer patients before starting chemotherapy (Sonia Ancoli-
Israel et al., 2006; Berger et al., 2007), confirming the hypothesis of Ancoli-Israel et al. (2006) 
that breast cancer patients are already sleep deprived prior to chemotherapy (Sonia Ancoli-Israel 
et al., 2006).  
 
Sleep Efficiency    
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Our findings also showed that the SE mean was 92% at baseline, and 92.8% at endpoint. 
SE is calculated by dividing the number of minutes of sleep by the number of minutes in bed, 
multiplied by 100. A cut-off of 85% for SE is suggestive of a good night’s sleep, therefore, a SE 
lower than 85% is an indicator of poor sleep (American Academy of Sleep Medicine, 2005).  
According to the available literature, we found that our patients presented comparable SE to other 
groups of cancer survivors as other studies showed that SE was not drastically affected (Berger et 
al., 2007; Dean et al., 2013; Dhruva et al., 2012; Enderlin et al., 2011; Palesh et al., 2014; 
Reinsel, Starr, O’Sullivan, Passik, & Kavey, 2015). In BCS who went through chemotherapy, SE 
was about 82%–92% (Berger et al., 2003), and greater than 85% in those who went through 
radiotherapy (Dhruva et al., 2012). Interestingly, two studies that measured actigraphy during 
seven nights found a low SE of 78% (Otte et al., 2011) and 92.92% (Alexander et al., 2009) in 
BCS. 
 
 Sleep Onset Latency  
 
In regard to SOL, the trajectory of this measure shows minor improvement at assessment 
2 (= 4.6 minutes) and endpoint (=3.9 minutes) in comparison to baseline (=3.8). A desirable SOL 
is usually less than 20 minutes (American Academy of Sleep Medicine, 2005). 
As a result of a significant interaction between Cancer Stage and Time found in this 
study, important differences in SOL for each group of Cancer Stage between Timepoints were 
revealed. These differences can be explained by the fact that factors like cancer stage, cancer type 
and treatment side-effects are likely to precipitate sleep problems (Berger et al., 2007; 
Miaskowski et al., 2004). 
 When comparing results from our patients to available polysomnography (PSG) and 
actigraphy values in the literature, we found that our patients reported quite lower SOL compared 
to other groups of cancer patients (Berger et al., 2007; Dean et al., 2013; Enderlin et al., 2011; 
Palesh et al., 2014; Reinsel et al., 2015) and to samples of healthy women in a similar age range 
(Mitterling et al., 2015; Ram, Seirawan, Kumar, & Clark, 2010; Vitiello et al., 1996; Webb, 
1982). For instance, according to the literature, cancer patients reported a SOL of 11 to 72 
minutes, on average (Berger et al., 2007; Dean et al., 2013; Enderlin et al., 2011; Palesh et al., 
2008). In healthy adults SOL ranges from 19 to 24 minutes (Enderlin et al., 2011; Mitterling et 
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al., 2015; Ram et al., 2010; Vitiello et al., 1996; Webb, 1982). In BCS, previous studies reported 
a SOL mean of 13.1 minutes (Reinsel et al., 2015), 17.4 minutes (Epstein & Dirksen, 2007), 
average 15 minutes after radiotherapy completion (Dhruva et al., 2012), and 34.8 minutes in 
patients who went through chemotherapy (Enderlin et al., 2011). Additionally, studies reported 
mean SOL of 67 minutes (Otte et al., 2011) and 26.66 minutes (Alexander et al., 2009) based on 
seven nights of actigraphy. Our patients showed a significant low SOL at baseline and during the 
course of the study, possibly meaning severe sleep deprivation (Blytt et al., 2017; Carskadon, 
1986). It must be emphasized that, SOL can be influenced by other aspects such as mood, 
depression and BMI, which were not evaluated in this study, making it difficult to establish any 
definite conclusion on why our patients showed lower SOL (Berger, Hertzog, Geary, Fischer, & 
Farr, 2012; Dhruva et al., 2012; Palesh et al., 2008; Talbot, Hairston, Eidelman, Gruber, & 
Harvey, 2009). 
  
Wake After Sleep Onset  
 
According to the results of the present study, WASO significantly decreased from 
baseline (=36.7) to assessment 1 (=20.7) and from assessment 2 (=39.8) to endpoint (=26.9). 
According to the American Academy of Sleep Medicine, in adults sleeping an average of 420 
minutes per night, WASO is usually less than 42 minutes (American Academy of Sleep 
Medicine, 2005). In BCS submitted to chemotherapy WASO was 50 minutes (Berger et al., 
2003), and 71.44 minutes as demonstrated by another study (Palesh et al., 2008).  
It should be noted, however, that studies in BCS have found that WASO is either 
influenced or predicted by other aspects such as depression, fatigue, BMI (Berger et al., 2012; 
Dhruva et al., 2012; Palesh et al., 2008). For instance, a study found that BMI predicted 
variability in WASO in a sample of 73 BCS (Dhruva et al., 2012). At one-year follow-up for 
chemotherapy, a BMI of 30 significant correlated with circadian parameters, anxiety, fatigue, and 
physical functioning in BCS (Berger et al., 2012). In addition, depression and fatigue have been 
also found as predictors of longer WASO in BCS (Palesh et al., 2008). Therefore, even though 
our patients presented lower WASO in comparison to other BCS populations, which is reflected 
in the SE values found in our sample, other aspects must have been taken in consideration when 
analysing these results.  
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Sleep and MT  
 
Sleep problems are among the most commonly reported problems by BCS (Campos et al., 
2011; Couzi et al., 1995; Davidson et al., 2002; Lindley et al., 1998; Miaskowski et al., 2010). 
Our study provided preliminary evidence that MT has the potential ability to produce beneficial 
effects in sleep in BCS.  
MT is commonly regarded as a therapeutic tool to manage stress, but far less studied as a 
plausible sleep improving modality. Its capacity in managing sleep problems has been previously 
showed by improving insomnia in postmenopausal women (Hachul, Oliveira, Bittencourt, 
Andersen, & Tufik, 2014), improving sleep quality in cancer patients (Kashani & Kashani, 2014; 
Pruthi et al., 2009), with less focus on BCS population. However, how MT actually works in 
improving sleep is not well understood. As previously mentioned in this chapter, MT is known to 
stimulates the venous, arterial and lymphatic vessels’ flow, the connective tissue and muscle 
physiology. It is speculated that the muscle-cutaneous stimuli act on receptors for touch, pressure, 
heat, vibration, and pain, which can trigger neurochemical reactions capable of improving sleep, 
inducing relaxation, tranquility along with physiological changes (i.e. HR, BP, oxygen levels, 
peristalsis) (Field et al., 2005). 
These dermal and pressure stimuli are transduced via the peripheral and autonomic 
nervous systems (ANS) to the central nervous system and are hypothesized as inducers of 
serotonin production - a chemical precursor to melatonin. Therefore, as a positive sleep-inducing 
hormone, melatonin production following MT can influence the sleep quality and other aspects of 
an BCS’s circadian rhythm. Noteworthy that this possible link calls for further research exploring 
the direct effects that MT has on serotonin and melatonin (Agarwal et al., 2000; Field et al., 
2005; Jane et al., 2011).  
  
5.1.2   Changes in Inflammatory Markers  
 
 
Table 5.1 shows the principal actions of the selected biomarkers, although each marker 
contains multiple other functions (Andoniou, Andrews, & Degli-Esposti, 2006; Corwin, 2000; 





Principal action of selected biomarkers. 
 
5.1.2.1    Cortisol 
 
In our study, MT contributed to cortisol responses in a positive direction. Levels of this 
biomarkers decreased at the end of the intervention and showed statistically significant 
improvements from baseline to assessment 1, and from assessment 1 to assessment 2.  
Biomarker Principal Actions 
Cortisol Steroid-based hormone, in the glucocorticoid class of hormones. 
It is known as a stress hormone involved in the response to physical 
and/or emotional stress, but it also controls blood sugar levels, regulates 
metabolism, manufacturing glucose from fatty acids, helps reduce 
inflammation, and assists with memory.  
 
CRP Clinically established marker for inflammation. It is an acute-phase 
protein that increases following IL-6 secretion by macrophages and T 
cells. IL-6 is reported to be the main inducer of CRP gene expression, 
with IL-1 enhancing the effect. 
 
IL-6 Secreted by a wide range of cells. Has roles in B-cell differentiation and 
in promoting inflammation. Inducer of acute phase proteins and 
“sickness behaviour”. Its biological activities partly overlap those of IL-
1 and TNF. 
 
IL-1β Synthesized as a larger precursor, which is then converted to the active 
forms IL-1α or IL-1β. Modulates hematopoietic cell growth, regulates 
acute phase reaction, and induces tissue repair. Activates lymphocytes, 
induces hematopoietic cell growth, and infiltration of leukocytes at sites 
of infection. Related to fever and anorexia. 
 
TNF-α Produced by macrophages. It is an endogenous pyrogen; also induces 
tumor cell apoptosis, cachexia and inflammation. Causes widespread 
tissue damage to the gastrointestinal tract, kidneys, and lungs during 
septicaemia. 
 
IFN-! Wide range of effects. Inhibits viral and bacterial replication and 
enhances natural killer cell activity. It is an important activator of 
macrophages and orchestrates activation of the innate immune system. 
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 The positive MT effect in cortisol levels has been shown by previous studies with breast 
cancer patients (Listing et al., 2010; Stringer, Swindell, & Dennis, 2008) and in different 
populations such as children with cancer (Post-White et al., 2008), pregnant woman (Field, 
Diego, Hernandez-Reif, Schanberg, & Kuhn, 2004), adolescents (Field et al., 1998) victims of 
sexual abuse (Field 1997), HIV patients (Ironson et al., 1996), family caregivers of cancer 
patients (Pinar & Afsar, 2016), among other populations (Hart et al., 2001; Ouchi et al., 2006) – 
in saliva, urine and blood specimens. Different from the reduction in cortisol levels in our study, 
other studies did not find any decrease in salivary and blood cortisol levels in BCS (Fernández-
Lao et al., 2012) and breast cancer patients (Billhult et al., 2009; Green et al., 2010; Hernandez-
Reif et al., 2004). Nevertheless, a recent metanalysis did not find any significant effect of 
different forms of MT in cortisol levels in patients who suffered from different diseases (Moyer, 
Seefeldt, Mann, & Jackley, 2011). Contradictory findings were also found by two studies on MT 
effects in urinary cortisol levels in breast cancer patients (Field, Diego, Hernandez-Reif, 
Schanberg, & Kuhn, 2004; Field et al., 2005), and other studies on MT and urinary cortisol levels 
in different population types (Bost & Wallis, 2006; Field et al., 2004; Ironson et al., 1996; Taylor 
et al., 2003). 
To compare our raw cortisol values with other studies is particularly challenging due to 
important differences between studies’ methodologies. The main drawback is that our study was 
not designed to assess immediate effects of MT, therefore, no pre and post measurements were 
taken, whereas the majority of the studies performed single measurements (immediate pre and 
post intervention), cortisol awakening response (CAR) or cortisol diurnal slope, which are 
different from the reactivity indicator used in our study (i.e. AUC). Moreover, AUC values tend 
to be much higher than the other indices (i.e. single measurements, CAR and diurnal slope), as it 
represents total daily cortisol production and requires a higher number of saliva samples across 
days.  
Additional factors also create great heterogeneity among published studies regarding 
cortisol results. First, the method of saliva collection shows great variability across studies (i.e., 
passive drool or salivary swab), along with the specimen of choice (salivary, urinary, serum), and 
characteristics of the collection tubes. Steroid hormones such as cortisol can lead to different 
results when collected in different plastic tubes or containers. Low affinity plastic containers are 
considered the most appropriate ones (Mert et al., 2013). Secondly, different detection methods, 
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such as commercial luminescence immunoassay, radioimmunoassay (RIA), multi-analyte 
profiling bead-based assay and enzyme-linked immunosorbent assay (ELISA). Different 
detection techniques have great implications in the interpretation of the studies since different 
methods detect cortisol in different measuring units (ng/mg, ng/ml, μg × min−1, nmol/l), as well 
as based on different detection limits. For instance, the study by Fernandez-Lao et al. (2012) in 
BCS and MT assessed salivary cortisol (using ELISA detection method) in μg × min−1 
(Fernández-Lao et al., 2012). Two other studies in breast cancer patients reported serum cortisol 
mean in ng/mg (Hernandez-Reif et al., 2004) and in ng/ml (Green et al., 2010) – both using 
ELISA method. Other studies with BCS and patients presented means of log-transformed 
salivary cortisol values making it difficult to proceed with any comparison (Bower, Ganz, 
Dickerson, et al., 2005; Campo et al., 2015; Listing et al., 2010). 
 Diurnal cortisol concentrations found in this study were within the range of the laboratory 
assay and in accordance to the manufacture’s standards. Our mean cortisol values were lower 
than the normal range in healthy subjects, which is not in line with previous studies that showed 
no difference in diurnal cortisol profiles between BCS and healthy controls (Couture-Lalande, 
Lebel, & Bielajew, 2014; Hsiao et al., 2012; Wan et al., 2019). Our values were also a bit lower 
than those found in long-term BCS (Couture-Lalande et al., 2014; Wan et al., 2019), and lower 
than in breast cancer patients in treatment (Webster, Chandrasekaran, Vijayaragavan, & Sethu, 
2016). One factor that must be taken into consideration is how shortly after the completion the 
treatment the patient is being assessed for cortisol. Noteworthy that a major difference between 
these studies is that our participants were short-term BCS, while Wan at al. (2019) recruited BCS 
who completed treatment at least 6 months prior to the study start date (hormonal treatment 
excepted) and Couture-Lalande et al. (2014) recruited long-term BCS (more than 4 years since 
diagnosis).  
In different types of population, salivary cortisol have yielded inconsistent results, 
however, it is well known that cortisol has a relatively stable circadian pattern secretion in 
healthy individuals (Foley & Kirschbaum, 2010; Stone et al., 2001). In addition, the pattern of 
cortisol production in BCS and patients is not fully understood (Sephton, 2000; Spiegel, Giese-
Davis, Taylor, & Kraemer, 2006; Wan et al., 2016). The hormonal system HPA axis is thought to 
be involved in this scenario since it triggers the production of the stress hormone cortisol 
(Stephens & Wand, 2012). One possible explanation to the lower cortisol levels in our sample is 
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the hyporeactivity of HPA axis, which has been reported in BCS populations (Bower, Ganz, & 
Aziz, 2005; Couture-Lalande et al., 2014; Spiegel et al., 2006). One possible explanation is that, 
during cancer trajectory, a prolonged accumulation of stressors activates the stress system leading 
to a HPA axis dysregulation. This dysregulation and chronic stress are carried forward to the 
survivorship period, which has been suggested as one of the causes leading to HPA axis 
hyporeactivity in cancer survivors  (Bower, Ganz, Dickerson, et al., 2005; Van Der Pompe, 
Antoni, & Heijnen, 1996). Thus, a sustained accumulation of stressors, and therefore, a chronic 
activation of the HPA axis may lead to its ‘wear and tear’ and may be potentially associated with 
a diminished physiological cortisol reactivity (Couture-Lalande et al., 2014). 
Cortisol levels are strongly correlated with stress in healthy population and in a range of 
diseases (e.g. depression, pain, eating disorders, asthma, chronic fatigue, HIV and breast cancer) 
(Field et al., 2005). Salivary cortisol relation to serum cortisol have been determined by 
radioimmunoassay showing a strong non-linear correlations between the cortisol concentrations 
in serum and saliva, which is suggestive that salivary cortisol may be used in situations where 
blood sampling is difficult to perform (Aardal & Holm, 1995; Teruhisa et al., 1981). 
Overall, lower levels of cortisol would provide a psychological index of less stress 
(Billhult et al., 2009). Benefits of MT on stress levels had been shown to be mediated by the 
activation of brain’s areas involved in the relaxation process. A study by Ouchi (2006) showed a 
reduction of cortisol levels and increase in blood flow in the parietal and occipital regions of the 
brain after MT (Ouchi et al., 2006). Other studies have shown in different types of population, 
including paediatric population, a variety of possible mechanisms of stress reduction after MT, 
such as, increased incidence of delta waves in the brain (Field et al., 2004), stimulation of nervus 
vagus (Diego, Field, & Hernandez-Reif, 2005), increased levels of oxytocin, which is a 
modulator of stress in several areas of the limbic system (Uvnäs-Moberg & Petersson, 2005), and 
parasympathetic response mediated by the stimulation of type 3 and 4 mechanoreceptors (Purves 
et al., 2012).   
 
5.1.2.2     CRP 
 
There was not a statistically significant change in CRP during the study. Therefore, our 
findings do not suggest any improvement trends in CRP levels after the MT program. No studies 
in BCS and MT were found in the literature. The only similar study found on cancer population 
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was on the effects of prostatic massage on CRP levels in prostate cancer patients. This study 
showed that four and six weeks of MT showed a significant reduction in CRP and PSA levels 
(Fathollahi, Dabidiroshan, Sheikh, & Nuri, 2016). 
In non-cancer population, MT has been found to reduce CRP levels in coronary artery 
bypass graft patients (Sheikhsaraf et al., 2016). On the other hand, in healthy individuals, muscle 
massage before strength training exercise showed no significant differences on CRP levels 
between control (n=12) and treatment (n=12) groups (Garrido, Oliveira, Mendes, Sousa, & 
Sousa, 2013). 
Plasma and serum CRP are general and reliable indicators of systemic inflammation and 
are easily measured in daily clinical practice. Salivary CRP relation to serum and/or plasma CRP 
have been determined by radioimmunoassay showing a strong correlation under specific 
conditions (Ouellet-Morin, Danese, Williams, & Arseneault, 2011). For instance, salivary CRP 
may reflect low-grade inflammation and have the potential to serve as a screening marker for 
cardiovascular risk status (Out, Hall, Granger, Page, & Woods, 2012), as biomarker for metabolic 
syndrome (Dezayee & Al-Nimer, 2016) and rheumatic disease (Sikorska et al., 2018). 
Nevertheless, in healthy adults, concentrations of CRP in saliva did not correlate significantly 
with those in serum (Kopanczyk et al., 2010).  
In young healthy adults, salivary CRP concentration ranged from 0.05 to 64.3 ng/mL 
(median=1.2 ng/mL) when measured through ELISA (Kopanczyk et al., 2010) and around 950 
pg/mL according to another study in healthy young adults (22–26 years) also through ELISA (La 
Fratta et al., 2018). CRP concentrations found in this study were within the range of the 
laboratory assay and in accordance to the manufacture’s standards. Our mean CRP concentrations 
(all three days) were 677.18 pg/mL (67.7 ng/mL) at baseline and 672.06 pg/mL (67.2 ng/mL) at 
endpoint. In comparison to BCS, our CRP findings were lower than salivary CRP concentrations 
found in a previous study with BCS at least six months from the completion of the adjuvant 
therapy (4899.04 pg/ml; SD 1085.25) (Lozano-Lozano et al., 2019), as well as in serum and 
plasma CRP in BCS diagnosed on average 3.6 years previously to the study start date (Bower et 
al., 2014), in overweight postmenopausal BCS (Thomson et al., 2009), in BCS 12 months after 
diagnosis (Villaseñor et al., 2011), and postmenopausal BCS at any time after treatment (Fairey 
et al., 2005). 
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One possible explanation to why our CRP levels were lower in comparison to other BCS 
populations is that it is associated with several additional factors, such as waist circumference, 
smoking status, tamoxifen use and treatment underwent. Tamoxifen, for instance, have been 
shown to decrease serum CRP (Bonanni et al., 2003; Cushman et al., 2001). In addition, the 
studies found in the literature worked with heterogeneous samples of BCS (i.e. short and long-
term survivors, postmenopausal, overweight).  
 
5.1.2.3    Cytokines  
 
 
Our results showed that TNF-α levels significantly decreased at endpoint. No statistically 
significant differences were found in IL-6, IL-1β and IFN-! over time, however, all biomarkers 
decreased in concentration at endpoint in comparison to baseline, therefore, responding in a 
positive direction at the end of the MT program.   
Our study is the first to show significant improvements in salivary TNF-α concentration 
after an 8-week MT intervention. Previous studies with BCS did not find any changes in TNF-α 
concentration after a 6-week MT intervention (Krohn et al., 2011). However, a study on exercise-
induced muscle damage found that MT attenuated the production of the TNF-α and IL-6 in 
young male (Crane et al., 2012). Interestingly, TNF-α is a cell signaling protein involved in 
systemic inflammation and tumor progression in cancer. The fact that, in our study, this cytokine 
showed significant decrease after the MT program, along with important associations with 
Cancer Stage, among other covariates, reveals a promising finding with important implications in 
the c-Jun N-terminal kinase (JNK) signaling pathway. The JNK pathway is one of the major 
signaling cassettes of the mitogen-activated protein kinase (MAPK) pathway that regulates TNF-
α, having a crucial role in the TNF paradox in cancer progression and immunotherapy (Montfort 
et al., 2019). 
As a result of two significant interactions found in this study, the first one between Cancer 
Stage and Timepoints, and the second one between Hormone and Timepoints, important 
differences in IL-1β concentrations for each group of Hormone Therapy and Cancer Stage were 
revealed. Although not all these differences were statistically significant, it is worth mentioning 
that, both hormone therapy and cancer stages, are important factors that are likely to alter IL-1β 
concentrations in cancer patients even after treatment (Mantovani et al., 2000; Tas et al., 2005; V 
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et al., 2014). In fact,  IL-1 is a major pleiotropic cytokine in tumor–host interactions, and 
therefore, might play an important role in how patients navigate through cancer survivorship 
(Apte & Voronov, 2002). Interestingly, a previous study has also reported how in non-cancer 
perimenopausal women, hormone replacement therapy increases serum soluble IL1ra 
(Abrahamsen, Bonnevie-Nielsen, Ebbesen, Gram, & Beck-Nielsen, 2000).  
Taken together, the overall improvements in cytokine levels seemed to show favorable 
immune changes in this study. This overall decrease on cytokine levels found in our study is, to 
some extent, comparable with other studies that have found an increase of cellular immunity after 
MT. Similar to our findings, several studies found a trend towards improvement of 
immunological markers, but could demonstrate significant changes concerning immune cell 
counts, cytokine concentration and immune system activations after MT in breast cancer patients 
(Billhult et al., 2009; Hernandez-Reif et al., 2005, 2004; Krohn et al., 2011), HIV-1 positive 
patients (Shor-Posner et al., 2006) and healthy individuals (Rapaport, Schettler, & Bresee, 2012). 
The results of the present study are consistent with findings of most of the previous studies which 
revealed no significant changes in IFN-! concentration after 6-week MT intervention in BCS 
(Krohn et al., 2011), and IL-6 and IFN-! (Kang et al., 2011). 
One speculation for the non-statistical significance of some cytokines in our study is 
insufficient power. It must be also taken into consideration that BCS are recovering from therapy 
and their immune responsivity to a relaxation activity (i.e. MT practice) might have been 
diminished by slow recovery of immune system and chronic stress (Kang et al., 2011). 
Furthermore, even though we designed a comprehensive 3-day scheme for saliva sampling to 
account for diurnal variations, other host and environmental factors also play an important role in 
the expression of cytokines, cortisol, CRP, and therefore, variability of immune response. Many 
of these factors were not explored in this study, such as the genetic make-up of the host (i.e. 
genetic polymorphisms), the intestinal microbiome, diet, physical activity levels, hormone levels, 
BMI (Ice, 2005; Stachowicz & Lebiedzińska, 2016; ter Horst et al., 2016). 
Cytokine concentrations found in this study were within the range of the laboratory assay 
and in accordance to the manufacture’s standards. Noteworthy that there are still not definite 
reference values or normative data concerning salivary cytokines and their changes under each 
medical condition and therapeutic interventions (Pollmächer, Haack, Schuld, Reichenberg, & 
Yirmiya, 2002). Relating to the reliability of the blood and saliva to measure cytokines, previous 
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studies have showed a significant plasma-saliva correlation in several populations (La Fratta et 
al., 2018; Riis et al., 2014).    
Noteworthy that our study showed higher concentrations of some cytokines in 
comparison to baseline results from studies with BCS. For instance, our IFN-! were higher in 
comparison to plasma IFN-! levels in breast cancer patients (Krohn et al., 2011) and our IL-6 
levels were higher than salivary IL-6 in BCS (Lozano-Lozano et al., 2019) - both at baseline. On 
the other hand, our study showed lower IL-6 and IFN-! in comparison to IL-6 and IFN-! salivary 
concentrations in a study with BCS and MT at baseline (Kang et al., 2014). The lack of 
consensus on cytokine levels between studies can be explained by the fact that it has been not 
well explored in cancer patients, and precisely in BCS. However, it should be noted that 
inflammation has emerged as one important aspect in cancer survivorship. In addition to an 
increased persistence of CRS, prominent increases in proinflammatory cytokine activity occur in 
cancer survivors (Irwin, Olmstead, Ganz, & Haque, 2013).  
The higher concentrations found in our study in comparison to blood samples can be 
explained by the fact that, although there is a correlation between salivary and plasma cytokine 
concentration, salivary concentration tend to be higher than the plasmatic level (La Fratta et al., 
2018). This difference in concentration could be associated with the salivary glands’ faster 
reactivity in comparison to circulating cellular production of cytokines (La Fratta et al., 2018). 
 
Inflammatory Markers and MT   
 
Our study provided important preliminary evidence of immunomodulatory effects of MT 
in BCS by assessing cortisol, CRP, IL-1β, IL-6, TNF-α and IFN-!. All biomarkers showed a 
decrease after the MT program, suggesting that salivary immunological measures are potentially 
sensitive to immunomodulatory effects of MT in BCS.  
In MT research, it is critical to continue exploring the effects of mechanical manipulation 
of body tissues and immunomodulation. Besides the changes in the inflammatory markers 
presented by our study, previous works have shown positive biological effects of MT on IgA 
levels (Cantarero-Villanueva et al., 2011; Fernández-Lao et al., 2012), α-amylase (Cantarero-
Villanueva et al., 2011; Fernández-Lao et al., 2012; Tiffany Field et al., 2005), serotonin (Field et 
al., 2005; Listing et al., 2010), NK cells (Billhult et al., 2009; Hernandez-Reif et al., 2005), 
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lymphocytes (Green et al., 2010; Hernandez-Reif et al., 2005, 2004), catecholamines (Field et al., 
2005; Hernandez-Reif et al., 2004), some Th1 and Th2 molecules (Green et al., 2010) and 
peripheral blood mononuclear cell (Billhult et al., 2009). 
  Other studies on sport-related muscle injuries in animal models, have also brought 
remarkable insights on immunomodulatory effects of MT. For instance, a study in rats found that 
the immunomodulatory response exerted by MT is dependent upon the applied load. Utilizing a 
custom-fabricated massage mimetic device, this study assessed the effects of various loading 
magnitudes on healthy skeletal muscle in rats. Animals received massage for 30 min, once a day, 
for 4 consecutive days using four loading conditions: control, low, moderate, and high. Different 
cyclic compressive loads provoked different profile expression in 534 genes between the three 
groups and modulation of key immune cells involved in the inflammatory response in rats 
(Waters-Banker, Butterfield, & Dupont-Versteegden, 2014). Additionally, another study in rats 
found that MT promotes enhanced skeletal muscle regrowth and remodelling even on 
contralateral non-massaged hindlimb, indicating that there is a systemic response to MT (Miller 
et al., 2018).  
Therefore, MT seems to have a potential in manipulating the host inflammatory response 
and attenuating the potentially negative consequences of CRS in BCS.  To explain our results on 
how inflammatory markers are capable of responding to MT and changes in mechanical activity 
exerted on muscles, we conjectured that: (1) cell signaling is activated by mechanotransduction 
provoked by MT, which transfers mechanical energy into a chemical response in the cells; (2) As 
suggested in previous studies, MT might alter the behavior of NFkB, causing less of this key 
inflammatory mediator to be released. Consequently, the NFkB-regulated cytokines (i.e. IL-6, 
TNF) become less active, a sign of less cellular stress and inflammation; (3) due to muscle 
manipulation, MT can cause the release of cytokines and myokines (cytokines synthesized by 
myocytes in the muscle tissue and released in response to contractions, which are intricately 
involved in the inflammatory response of skeletal muscle); (4) MT activates the SNS to cause 
muscle relaxation through direct neural mechanisms as well as endocrine-like mechanisms 
(Crane et al., 2012; Miller et al., 2018).  
Although it is becoming clear that the perceived positive effects of MT are a result of an 
attenuated production of inflammatory markers, it remains to be determined whether all cancer 
types respond in similar fashion and if these results can reach statistical significance in a larger 
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clinical trial. Therefore, biological mechanism(s) behind the beneficial effect of MT still require 
further investigation.   
 
 
5.1.3 Physiological Parameters  
 
 
5.1.3.1     Blood Pressure Changes Following MT Session 
 
Contrary to our hypothesis, SBP and DBP increased right after the MT sessions at all 
weeks. There was a decrease in the SBP from baseline to endpoint, whereas DBP increased from 
baseline to endpoint. However, these differences failed to reach significance for both diastolic 
and systolic blood pressure. Worth pointing out the changes were small and likely not relevant 
clinically. 
MT has been widely studied in healthy patients, however, additional scientific research 
with BCS is warranted. Our results are not in accordance with previous studies that support the 
ability of MT to improve BP in breast cancer patients (Billhult et al., 2009; Ferrell-Torry & 
Glick, 1993; Post-White et al., 2003) and other population types such as family caregivers of 
patients with cancer (Pinar & Afsar, 2016), middle-aged women (Lee & Yeun, 2017), 
hypertensive women (Hernandez-Reif et al., 2000; Supa’At et al., 2013), patients undergoing 
autologous bone marrow transplantation (Ahles et al., 1999), and in women with pre-
hypertension (Moeini, Givi, Ghasempour, & Sadeghi, 2011). It should be noted that, the above 
mentioned study with breast cancer patients found that MT lowered SPB, but not DBP (Billhult 
et al., 2009). 
Conflicting results have been also found in the literature regarding BP and MT. In a 
sample of patients with metastatic bone cancer, no significant changes on BP were found after 
MT (Jane et al., 2011). Hand massage in cancer patients receiving radiotherapy, elicited a non-
statistically significant decrease of SBP, and a statistically significant decrease in DBP in the 
experimental group (Park & Suh, 1995).  
 Although we did not find a statistically significant reduction in BP we view the reductions 
in SBP at endpoint as noteworthy, and we speculate that due to sample size we were not able to 
attain statistical significance. In regard to the immediate increase of BP right after the MT sessions, 
one possible reason for that is that physiological measurements were not taken while the participant 
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was still in supine position on the massage table. Instead, right after the massage session, patients 
were asked to get up from the massage table, get dressed and walk to the next room - approximately 
7 meters distance to perform the measurements. Most importantly, our patients did not raise any 
concerns with their BP being slightly elevated after MT, by already knowing that their blood 
pressure at home is under consistent control, which is clinically more relevant than getting isolated 
readings at a clinic or ambulatory setting (Pierdomenico, Bucci, Lapenna, Cuccurullo, & Mezzetti, 
2001). 
  Different pressure massage (i.e. moderate pressure or a light pressure massage) has been 
also speculated as a possible effect moderator in MT studies. Moderate pressure massage has 
been shown to increase vagal activity, which in turn, is associated with lower HR and BP and 
decreased cortisol levels (Diego & Field, 2009; Porges, 2001). Inversely, light pressure has been 
shown to decrease vagal activity, and has been associated with increased cortisol levels (Diego & 
Field, 2009; Spangler, 1997).  
 
 
5.1.3.2    Heart Rate Changes Following MT session 
  
 
In our study, HR values decreased right after MT sessions at each week of the program, 
validating our hypothesis. In addition to the immediate pre and post significant changes 
throughout the MT program, this decrease was also statistically significant between baseline and 
endpoint. 
MT has been widely studied in healthy patients, but scarcely in BCS. It is already known 
that MT elicits a slight change HR due to a vagal activity, possibly through the activation of vagal 
afferent fibers. Therefore, the stimulation of dermal pressure receptors leads to an increase in vagal 
activity, and therefore, exhibits a parasympathetic nervous system response characterized by a 
decreased HR  (Field, Diego, & Hernandez-Reif, 2010).  
In healthy subjects, previous studies suggest that there is a relationship between 
maximum HR slowing and the degree of vasodepression during massage (range 2-80 
msec/mmHg) in several populations (Kaye et al., 2008; Mcintosh, Lawson, & Kenny, 1994). The 
stimulation of pressure receptors by MT is associated with decreased heart rate. The MT effects 
on HR might be mediated by increased vagal activity (Field, 2014).  
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 In conformity with our results, several studies have found that MT elicited a decrease in 
HR in breast cancer patients (Billhult et al., 2009; Post-White et al., 2003). Billhult et al. (2009), 
for instance, found that a single full-body light pressure effleurage massage in women with breast 
cancer who were undergoing radiation therapy lowered the HR. HR also decreased in a sample of 
HIV adolescents submitted to moderate massage (Diego et al., 2001), in healthy elderly subjects 
(Mcintosh et al., 1994), and family caregivers of patients with cancer after back massage (Pinar 
& Afsar, 2016). 
Conflicting results were also found by previous studies. For instance, in a sample of 
patients with metastatic bone cancer, no significant changes on HR were found after MT (Jane et 
al., 2011).In a sample of healthy individuals who received a moderate pressure massage an 
increase in HR was detected. However, the same study also detected that those who received a 
light pressure massage showed a decreased heart rate (Diego & Field, 2009). A third study aimed 
to assess the effects of three different types of massage (1) moderate pressure massage, (2) light 
pressure massage, or (3) vibratory stimulation group. The moderate pressure massage group 
exhibited a decrease in HR. In contrast, the light pressure massage and vibratory stimulation 
groups showed an increase in HR after massage (Diego, Field, Sanders, & Hernandez-Reif, 
2004). Additionally, one study did not detect any statistically significant changes on heart rate 
variability in BCS (Fernández-Lao et al., 2012). Opposing results were also found by a study 
assessing short-term effects of manual therapy in patients with chronic tension-type headache. 
They found that the a single session of manual therapy elicited an immediate increase of heart 
rate variability, although it also prompted a decrease in tension, anger status, and perceived pain 
(Toro-Velasco, Arroyo-Morales, Fernández-de-las-Peñas, Cleland, & Barrero-Hernández, 2009).  
 
5.1.3.3    Oximetry Changes Following MT session 
 
 
  Our findings show that oximetry values increased right after MT sessions at all weeks of 
the program, validating our hypothesis. This increase was only statistically significant at weeks 2, 
4, 7 and 9, but not between baseline and endpoint. Our findings are in line with previous studies 
that reported an increase in oxygen saturation after several modalities of MT in patients with 
metastatic bone cancer (Jane et al., 2011), middle-aged women (Lee & Yeun, 2017), congestive 
heart failure (Chen et al., 2013), in neonates (Elsagh, Lotfi, Amiri, & Gooya, 2019) and in liver 
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transplant patients (Demir & Saritas, 2019). Two other studies, however, found that 
MT decreased oxygen saturation (Rudnicki et al., 2012; Valizadeh, Hosseini, Asghari Jafarabadi, 
& Ajoodanian, 2012).  
One of the most reported effect of MT is an increase in tissue blood flow (Fritz, 1995; 
Moyer, Rounds, & Hannum, 2004; Munk, Symons, Shang, Cheng, & Yu, 2012; Weerapong, 
Hume, & Kolt, 2005). Changes in parasympathetic activity following MT result in a relaxation 
response. Therefore, as found in our study, an increase in oximetry is expected after massage. 
The conjectured mechanisms behind it, is that MT increases blood supply and oxygen by 
improving circulation throughout the body. MT incites an increase in circulation due to the 
pressure created by massage strokes and techniques (i.e. effleurage and petrissage) that actually 
moves blood through the vessels promoting an increase in oxygenation (Li, Li, Lin, & Li, 2017). 
However, MT effects on tissue blood flow are conflicting and inconclusive mainly due to design 
and measurement limitations of previous studies (Munk et al., 2012; Weerapong et al., 2005). 
 
5.1.4   Correlations Between Outcomes  
 
 
  QoL and Cytokines Correlations   
 
In our study, correlations were also demonstrated between IL-6, TNF-α and IFN-! and 
the QoL subscale “additional concerns”. Additionally, there was a statistically significant 
relationship between CRP and the QoL subscale “emotional well-being”. These correlations 
mean that less concerns and better emotional well-being (higher QoL) were associated with lower 
levels of inflammatory markers.   
Associations between inflammatory markers and both total QoL score and its subscales 
have been reported before. In patients with advanced cancer, the EORTC-QoL subscale “appetite 
loss” was independently associated with high serum IL-6 and CRP; and the subscale “role 
function”, was independently associated with serum IL-6 and CRP concentrations (Paulsen et al., 
2017). Moreover, in a second study with patients with advanced cancer, “appetite”, “fatigue”, and 
“role function” were the only EORTC-QoL subscales independently associated with systemic 
inflammation (Laird et al., 2016). 
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Similar to our findings, correlation between QoL and both IL-6 and IL-1β in cancer 
patients were found (Meyers, Albitar, & Estey, 2005), as well as QoL and TNF-α (Fung et al., 
2013; Panju, Danesh, Minden, Kelvin, & Alibhai, 2009) and QoL and IFN-α (Panju et al., 2009). 
In addition, Panju et al., (2009) reported significant correlations between QoL and IL-2, IL-5 and 
IL-8 (Panju et al., 2009). More recently, one study showed that among men with early-stage lung 
cancer, a marginal significance was observed for IL-1A C-889T. Man with C/T or T/T genotype 
had a lower risk of severe fatigue compared with those with genotype C/C (Reyes-Gibby et al., 
2013).   
On the other hand, in a sample of patients with acute myeloid leukemia no correlation 
between QoL and IL-1β were found (Fung et al., 2013; Panju et al., 2009). Also, in accordance to 
our findings, no significant relationships between perceived stress the cytokines IL-1β, IL-6, 
TNF-α, and CRP were reported in a sample of breast cancer patients (Xiao et al., 2017). 
Relationships between stress and CRP and IL-6 were only found in a sample of women receiving 
radiation for breast cancer, but only among those patients with a history of childhood trauma 
(Han et al., 2016). 
Part of these symptoms occurring in cancer patients were observed for the first time in 
laboratory animals submitted to the induction of infectious conditions and the injection of pro-
inflammatory cytokines. The result of this induction was a phenomenon called sickness behavior. 
This term was coined in 1992 by Stephen Kent and collaborators and is characterized, in animals, 
by a set of physiological responses (fever, pain, increased activity of the HPA axis and ANS) and 
behavioral responses (fatigue, dysphagia, changes in sleep patterns, apparent loss of interest in 
daily activities, depressive behavior, decreased social interaction and sexual interest) (Kent, 
Bluthé, Kelley, & Dantzer, 1992). Interestingly, in humans, fatigue, pain, insomnia, depression 
and cognitive disorders were observed in cancer patients who presented high levels of pro-
inflammatory cytokines (Barsevick, 2007). Therefore, to consistently explore all these possible 
correlations, it is crucial to capture the dynamic and continuous response of the immune system 
to cancer, considering the involvement of cells, organs and pro and anti-inflammatory biological 
markers. 
 




Our results demonstrated several correlations between PROs (i.e. QoL, Fatigue and 
Stress). Generally, the higher the levels of stress, the lower the QoL; as well as the higher the 
fatigue score (denotating less fatigue), the better the QoL. These confirm our hypothesis that 
QoL, fatigue and stress are correlated and can potentially play a role in the genesis and severity 
of each other.  Fatigue and its correlation with QoL - both following and during breast cancer 
treatment, have been reported by previous studies (Canário et al., 2016; Charalambous & Kouta, 
2016; Gupta, Lis, & Grutsch, 2007; Kluthcovsky & Urbanetz, 2015; Paraskevi, 2012; Tabrizi & 
Alizadeh, 2017). In accordance to our findings, a study with 202 BCS, found that total and 
subscale fatigue scores were correlated to lower QoL (Kluthcovsky & Urbanetz, 2015). Similarly, 
in a sample of 215 breast cancer patients, mean scores for QoL were significantly lower among 
fatigued women (Canário et al., 2016). Another study in patients with lung cancer found similar 
results reporting that the higher the levels of pain, fatigue, sleep disorders and stress, the lower 
the QoL (Lin, Chen, Yang, & Zhou, 2013). 
QoL is considered an important endpoint in cancer care and in clinical trials, while fatigue 
is one of the most troublesome and frequent symptoms described by cancer patients and 
survivors. QoL is often associated with symptoms such as fatigue, insomnia, and psychological 
stress (Ahlberg, Ekman, Wallgren, & Gaston-Johansson, 2004; Portenoy, 2000; Stone, 
Richardson, et al., 2000; Vogelzang et al., 1997; Yellen, Cella, Webster, Blendowski, & Kaplan, 
1997).  Our findings corroborate the argument that QoL and CRS are intrinsically correlated in 
the cancer trajectory, influencing one another as a cluster of symptoms, in both patients and BCS 
(Cleeland, 2007; Cleeland et al., 2013; Dantzer et al., 2012; Dodd, Miaskowski, & Paul, 2001; 
Dodd, Miaskowski, & Lee, 2004).  
 
  Sleep Parameters Correlations  
 
Significant associations between sleep parameters were found at all time points. Strong 
statistically significant relationships between the WASO and SD were found. Similarly, WASO 
was associated with SOL meaning that the longer patients took to fall asleep, more awakening 
episodes they had after sleep onset.    
The significant correlations between sleep parameters in our sample represent to some 
extent the microstructure of sleep architecture. To further explore these relationships, we tested 
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for other correlations between sleep and PROs (i.e. QoL, fatigue and stress). However, no 
correlations were found between QoL, fatigue and/or stress and the actigraphy sleep 
measurements in our study. These observations correspond to findings from other trial that failed 
to find relationships between actigraphy sleep measurements and subjective health-related 
measures (i.e. PROs and health-related symptoms) (Aili, Åström-Paulsson, Stoetzer, Svartengren, 
& Hillert, 2017). In patients with atopic dermatitis, among the 9 actigraphy sleep measures, only 
5 approached significant correlations with QoL (Bender, Leung, & Leung, 2003). In addition, 
other study where sleep was assessed subjectively also failed to find relationships between sleep 
and QoL (Sonia Ancoli-Israel et al., 2003). Similarly, in the same study mentioned above with 
atopic dermatitis patients, of the 8 subjective sleep measures, none correlated with the QoL score 
(Bender et al., 2003).  
The low overall correlation between actigraphy sleep measurements and PROs in our 
study creates a number of discussion points. First, as proposed by Ancoli-Israel et al. (2003), is it 
that the actigraphy measurements are not reliable enough to capture the relationship between 
sleep changes and PRO’s measures, or, is it that, in fact, there is no relationship between sleep 
and PRO’s measures? (Sonia Ancoli-Israel et al., 2003). These findings might suggest that 
actigraphy measurements and subjective health-related measures do not correlate, but rather 
complement each other. Albeit a definite explanation for these results are not clear-cut, one 
speculation is that the participant responses to the FACT (i.e. QoL and fatigue) and PSS (ie.e 
stress) scales have a 1-week recall period, whereas the actigraphy recorded sleep during another 
timeframe.   
 Different from our results, a previous study have shown an inversely proportional 
relationship between fatigue in cancer patients and actigraphy sleep measurements (Berger, 
1998). Also, in adolescents with cancer, a correlation between QoL and sleep was also observed 
(n=20) (Erickson et al., 2011). Indeed, the relationship between fatigue and sleep in health and 
other illnesses has been widely studied. It is unknown, however, how fatigue influences the 
quality or quantity of sleep or its actual relationship with the biological circadian rhythmicity 
(Ancoli-Israel, Moore, & Jones, 2001). Sleep/wake circadian rhythm cycle, independent of its 
relationship to fatigue, may play an important role in CRS. There is robust evidence to suggest, 
however, that disruptions in sleep/wake circadian rhythm cycle are relevant to cancer and other 
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chronic diseases (Mormont & Lévi, 1997; Wang et al., 2017; Zhang, Xie, Yu, Zhang, & Qian, 
2019).   
 A lack of correlation has been also identified between actigraphy measures and subjective 
measures of sleep. As demonstrated by previous studies, a discrepancy between objective 
sleep/wake measures (i.e., actigraphy) and self-reported sleep (i.e., the PSQI and CSD) has been 
found (Aili et al., 2017; Ancoli-Israel et al., 2003; Berger et al., 2007; Girschik, Fritschi, 
Heyworth, & Waters, 2012). By no means it is suggested that any of these measures are 
unimportant. Actigraphy reflects an important aspect of sleep quality, as is true for subjective 
measures. Clearly, subjective and objective measures of sleep quality target very different aspects 
of sleep quality—each providing valuable insights (Sonia Ancoli-Israel et al., 2003; Landry, Best, 
& Liu-Ambrose, 2015), therefore, the best practice would be including both subjective and 
objective measures when examining sleep quality in BCS (Landry, Best, et al., 2015). 
 
Relationship between Sleep Onset Latency and Sleep Duration 
 
Although we did not find any significant correlations between Sleep Onset Latency (SOL) 
and Sleep Duration (SD), the relationship between these two variables is worth discussion given 
their important role in the microstructure of sleep architecture. On average, our patients showed 
an ultra-short (≤5 min.) SOL, along with a short SD. Therefore, on the assumption that there is a 
strong synchronicity between these two variables, we hypothesize that SOL and SD are positively 
correlated. However, there is insufficient knowledge regarding SOL and SD in BCS population 
to compare our data. In other population types, strong correlations have been found between SD 
and SOL (Ishihara, 2002),  as well as associations of increased SOL with insufficient total sleep 
duration (Gau & Soong, 1995; Liu & Zhou, 2002). Contrary to that, a previous study found that 
an increase in SD was associated with an enhanced risk of prolonged SOL (Alexandru et al., 
2006). Interestingly, in mice, prolonged or delayed SOL was associated with chronic sleep 
restriction, in other words, SOL increased as a function of sleep restriction or lower SD. (Kim, 
Hwang, Kim, & Choi, 2013). 
 
Sleep and Cortisol Correlations   
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Overall, the higher the levels of inflammatory markers, the poorer the sleep quality. For 
instance, our study showed that high cortisol levels correlated with worse WASO. The 
association between cortisol and sleep have been previously studied in several types of 
populations. In old adults, it has been demonstrated that impaired nighttime sleep is associated 
with elevated plasma cortisol (Vgontzas et al., 2003). Alterations in cortisol concentrations can 
interfere with sleep (Vgontzas et al., 2001), which may trigger elevations in proinflammatory 
cytokines and fatigue, creating a positive feedback loop (Vgontzas, Mastorakos, et al., 1999; 
Vgontzas, Papanicolaou, et al., 1999). The current findings indicate that sleep deprivation 
modulate cortisol levels and increases plasma concentrations of pro- and anti-inflammatory 
proteins – such as cytokines (Wright et al., 2015). 
 
Sleep and Cytokines Correlations   
 
           Short SD was also correlated with higher IL-1β levels in our study. Elevated plasmatic 
pro-inflammatory cytokines have been associated with sleep disturbances in BCS and breast 
cancer patients (Collado-Hidalgo, Bower, Ganz, Cole, & Irwin, 2006; L. Liu et al., 2012a). 
Inflammation has been associated to disrupted sleep in cancer survivors, with a few key 
endogenous factors leading to inflammatory activity, such as nuclear factor-κB (NF-κB), and 
major inflammatory cytokines, such as IL-1β, IL-6, and TNF-α (Karin, 2006). Decreased SD and 
disrupted sleep have deleterious effects that shift the metabolism and produce a chronic elevation 
of plasmatic CRP, IL-6 and TNF-α (Rico-Rosillo & Vega-Robledo, 2018; Rockstrom et al., 
2018; Vgontzas et al., 2001). It’s been also demonstrated that inflammatory cytokines IL-1β, IL-
6, and TNF-α increase non-rapid eye movement sleep, whereas anti-inflammatory cytokines such 
as IL-4 and IL-10 decrease it (Rico-Rosillo & Vega-Robledo, 2018). In contrast, other 
investigators have noted that IL-6, but not IL-1β or TNF-α, was related to a symptom cluster 
composite of sleep quality, pain, fatigue, depression, weight loss, and cognitive disturbance in 
patients with advanced pancreatic cancer (Tobias, Rosenfeld, Pessin, & Breitbart, 2015).    
  
Sleep and CRP Correlations   
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We also identified that, high CRP levels correlated with worse SOL. The relationship 
between salivary CRP and sleep is not fully understood in BCS and have been scarcely 
researched to date. Elevated CRP in plasma have been associated with sleep disturbances in BCS 
(Collado-Hidalgo et al., 2006) and breast cancer patients (L. Liu et al., 2012a). The importance of 
this molecule as a predictive element in cancer survivorship has been supported by previous 
studies suggesting an increased mortality rate associated with higher CRP levels (Pierce et al., 
2009). Furthermore, previous studies reported a relationship between elevated levels of CRP and 
circadian misalignment  in night-shift workers (Kim et al., 2016; Morris, Purvis, Mistretta, Hu, & 
Scheer, 2017). By contrast, other investigators have reported inconsistent correlations between 
CRP and sleep disturbance over 2 years in women with early-stage breast cancer (Starkweather et 
al., 2017).  
The interplay between cytokines, CRP and cortisol in modulating sleep and CRS have 
been investigated before. Accumulating data suggest an interaction among sleep, circadian 
rhythms, and circulating concentrations of IL-6 in relation to the secretory profiles of cortisol, 
and melatonin (AlDabal, 2011; Bauer et al., 1994; Redwine, Hauger, Gillin, & Irwin, 2000). 
Sleep deprivation may decrease IL-6 levels, with effects on the integrity of immune system 
functioning (AlDabal, 2011; Bauer et al., 1994; Redwine et al., 2000). Interestingly, CRP is 
synthesized in response to IL-1 and IL6 stimulation, and it has been found in association with 
fatigue in breast cancer patients (Alexander et al., 2009; Alfano et al., 2012; Orre et al., 2011; 
Pertl et al., 2013; Wratten et al., 2004). Fatigued BCS showed elevations in serum markers 
associated with pro-inflammatory cytokines activity an average of 5 years after diagnosis (Bower 
et al., 2002). Furthermore, elevations in IL-6 and alterations in cortisol have been reported in a 
variety of cancers, and both have been associated with fatigue (Murali, Hanson, & Chen, 2007; 
Schrepf et al., 2013). 
         The pursuit of timely, cost-effective, accurate, and non-invasive methodologies to 
measure sleep quality and sleepiness have led scientists to explore saliva (Seugnet et al., 2006), 
exhaled breath and exhaled breath condensate (Carpagnano, 2011) as promising mediums of 
diagnostic and prognostic value (Michael, Valle, Cox, Kalns, & Fogt, 2013; Yoshizawa et al., 
2013). In sleep medicine, inflammatory markers such as IL-6, TNF-α, von Willebrand factor, α-
amylase and CRP have drawn considerable attention (Clinton et al., 2011; Miller, 2011). 
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However, most of the previous studies are in fruit flies (Drosophila melanogaster) and humans 
(Seugnet et al., 2006), but not BCS.   
 
 Inflammatory Markers Correlations  
 
 
Several correlations between inflammatory markers were found in our study. There were 
important statistically significant relationships between all pro-inflammatory cytokines as well as 
between the cytokines and CRP levels. These confirm our hypothesis that inflammatory markers 
are influencing one another as a result of an orchestrated symbiosis in the human body.   
  Overall, the higher the cytokine levels, the higher the CRP levels. The relationship 
between CRP and the cytokines measured in our study is not well understood in BCS. The 
relationship between CRP and IL-6 has been well studied in other populations, such as patients 
with systemic sclerosis, acute coronary syndrome, schizophrenia and bipolar disorder (Daniels, 
2017; Misiak et al., 2018; Muangchan & Pope, 2013). CRP is synthesized in response to IL-1 and 
IL-6 stimulation, therefore, a relationship between these two cytokines were expected. 
Interleukin-6 works upstream of CRP and downstream of IL-1β and activates its 
proinflammatory response via stimulation of membrane-bound IL-6 receptors on the cell surface 
(Daniels, 2017). Interestingly, CRP and IL-1β have been linked to the development of fatigue. A 
study with 111 stage 0-III BCS at 1 year post-radiotherapy, found that depressive symptoms, 
CRP, IL-1β (antagonist receptor) and TNF- α (receptor 2) were risk factors of fatigue (Xiao et 
al., 2017).  
 As of particular importance, our study showed that all cytokines positively correlated to 
each other. Cytokines are small signaling proteins released by a variety of cells acting in cell 
development and growth. These proteins play a central role in the immune system, in which they 
influence the host's responses to infections, inflammations, chronic and acute diseases (Corwin, 
2000; Roshene & Ramesh, 2017). Initially they were categorized as mediators of interactions 
between immune system cells, recently however, they have been also considered essential factors 
for the interaction between the immune system and the central nervous system (Haack et al., 
1999). Members of this large and diverse family of signaling polypeptides, produced by cells of 
different embryonic origins, are traditionally classified as lymphokines (cytokines produced by 
activated lymphocytes), interleukins (cytokines that act as mediators between leukocytes), or 
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chemokines (cytokines) (Hiscott & Ware, 2011; Janssen et al., 2010; Ransohoff & Benveniste, 
2006). 
Although their specific biological activities vary, two general categories of cytokines can 
be distinguished, pro-inflammatory and anti-inflammatory. The first group consists of cytokines 
that are directly or indirectly involved in inflammatory processes, such as IL-1, IL-6 and TNF-α. 
The other group consists of cytokines that are known to regulate the immune response by 
decrease cell activation and the production of pro-inflammatory mediators. This group includes 
IL-4, IL-10 and IL-13, among others (Hiscott & Ware, 2011; Meager, 1991; Schiepers, Wichers, 
& Maes, 2005). 
Cytokines are pleiotropic (i.e. one cytokine can have different effects on different cells), 
they can be redundant (i.e. different cytokines can have the same effects), they are able to 
synergize and antagonize with each other and they can induce a cascade effect (i.e. some 
cytokines enhance or inhibit the action of other cytokines in complex ways). 
The results of our study support the idea that cytokines follow an orchestrated mechanism 
of expression, suppression and production. Their expression and their receptors are highly 
regulated and correlated to each other, influencing one another. TNF- α, IL-1β  and IL-6 have 
been most extensively studied given its roles in the inflammatory process (Hazelzet, van der 
Voort, Lindemans, ter Heerdt, & Neijens, 1994; Kowsar, Keshtegar, & Miyamoto, 2019; 
Schindler et al., 1990). In general, inflammation involves signalling through IL-1β, TNFα and 
IL-6 cytokines as the biological activities of IL-6 partly overlap those of IL-1 and TNF. In 
addition, IL-6 is probably also involved in the regulation of TNF and IL-1 production (Hazelzet 
et al., 1994; Schindler et al., 1990).  
 
Correlations Between Outcomes and MT  
 
Several correlations between inflammatory markers, sleep and PRO were found in our 
study. We provide preliminary evidence of a sustained pattern of correlation between the 
symptoms itself and between these with inflammatory markers throughout a MT program in BCS 
across different timepoints. These confirm our hypothesis that these outcomes are synergistically 
correlated and can potentially influence one another.  
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In the context of a MT trial, these correlations are particularly meaningful given its 
consistency throughout the program. For instance, stress and fatigue correlated to each other at all 
timepoints. It means that improvement in these symptoms at each timepoint were accompanied 
by a repetitive pattern of correlations between them. This consistent correlation pattern endorses 
the necessity of screening and managing CRS simultaneously, and not as isolated symptoms. 
Although the actual hierarchy between these symptoms’ occurrence is not well understood, our 
results corroborate the hypothesis that these symptoms occur together as a cluster due to a 
possible common underlying inflammatory, neuroendocrine and immunologic etiology. 
Additionally, because most of these correlations were statistically significant, we can also assume 
that these associations were not attributed to chance.  
There has been a paucity of studies identifying the occurrence of symptom clusters in 
BCS across different points in the post-treatment trajectory. Currently, it is not known if these 
symptoms coexist after treatment or whether the clustering became weaker or stronger post 
treatment. Therefore, besides the persistence of CRS even after treatment detected in our study, 
the strong correlations between these symptoms might be an indicative of persistent symptom 
clustering. Evaluating and treating persistent CRS is an important part of survivorship care and 
MT seems to be a promising approach in this regard, since according to our results, it improved 
both CRS and inflammatory markers. 
 
5.2 Strengths and Limitations of the study 
 
5.2.1 Strengths  
 
 
Assessing the biological effects of MT by taking into account the circadian reactivity of 
inflammatory markers has been one of the major difficulties of earlier studies. A unique feature 
of this study was the repeated assessment of inflammatory markers for 3 consecutive days and at 
four timepoints throughout the study. The findings may prove useful for determining optimum 
sampling times for future studies, as well as it provides pioneering data of some salivary 
inflammatory markers in short-term BCS.  
While few studies have been done in assessing the effects of MT, it has been mainly done 
in cancer patients in treatment. This study amplifies the understanding of the benefits of MT to 
short-term BCS for the first time using salivary inflammatory markers. Our findings help to 
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reinforce and amplify the relationships between the sleep architecture’s variables in BCS, as well 
as the relationship between salivary markers and sleep in BCS. 
Another strength of this study is the fact that only one patient withdrew from the study 
(representing a drop-out rate of 4.1% of the original sample). A low drop-out rate is a good 
indicator of study adherence and feasibility of the MT protocol.  
This study also expands on previous work by designing a fairly long intervention period 
(8 weeks) and by assessing the long-term and cumulative MT effects rather than immediate 
effects. Hence, our findings provide rich insights in establishing an accurate dose-response for 
MT and to guide treatment protocols, as an important aspect for patient care. The theoretical basis 
of the research and the MT protocol development were also a strength of this study, since careful 
analysis of previously published MT protocols and input from experienced RMT were appraised 
before putting together an intervention protocol for this study.  
Despite the limitations, the study’s findings would serve as a basis for many forthcoming 
investigations in BCS on sleep, stress, fatigue, QoL, immune response, and MT practice, dose 





There are numerous challenges in integrative oncology research, particularly in 
therapeutic massage research. These challenges create methodological restrictions to 
interventional studies, and a number of these merit discussion. Due to budgetary limitations, a 
within-subjects, single group design was used for testing our hypotheses. Additionally, due to a 
small sample size, the study was underpowered, being more representative of a pilot or a 
feasibility study. Hence, findings should be replicated with a larger sample, as less study 
participants may not be accurately representative of patient homogeneity observed in larger 
studies. The consistency of this study's results over a number of variables, suggests that the 
differences found in our study are likely to be real and replicable in a larger sample. In addition, 
it may be possible that an 8-week MT can induce longer-lasting effects, however, due to the lack 
of a follow-up assessment, we could not elucidate this assumption. 
Among the many inherent challenges associated with MT research, there is the 
consistency in the delivery of massage, or in other words, the limitations around inter and intra-
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therapist variability at each MT session. Due to feasibility reasons, it was not possible to have 
less therapists involved in the study. To overcome this problem in our study, each patient had the 
same therapist during the entire study. On the other hand, having the same therapist or a reduced 
number of therapists performing all sessions in all patients may limit the generalizability of the 
results; since it is expected that any trained therapist must be able to deliver the same MT 
protocol with similar results.  
Given that the current literature does not provide a reasonable estimate of expected 
differences in the inflammatory markers investigated, our power analysis had to be done based 
only on our primary outcome’s expected change (i.e. QoL). Another important limitation of our 
study is that past medical history of sleep disorders was not collected from participants. Patients 
were only asked if they were currently on any medication for sleep problems or any sleep aids. 
The analysis of personality traits on the adherence to MT program, was not included in our study 
either. The inclusion of other psychological covariates in this study (i.e. personality traits) could 
have better explained the trajectories of this study’s outcomes. 
In home-based clinical trials, in which the majority of the patient’s data and/or samples 
are obtained from their own home, ensuring protocol compliance is a challenge. Even though we 
asked for participants to record the date and time for each saliva collection, some of them forgot 
to do so, and some participants reported difficulties in complying with the collections. An event 
monitoring system is a gold standard in home-based clinical trials, and it could have been used in 
this study to increase compliance. It is a simple, yet expensive small-box size device, that records 
and stores up to 4,000 events corresponding to the date and time when a patient opens it to get the 
sample collection aids and collectors. In our study, in order to mitigate the effects of 
noncompliance, the use of scheduled text messages (RedOxygenTM) was employed to remind 
participants of sample collection times.  
The variability across findings and some methodological drawbacks in published studies 
limited the extent to which our data could be compared to the literature. A significant 
heterogeneity among the studies were found in regard to comparison groups, varying lengths of 
intervention, varying assessment instruments, different compliance criteria, or included subjects 
with various types of cancer. 
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5.3 Implications on Clinical Practice   
 
The study’s findings suggest that an 8-week MT program has positive effects on multiple 
immune responses and in QoL, fatigue, stress and sleep in short-term BCS. Results of this 
research represent a significant contribution to integrative oncology by bringing scientific 
evidence to support mainstream clinical guidelines and the decision-making process in BC 
survivorship care. Providing scientific evidence on MT benefits gives BCS a choice for symptom 
management and supports acceptance of the use of MT by institutions, patients and clinicians. 
However, further studies with rigorous design and larger sample sizes are demanded to validate 
our findings. Once our findings are validated, the outcomes measured in this study should be 
routinely assessed in clinical practice to provide healing-oriented medicine encompassing the 
whole person.  
Results of our study also adds to the discussion of multimodality treatment regimen, 
reinforcing that integrative medicine therapies must be provided to patients and their families 
using a patient-centered approach and in concert with mainstream care to manage symptoms, 
improve QoL, and psychological and physical health.  
  Symptom control in short-term BCS is an under researched area of study. Our study 
provided evidence that can enable researchers, health care practitioners, and policy makers to 
foster the development and implementation of health promotion initiatives. The high adherence 
rate of this study demonstrates a current demand of BCS in Saskatchewan willing to receive 
massage treatment to manage their symptoms during the transition period after BC treatment. The 
study’s logistics was also set with local partners to deliver MT in a manner that can be 
incorporated into survivorship cancer care services provided in Saskatchewan. As such, 
partnerships could be potentially arranged between SCC and our partners in order to provide MT 
services for BCS without requiring any physical space or new infra-structure to be implemented 
at SCC. 
Many cancer patients use integrative medicine therapies or are interested in these 
therapies. Yet, the majority of patients frequently neglect to disclose its use to their oncologists. 
Reasons for non-disclosure include lack of inquiry from medical providers, fear of physician 
disapproval, physician's disinterest, belief providers lacked integrative therapies knowledge, 
lacking time, and belief integrative therapies are safe (Cramer, Cohen, Dobos, & Witt, 2013;  
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Foley, Steel, Cramer, Wardle, & Adams, 2019). Therefore, by providing evidence that MT can 
help BCS with CRS management, our study helps to close this gap between professionals’ and 
patients’ practices and believes. As a patient-oriented research, our study endorses that research 
needs to be done in partnership with patients, their families and communities to substantially 
answer questions that matter to them and aims to improve health care. Given the frequent number 
of IM users it is important that more studies are done, and that health care professionals, 
educators, and patients engage in a dialog about useful integrative therapies during and after 
cancer treatment. 
  
5.4 Research Contributions Summary 
 
There are limited interventional studies exploring how IM therapies can help BCS in the 
transition period. Our findings provide new evidence on how MT can improve BCS’ QoL, 
fatigue, stress and sleep during the transition period. It contributes to the understanding of how 
CRS can be managed after cancer treatment by the utilization of IM therapies.  
Given the link between inflammation and breast cancer, our study provides new evidence 
to understand the potential salutary associations between inflammatory markers, sleep problems 
and persistent CRS in BCS. Hence, it contributes to the understanding of how cortisol, CRP, IL-
1β, IL-6, TNF-α and IFN-! can be potentially involved in the development and persistence of 
CRS and sleep problems.  
In addition, our study also provides preliminary evidence of saliva as a promising body 
fluid to detect and measure biomarkers related to sleep problems and CRS in BCS. This is an 
important contribution to the emerging field of interdisciplinary salivary bioscience. In the 
oncology context, it serves as a foundational reference guide to the collection, analysis, and 
interpretation of inflammatory salivary data in BCS, as well as its myriad applications in health 
care (e.g. surveillance, public health etc.). 
To the best of our knowledge, this is the first trial to report correlations between salivary 
cytokines and CRP, as well as correlations between cytokines in BCS. These findings add to the 
literature by suggesting that salivary inflammatory markers might also act within an extensive 
tightly orchestrated biochemical network. Understanding inflammatory markers’ interactions 
under different biological, clinical or experimental conditions is of great importance and should 
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be considered, especially in case of therapeutic treatment. Comprehend the hidden relations 
between pro- and anti-inflammatory cytokines can lead to new important understanding in cell 
signalling and inflammation. Clearly, the study of the correlations among inflammatory markers 
in cancer survivorship is particularly warranted given the well-established connection between 
cancer and inflammation (Coussens & Werb, 2002; Murata, 2018; Singh, Mishra, & Aggarwal, 
2017).  
Correlations between PROs also adds to the literature by suggesting that several 
symptoms might niche-adapt in clusters during breast cancer survivorship, even under the 
benefits of BCS. That means that even though there were improvement of all CRS, they were still 
highly correlated with each other throughout the program. The understanding of symptoms 
clustering can help in the management of CRS and in the design of new interventions.  
This study provides a better understanding of the mechanisms underlying the 
psychological, physiological and immunomodulatory effects of MT in BCS and serve as an aid 
for patients’ informed decision, as well as to sensitize the general public and clinical practitioners 
by raising awareness of the potential benefits of MT.  
 
5.5 Recommendations  
 
There is an eminent need for more scholarly inquiry in IM field, along with more 
standardized education, training, and regulation of integrative therapies in clinical and academic 
settings. World Health Organization (WHO) has repeatedly reinforced its support of integrative 
therapies. In 2008, the WHO Congress of Traditional Medicine promulgated the Beijing 
Declaration, which has as one of its major policy directions, to strengthen the communication 
between allopathic health professionals and integrative therapists, along with the need to develop 
appropriate IM training programs for health professionals and health-related fields students 
(World Health Organization, 2013). Reverberating WHO’s endorsements, and to close the gap 
between perceptions and reality around IM, it is recommended to incorporate evidence-based IM 
education for health professionals, especially for those who work in primary health care. The 
relevance of training health professionals who are not specialists in integrative medicine, is 
endorsed, particularly in the recognition of patients, families and communities who would benefit 
from integrative therapies. Therefore, it is reinforced the creation of a minimum competency 
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profile in integrative medicine to be adopted in all universities at both undergraduate and 
postgraduate levels.  
Strengthening IM research in clinical settings to help establish IM services into standard 
cancer care is one of the major recommendations of this study. Clinical audits are crucial to 
evaluate the cost-benefit and relevance of MT integration into standard cancer care in hospital 
settings. In North America, a number of hospitals offer a range of IM services among the 
spectrum of integrative oncology services offered as standard of care (Cramer et al., 2013). In 
Saskatchewan, the SCC has not yet implemented integrative services for either cancer survivors 
or patients in treatment. This represents a disparity in cancer care as several other provinces in 
Canada have already established IM services (e.g. Cancer Care Manitoba, Integrative Health 
Institute in Edmonton, and Tom Baker Cancer Centre in Calgary).  
Prevention of new and recurrent cancers are important aspects of cancer survivorship, but 
surveillance must also rigorously incorporate behavioral, psychosocial and sleep screenings. 
Therefore, future practical recommendations include establishing screening and evaluation of 
CRS and sleep problems throughout cancer trajectory and survivorship. By monitoring the onset 
and progression of symptoms, whether they started before treatment, after treatment or during 
one of the treatment phases, a relationship to the phase of treatment (or not) can be suspected.  
 
5.6 Future Research Directions 
 
 
Although this study used a one-group pre/post-test design with adequate, but relatively 
small sample size, it opens new research avenues on integrative oncology, salivary bioscience, 
symptomatology and management in BC survivorship. Future steps in this field include creating 
more evidence to support informed decisions on the use of integrative therapies by cancer 
patients and survivors. A larger replication of this study must consider a follow-up assessment, 
stricter control of saliva specimens’ collection, and a control group. It is also strongly suggested 
that future studies should test different dosages and durations of MT interventions. In addition, 
giving detailed information of both research methods and interventions protocols is another 
important aspect to be acknowledged by further studies.  
Not many studies have been interested in understanding the biopsychosocial aspects in 
cancer survivorship. Future investigations should focus on the study of early predictors of 
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prolonged recovery in BC survivorship, as well as the evaluation of underlying biopsychosocial 
changes during cancer survivorship. In addition, subsequent studies in BCS should attempt to 
evaluate the possible clinical long-term outcomes of the use of MT and other non-
pharmacological interventions. 
Incorporation of qualitative data collection in another recommendation for future 
research, as this type of data is able to capture experiences, perceptions, and factors that can help 
researches in evaluating the impact of an intervention. Rigorous qualitative research can provide 
meaningful conclusions that can inform policy and practice in clinical settings. 
Areas for further research include understanding and identifying the pitfalls of 
implementing a comprehensive practical screening for sleep-wake disturbances, fatigue and 
psychological stress throughout cancer trajectory, along with identifying ways of overcoming the 
barriers in offering integrative oncology services as part of standard cancer treatment. 
Additionally, more scholarly research is warranted on patient safety, dosage, potential harms, 
discomforts, side effects and contraindications on integrative therapies.  
  Future steps in salivary biomarkers field include defining what target sensitivity and 
specificity values might confer clinical utility. Therefore, to identify whether salivary cytokines, 
cortisol and CRP are possible markers and/or predictors of persistent CRS and sleep quality in 
BCS, further early phase biomarker studies must determine target performance values for 
sensitivity and specificity of these molecules. In addition, further studies must also determine the 
effectiveness of MT on other sleep-reactive physiological measures such as serotonin and 
melatonin.  
One important aspect to consider when investigating the immunomodulatory effects of 
MT is the pressure-dependent response. As described before, different pressure massages (i.e. 
moderate pressure or a light pressure massage) has been shown to yield different physiological 
outcomes (Diego & Field, 2009; Porges, 2001). Therefore, further studies should investigate to 
what extent the immunomodulatory response exerted by MT is dependent upon the applied 
pressure.   
Our findings show that oximetry values increased right after MT sessions at each week of 
the program, validating our hypothesis. However, this increase was only statistically significant 
at week 2, 4m 7 and 8. Future studies should consider the use of near-infrared spectroscopy 
(NIRS), which provides a non-invasive technology to assess the concentration change in oxy-
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hemoglobin (HbO2), deoxy-hemoglobin (Hb), and blood volume. It is possible that because we 
used pulse oximetry in the present study, we were not able to identify more significant changes. 
Pulse oximeter assesses only the arterial compartment, while NIRS assesses all of the vascular 
compartments (arterial, venous and capillary). It also measures hemodynamics and gives the 
exact oxygen level in the blood (microcirculation).  
There are a number of psychological factors which were not explored in this research that 
are warranted to be assessed in future studies. One of these factors is the influence of personality 
traits and personal beliefs on adherence to MT programs and other IM practices. It is known that 
personality types and other psychosocial aspects have an influence on reported adherence to 
pharmacological therapies, non-pharmacological interventions and e-therapies (Axelsson, Brink, 
Lundgren, & Lötvall, 2011; Donkin et al., 2011; Emilsson et al., 2011; Hilliard, Brewer, 
Cornelius, & Raalte, 2014; Jerant, Chapman, Duberstein, Robbins, & Franks, 2011; Sirois & 
Purc-Stephenson, 2008). However, more methodological work is needed on how to robustly 
determine the influence of personality traits on adherence to IM practices, including MT.  
 
5.7 Conclusion  
  
This study sought to examine the effects of an 8-week Swedish MT program on quality of 
life, fatigue, stress, sleep, cortisol, CRP and pro-inflammatory cytokines in BCS. It revealed 
evidence of a positive effect of MT in QoL, fatigue, stress and sleep quality in BCS. Oxygen 
levels and heart rate also demonstrated improvements. Our findings also indicated significant 
improvement in cortisol, IL-1β and TNF-α levels in BCS and showed improvement trends in 
most of the other inflammatory markers analyzed. Besides that, this study provides pioneering 
data of salivary inflammatory markers in BCS.   
MT has been associated with alleviating CRS in cancer patients, nevertheless, given the 
number of restrictions of previous studies, inconsistencies and methodological drawbacks, long-
term and biological effects of MT interventions in BCS are still inconclusive. Overall, it 
highlights the importance of testing non-pharmacological interventions for the management of 
CRS and sleep problems in BCS, as well as understanding its burden in this population.  
With regards to CRS clustering, this study further supports the concept of the 
development of symptoms clustering during cancer survivorship. For instance, important 
relationships within PROs, and between PROs with sleep and cytokines were found in this study, 
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indicating that these symptoms might have the same biological underpinnings, leading to a 
possible interconnection between its development, severity and persistence. To our knowledge, 
our study provides new data on associations between salivary inflammatory biomarkers, sleep 
and PROs in the setting of an intervention trial with BCS. Therefore, findings from this 
dissertation employed the use of objective and biological measures in combinations with 
subjective symptom assessment.   
The results concerning inflammatory markers indicate that there is a potential in MT’s 
effects in reducing inflammation, however, larger studies are needed to determine 
immunomodulatory changes under MT in BCS.  
  Results of our study must be interpreted with caution given its limitations. However, 
based on our findings, MT for BCS has potential clinical value for relieving CRS and 
improving sleep, QoL, stress and decreasing fatigue. Our results on the biological effects of MT 
also provide promising evidence that manipulative therapies may be justifiable in clinical 
practice. Therefore, integration of MT during treatment phase and/or survivorship care, 
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Appendix C - Consent Form 
 
 
You are invited to participate in a research project entitled: 
 
 Effects of Swedish massage on quality of life, sleep, stress, fatigue and on biological 
markers levels in recently treated patients with breast cancer 
 
    You are invited to take part in this research because you may potentially qualify for the 
study since you have been diagnosed with breast cancer and have finished the treatment in the 
last month.  
  Your participation is voluntary. It is up to you to decide whether or not you wish to take 
part. If you wish to participate, you will be asked to sign this form. If you do decide to take part 
in this study, you are still free to withdraw at any time and without giving any reasons for your 
decision.  If you do not wish to participate, you will not lose the benefit of any medical care to 
which you are entitled or are presently receiving. It will not affect your relationship with the 
Saskatoon Cancer Centre. 
 Please take time to read the following information carefully, and feel free to ask questions 
you might have. 
You can ask the researcher to explain any words or information that you do not clearly 




Kalyani Premkumar MBBS MD MSc(Med Ed) PhD MBA (c) 
Director (Acting), Division of Faculty Development, 
Associate Professor, 
Room 3226, E Wing,  
Department of Community Health & Epidemiology, 
College of Medicine, University of Saskatchewan, 
Saskatoon, SK Canada S7K 5E5 
Phone: (306) 966 1409  Fax: (306) 966 7920 
email: kalyani.premkumar@usask.ca  
 
Student researcher: 
Emiliana Bomfim, RN, MSc, PhD Student 
University of Saskatchewan, College of Medicine  
Department of Health Sciences, 
Saskatoon (SK), Canada, S7N 5E5 
E-mail: e.bomfim@usask.ca  
Phone: (613) 406-1977 
 
 






Franco Vizeacoumar, MSc ,PhD 
Saskatchewan Cancer Agency 
4D01.5 Health Sciences Bldg. 
107, Wiggins Road 
Saskatoon (SK), Canada, S7N 4E5 
Phone: (306) 966 7010 
 
Purpose(s) and Objective(s) of the Research:  
• This study is being done to uncover and support the use of massage therapy - its efficacy 
and efficiency that help to define standards and trustworthy clinical practice guidelines. In 
other words, this study aims to explore the effects of Swedish massage on quality of life, 
sleep patterns, stress and fatigue in a population of patients with a recent history of breast 
cancer and also investigate the effects of Swedish massage on some substances, called 
biomarkers, that our body produces and that might be related to sleep, fatigue and stress in 
patients with cancer or who was recently treated for cancer. 
• The main research question of this study is: in recently treated breast cancer patients, could 
a 1-hour session of Swedish massage improve self-reported quality of life, sleep quality 
and, decrease stress, fatigue and biomarkers levels?  
 
Procedures: 
• Women over 18 years with a diagnosis of breast cancer who have completed therapy in the 
last 1 month will be invited to participate in this research. The weekly massage sessions be 
held at the Massage Therapist Association of Saskatchewan Inc. located at 1724 Quebec 
Ave, Saskatoon, SK S7K 1V9. As a participant, you will undergo 1 hour of massage therapy 
(MT) sessions, given by professional therapists using standardized protocol, over 8 weeks.  
 
Measurements: 
1. Quality of Life, stress and fatigue: will be measured four times during the study: (i) In 
the beginning of the study; (ii) upon week 4 and week 7 (iii) In the end of the study. 
They will be assessed by using appropriate scales (questionnaires). (see Figure 1 for an 































Figure 1. Description of when each assessment will be done. 
 
 
2. Sleep Quality: will be measured four times: (i) In the beginning of the study; (ii) upon 
week 4 and week 7 (iii) In the end of the study. Sleep will be assessed by a wrist 
actigraph, which is a tool similar to a watch and the participants will use it for at least 









    
Figure 2. Sleep watch. 
  
 
3. Biomarkers: are those substances that our body produces and that might be related to 
sleep, fatigue and stress in patients with cancer or in those who were recently treated 
for cancer. They will be measured four times: (i) In the beginning of the study; (ii) upon 
week 4 and week 7, right after and before the massage therapy sessions; (iii) In the end 
of the study. The levels biomarkers will be assessed through saliva collection (see 
Figure 3). These saliva kits are intended for use in the non-invasive collection of saliva 
samples. They are suitable to easily measure molecules that are present in the human 
saliva and have medical relevance. The saliva samples to assess these biomarkers will 
be collected using the passive drooling collection method (Figure 3). This method 
involves the collection of whole saliva by unstimulated passive drool. You will be asked 
to tilt your head forward, allowing the saliva to pool on the floor of the mouth, then pass 
the saliva into a polypropylene tube. Usually 1 min is enough to collect passive drooled 
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saliva using this method. Two saliva collections will be performed per day of massage 
session (pre and post intervention). One additional collection will be performed in the 
beginning of the study and another one in the end of the study. In total, each participant 










Figure 3. Saliva tube. 
 
4. Physiological parameters: these are biological characteristic that help us to understand 
the physiological function of human body. The oxygen saturation, blood pressure and 
heart rate are the physiological parameters that this study will measure in four times: (i) 
In the beginning of the study; (ii) upon week 4 and week 7, right after and before the 
massage therapy sessions; (iii) In the end of the study. Physiological parameters will be 
assessed by using an automated vital signs monitor, which is a non-invasive method, 
versatile, very simple and widely used in medical services to provide physiological 
parameters reading without needing someone to operate the cuff or listen to the blood 









Figure 4. Vital Signs Monitor. 
 
5.  Clinical Information: will be collected (type and stage of breast cancer, details about 
the treatment performed and some latest lab results), by the researchers reviewing your 
medical health records with your permission.  See the end of the consent form for 
checkbox.    
 
Please feel free to ask any questions regarding the procedures and goals of the study or 
your role. 
 
Funded by:  
• This study is being supported by internal funds from the Vice-Dean’s office. 
 
Potential Risks:  
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• Transient physical discomfort due to massage therapy sessions.  
• Activation of any embarrassment from answering questions that trigger memories of an 
unpleasant event. 
• Since personal medical information will be collected, the breach of confidentiality is a 
potential risk, however, many procedures will be followed to minimize this risk (please see 
the topic: "Confidentiality" below). 
 
Potential Benefits:   
• This study may directly benefit you at the time of your involvement by providing the MT 
sessions and a potential relief sensation, plus periodic symptoms evaluations.   
• It is hoped the information gained from this study can be used in the future to benefit other 
people with a similar condition. 
• Advice, care, and support by trained clinical staff who understand about the occurrence of 
late cancer-related symptoms.  
• Closer monitoring of your late symptoms, care and treatment 
• The opportunity to access a promising new treatment being the first to benefit from a new 
approach under study 
 
Safeguards to alleviate these risks: 
• There is no information on rates of harm related to massage therapy sessions in patients 
with cancer according to previous publications, however, you will be asked to report as 
soon as possible any side effects to the investigator. In general population, some rare side 
effects may occur in approximately 1.1% of clients receiving massage, such as: (i) physical 
discomfort; (ii) bruising; (iii) headache and (iv) tiredness. This study will receive the 
collaboration and supervision of Pam Fitchner, a registered massage therapist, and cranio-
sacral and somato-emotional release therapist for over 12 years. If any participant 
experiences any worries or discomfort, she will be referred to Ms. Fitcher who will be able 
to manage any side effects. Also, if you experience any worries or discomfort you will be 
informed about the possibility of withdrawing from the study. You may withdraw from the 
study at any time without any penalty or loss of benefits to which you are otherwise entitled 
(please see the topic "Right to Withdraw" below) 
 
Compensation:  
• There are no study-specific costs to the participants. Participants will be given a gift card 




• As a procedure to safeguard confidentiality of responses, handwritten notes taken during 
the data collection will be assigned an alpha-numeric code (each participant will receive a 
study code, which means that your name will be de-identified) and no identifying 
information will be associated with any name. In reporting findings, only summaries of 
the results will be disseminated, and your identity will not be revealed. 
• In Saskatchewan, the Health Information Protection Act (HIPA) defines how the privacy 
of your personal health information must be maintained so that your privacy will be 
respected. The study data will be stored securely (in a locked cabinet contained within a 
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locked office under the supervision of the principal investigator Dr. Premkumar) by the 
study team for a minimum of 5 years after the final results are published.  
• Research records and medical records identifying you may be inspected by the University 
of Saskatchewan Biomedical Research. 
• Ethics Board, or regulatory authorizes for quality assurance and monitoring purposes. 
• It is the intention of the research team to publish results of this research in scientific 
journals and to present the findings at related conferences and workshops, but your 




Storage of Data: 
• To protect the confidentiality of the participant data collection instruments will not contain 
information that could readily identify participants. Instead will be used study codes. Each 
sample will receive a unique study ID, comprising of an alphanumeric code (e.g.: mts01, 
mts02, mts03), which will be inserted onto their data document (questionnaires, medical 
chart, saliva tubes etc.). To link each participant with their responses/ data the study ID will 
be assigned to each participant prior to collecting data. On a separate file participants’ name 
will be typed along with their unique study ID - master list. Digitalized data will be coded 
and stored on researcher's personal computer as encrypted data and with a secured 
password. Paper data will be scanned and stored electronically and paper data will be 
destroyed after five (5) years. After the 5-year storage period the paper and electronic data 
will be destroyed by confidential shredding and permanent deletion, respectively. All saliva 
samples remaining will be unlabeled and then discarded in the lab facility according to the 
applicable institutional policies, and local and national regulations to handle discarding 
specimens process. No biobank or biorepository is intended to be created. 
• Ms. Bomfim will transport any data collected in a locked backpack from collection site to 
Health Sciences Building Hsc E wing room# 3226 at the University of Saskatchewan - 107, 
Wiggins Road. The saliva samples will be transferred into a small container using a sponge. 
Saliva samples collected using the method proposed by this study are stabilized and can be 
transported and/or stored long-term at ambient/room conditions. During the duration of the 
study, the saliva tubes will be also coded accordingly and stored at the Cancer Cluster 
Laboratory 4D01 Health Sciences Bldg. 107, Wiggins Road Saskatoon, SK at the 
University of Saskatchewan.  
 
Dissemination of Results:   
• The research data may be used to create poster presentations and/or conference abstracts, 
as well as for writing a journal article for submission to an academic journal. 
 
Right to Withdraw:  
• Your participation is voluntary, and you can answer only those questions that you are 
comfortable with.  You may withdraw from the research project for any reason, at any time 
without explanation or penalty of any sort. 
•  If you do not wish to participate, you will not lose the benefit of any medical care to which 
you are entitled or are presently receiving. It will not affect your relationship with the 
Saskatoon Cancer Centre. 
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• Should you wish to withdraw by any reason, for example: if you experience any worries or 
discomfort or even if you are not able to cope with the duration of the study. Regardless the 
reason, if you withdraw from the study your data and samples collected so far will be also 
discarded unless the data have been already de-identified.  
• Your right to withdraw statement to explain the point at which data withdraw may no longer 
be required. Your right to withdraw data from the study will apply until results have been 
disseminated. After this date, it is possible that some form of research dissemination will 
have already occurred and it may not be possible to withdraw your data. 
 
 What happens if something goes wrong? 
• It is important to mention that by signing this consent form it is ensured that you do not 
waive any of your legal rights.  
 
Follow up:  
• The study results will be presented to all participants and key informants in a small 
gathering in a location that will be favourable for all by the end of September 2018. 
During this gathering session, I will acknowledge the participation of all participants and 
thank any supporter institution, such as Saskatchewan Cancer Agency. You will receive a 
brochure with a summary of the principal results in layman's terms, although copies of the 
final research report will be available and send to you via mail or e-mail (please see 
below). You will be encouraged to ask any questions you may have or express their 
concerns about the research. For those that will be unable to attend, you will be contacted 
individually by call to be informed about the results of this study.  
 
Would you like to be informed about the final results of this study ?  
☐  NO 
☐  YES             If yes:      
                   by email: ______________________________                 
                   by mail: ________________________________________________ 
 
Questions or Concerns:  
• Contact the researcher(s) using the information at the top of page 1; 
• This research project has been approved on ethical grounds by the University of 
Saskatchewan Research Ethics Board.  Any questions regarding your rights as a 
participant may be addressed to that committee through the Research Ethics Office 
ethics.office@usask.ca (306) 966-2975. Out of town participants may call toll free (866) 
966-2975. 
 
If you have any questions concerning the research project, please feel free to ask at any point; 
you are also free to contact the researcher at the number provided if you have other questions.  
Your signature below indicates that you have read and understand the description provided; I 
have had an opportunity to ask questions and my/our questions have been answered. I consent 




Effects of Swedish massage on quality of life, sleep, stress, fatigue and on biological 
markers levels in recently treated patients with breast cancer 
CONSENT TO PARTICIPATE 
  
By signing this document, I am confirming that: 
 
·       I have read the information in this consent form. 
·       I understand the purpose and procedures and the possible risks and benefits of the 
study. 
·       I was given sufficient time to think about it. 
·       I had the opportunity to ask questions and have received satisfactory answers. 
·       I am free to withdraw from this study at any time for any reason and the decision 
to stop taking part will not affect my future medical care. 
·       I agree to tell the study doctor at once if I feel I have had any unexpected or 
unusual symptoms. 
·       I understand that this study may not provide any benefits to me. 
·       I give permission for the use and disclosure of my de-identified personal health 
information collected for the research purposes described in this form. 
·       I give permission for the access of my identifiable personal health information for 
the research purposes described in this form. 
·       I understand that by signing this document I do not waive any of my legal rights. 
·       I understand I will be given a signed and dated copy of this consent form. 
 
Would you permit that the researchers of this study have access to your medical chart 
to collect additional clinical data regarding your previous condition and health history? 
☐  NO 




    




    
Name of Researcher  Signature  Date 
 
 













































Appendix E - Functional Assessment of Cancer Therapy Version B (Fact-B) 
 
Below is a list of statements that other people with your illness have said are important. Please circle or mark 
one number per line to indicate your response as it applies to the past 7 days. 
 













GP1 I have a lack of energy 0 1 2 3 4 
GP2 I have nausea 0 1 2 3 4 
GP3 Because of my physical condition, I have trouble eating the 











GP4 I have pain 0 1 2 3 4 
GP5 I am bothered by side effects of treatment 0 1 2 3 4 
GP6 I feel ill 0 1 2 3 4 
GP7 I am forced to spend time in bed
 ......................................................................................................................  
0 1 2 3 4 
 













GS1 I feel close to my friends 0 1 2 3 4 
GS2 I get emotional support from my family 0 1 2 3 4 
GS3 I get support from my friends 0 1 2 3 4 
GS4 My family has accepted my illness 0 1 2 3 4 






















Q1 Regardless of your current level of sexual activity, please 
answer the following question. If you prefer not to answer it, 
please mark this box           and go to the next section. 
     
GS7 I am satisfied with my sex life
 ......................................................................................................................  























B1 I have been short of breath 0 1 2 3 4 
B2 I am self-conscious about the way I dress 0 1 2 3 4 











GE1 I feel sad 0 1 2 3 4 
GE2 I am satisfied with how I am coping with my illness 0 1 2 3 4 
GE3 I am losing hope in the fight against my illness 0 1 2 3 4 
GE4 I feel nervous 0 1 2 3 4 
GE5 I worry about dying 0 1 2 3 4 
GE6 I worry that my condition will get worse
 ....................................................................................................................... 
0 1 2 3 4 













GF1 I am able to work (include work at home) 0 1 2 3 4 
GF2 My work (include work at home) is fulfilling 0 1 2 3 4 
GF3 I am able to enjoy life 0 1 2 3 4 
GF4 I have accepted my illness 0 1 2 3 4 
GF5 I am sleeping well 0 1 2 3 4 
GF6 I am enjoying the things I usually do for fun 0 1 2 3 4 
GF7 I am content with the quality of my life right now
 ......................................................................................................................  
0 1 2 3 4 
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B3 One or both of my arms are swollen or tender 0 1 2 3 4 
B4 I feel sexually attractive 0 1 2 3 4 
B5 I am bothered by hair loss 0 1 2 3 4 
B6 I worry that other members of my family might someday get the 











B7 I worry about the effect of stress on my illness 0 1 2 3 4 
B8 I am bothered by a change in weight 0 1 2 3 4 
B9 I am able to feel like a woman
 ...................................................................................................................... 
0 1 2 3 4 



































Appendix F - Functional Assessment of Cancer Therapy Fatigue (Fact-F) 
 
Below is a list of statements that other people with your illness have said are important. Please circle or mark 
one number per line to indicate your response as it applies to the past 7 days. 
 











HI7 I feel fatigued 0 1 2 3 4 
HI12 I feel weak all over 0 1 2 3 4 
An1 I feel listless (“washed out”) 0 1 2 3 4 
An2 I feel tired 0 1 2 3 4 
An3 I have trouble starting things because I am tired 0 1 2 3 4 
An4 I have trouble finishing things because I am tired 0 1 2 3 4 
An5 I have energy 0 1 2 3 4 
An7 I am able to do my usual activities 0 1 2 3 4 
An8 I need to sleep during the day 0 1 2 3 4 
An12 I am too tired to eat 0 1 2 3 4 
An14 I need help doing my usual activities 0 1 2 3 4 










An16 I have to limit my social activity because I am tired
 ...........................................................................................................  



















Appendix H - Sleep Diary 
 
SLEEP DIARY 
PARTICIPANT ID: ___________________ 
 
Complete the diary each morning (answer in the morning after waking for the day). Do not 


























Time you went to 
bed last night  
 
 
    
Time you got out 
of bed this 
morning 
     
Number of times 
you woke up 
during the night  
     
Took off the 
sleep watch?  
















If yes, for how long? 
 
__________ 








If yes, for how long? 
 
__________ 






























took today (if 
any) 





If yes, how many 
cups? 
If yes, how many 
cups? 
If yes, how many 
cups? 
If yes, how many 
cups? 
If yes, how many 
cups? 
How did you feel 
when you woke 
up?  
☐Refreshed 























Appendix I - Clinical and Demographic Questionnaire 
 
                 
i. DEMOGRAPHIC DATA 
Participant ID#:  
File Number:  
Age:  
Level of education: ☐ No formal education          ☐ Less than high school           ☐ High School      
☐ College or Bachelor's degree           ☐ Less than high school          
Marital status: ☐ Married                    ☐ Not married           
 ☐ Stable Union           ☐ Divorced            
 ☐ Widowed                ☐ Other:________________ 
Birth country:  
Work: ☐ Not working           ☐Full time worker            ☐Part-time worker             
☐Domestic worker         
  ☐Pensioner  
Religion: 1. ☐ Christian           2. ☐Other:__________________             
Ethnicity: 1. ☐ Black            2. ☐White            3. ☐Native American             
 
ii. DISEASE CHARACTERISTICS 
Diagnosis:  
Date of diagnosis:  
Stage: ☐ Stage I                 ☐ Stage II         ☐ Stage III 
Disease Classification: 1. ☐ Primary neoplasm           2. ☐ Recurrent neoplasm  
If recurrent:   1. Date of recurrence:                                   
Week after the treatment:   1. Number of week (s) after the completion of treatment:  
Other characteristics: 1. Type of tumor: 
2. Size: 
3. Location:  
4. T (size):_____   N(node):______   M(metastasis):______ 
Medications in use:  __________________________________________________________ 
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iii. TREATMENT CARACTHERISTICS 
Treatment: 1. Chemotherapy:   
           ☐ No 
           ☐ Yes: 
           1.1 First day of treatment: ________________ 
           1.2 Last day of treatment: ________________ 
           1.3 Type of treatment: ________________________________ 
2. Radiotherapy:  
           ☐ No 
           ☐ If yes: 
           2.1 First day of treatment: ________________ 
           2.2 Last day of treatment: ________________ 
           2.3 Type of treatment: ________________________________ 
3. Surgery:  
           ☐ No 
           ☐ If yes: 
           3.1 Date of procedure:  
           3.2 Type of surgery:   
                   ☐ lumpectomy            ☐ quadrantectomy  
                   ☐ partial mastectomy          ☐ radical mastectomy   
                   
           3.3 Reconstructive or breast implant surgery:  
            ☐ No  
            ☐ If yes, which:__________________ When: ___________________ 
 
           3.4 Lymph node surgery:   
                   ☐ No      
                   ☐ If yes:     ☐ Sentinel node        ☐ Axillary node dissection         
☐ Other  
4. Hormone Therapy:  
  ☐ No      
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  ☐ If yes, which:__________________ When: ___________________ 
5. Other:     
☐ No      
☐ If yes, which:__________________ When: ___________________ 
iv. OTHER CLINICAL INFORMATION 
Comorbidities:  ☐ None                   ☐ If yes, which: ________________________ 
Latest lab results: Hemoglobin:                                    Hematocrit:                             Date:  
In use of any medication: ☐ No       ☐ If yes, which one (s):  
                                                     1.__________________ How long: 
___________________ 
                                                     2. __________________ How long: 
___________________ 



























Appendix J - Swedish Massage Therapy Protocol 
 
 
 This protocol was developed based on previous studies with breast cancer 
population 27, 28, 35, 36, 37, 39, 40, 41, 260, 135. Women will receive 1-hour massage sessions (1 massage 




























Observations before starting the protocol: 
 
1. No talking during massage except for asking for pressure and how they are 
feeling 
2. Same oil usage for all participants- fractioned coconut oil 
3. Relaxation massage – not treating muscles specifically or doing deeper 
pressure as week progress. Do light to moderate pressure. Little to no 
tapotement.  
4. If patient is unable to lie prone, then she can use the sidelying position 
5. If any area has lymphedema or swelling, the therapist can adapt by moving 
to another area. 
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PRONE (OR SIDELYING) 




[1 foot at a time for 2.5 
minutes each] 
FOOT MASSAGE: Along with 
diaphragm breathing. Begin with 
3 diaphragm breaths with your 
hand on the back of the 
participant’s diaphragm. Bring 
the kneed into 90 degrees’ 
flexion if possible. Flex/extend 
the foot – Get the patient to 
breathe in, do plantar flexion 
(foot down towards the table) 
and then breathe out, 
dorsiflexion (foot upwards 
towards the ceiling). Massage the 
bottom and top of the feet 
squeezing the heel. Could do 























[1 leg at a time for 5 
minutes each] 
LOWER LIMBS: Stroke and 
knead the calf muscles. Shake 
(gently rocking) the leg with the 
knee flexed onto therapist’s 
shoulder (if able to). Effluarge 
and Petrissage Strokes from the 
heel up to and over the buttock, 
circular stroking to the buttock 
area and stroking from the 























BACK: Effleurage 2 x on either 
side of the spine. Stroke from 
the base of the shoulders. Do 
deeper palmar or 
fingertip/thumb kneading. 
Squeeze neck and shoulder areas 
with compressions. Can use the 
edge of hand to rub alongside 
the spine from the top to the 
bottom of the back. Squeeze and 











[1 arm at a time for 3.5 
minutes each] 
UPPER LIMBS: Effleurage, 
Petrissage. Light stroke and 
gentle palmar or fingertip 
kneading; stroke from the base 
of shoulders to out over the arms 
to the elbow and effleurage back 






[1 leg at a time for 3.5 
minutes each] 
LOWER LIMBS: Ending 
together. Effleurage and 
Petrissage. Stroke and 
knead the anterior thigh 
region. Stroke from the hip 
to the calf and foot, 
holding both legs together 
at the heels and then 
pulling them with traction. 
Also, do a gentle pulling of 
the legs together to the 







[1 side of the chest at a 
time for 2.5 min.] 
TORSO/ BREAST 
AREA: Effleurage, 
Petrissage. Start with one 
hand on top of the other at 
the sternum and do a gentle 
compression with 3 deep 
breaths. Stroke and knead 
into the shoulder; do range 
of motion with the 
shoulder on the same side, 
then treat opposite side of 
chest. Do rib raking and 
stroking along rib cage- 3 
spots 3x each from below 
to axilla, depending on scar 
tissue and sensitivity. do 
slow progressive 
compressions from the 
armpit to the chest- 
alternate stroking from 
sternum along pectoralis 
minor to shoulder and 
fingertip kneading and 
stroking. Do compressions 






[1 arm at a time for 3 
minutes each] 
UPPER LIMBS: 
Effleurage and Petrissage. 
Stand at head facing 
towards chest. Press down 
on the shoulders with the 
palms of the hands and into 
any mid-shoulder trigger 
points. Stroke from the 
sternum to the armpit. 
Then, move to the wrist 
and stand facing towards 
the chest. Stroke from the 
wrist to the shoulder and 
do range of motion with 
each arm. 
 5 min. 
 
NECK, HEAD AND 
FACE: Effleurage and 
Petrissage. Stroke and 
fingertip knead and strip 
along neck. Circular knead, 
gentle stroke on face and 
scalp. 
 5 min. NECK: Lengthening of 
the neck by doing cervical 
traction with one hand on 
each side of the head and 
gently pulling. Stroke 
forehead, circular stroke 















Appendix L - Instructions on Collecting Saliva Samples 
 Before Saliva Collection: 







STEP 1:  Rinse mouth with water to remove food residue.  








STEP 2:  Open foil pouch and remove the Saliva Collection Aid. 
 
STEP 3:  Place the ribbed-end of the Saliva Collection Aid securely into 






STEP 4:  Allow saliva to pool in mouth. Then, with head tilted forward, 
gently force saliva through the Saliva Collection Aid into the tube. Fill 
to 2mL. Reserve a small amount of air space in the tube to accommodate 






STEP 5:  Remove and discard Saliva Collection Aid. Attach cap to 
collection vial and tighten. 
 
 
 After Saliva Collection: Immediately after collection, freeze samples at or below -
20°C (regular household freezer). If freezing is not possible 
 Avoid foods with high sugar (e.g. pop), acidity (e.g. alcoholic 















WHEN TO COLLECT 
SAMPLE 
COLLECTION START/ 

















































































































Appendix O - Template of the 96-well plate Used for Saliva Analysis 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Std1 
 
Std1           
B Std2 
 
Std2           
C Std3 
 
Std3           
D Std4 
 
Std4           
E Std5 
 
Std5           
F Std6 
 
Std6           
G Std7 
 
Std7           
H Blank 
 















Appendix P - Tables of Descriptive Statistics at All Timepoints 
 
Table A.1. Descriptive statistics of the total fatigue (FACT-B) scores at respective time-points and independent variables’ categories 
in a sample of BCS, Saskatoon. 
Outcome Baseline Assessment 1 Assessment 2 Endpoint 
 Mean±SD Mean±SD Mean±SD Mean±SD 
Total QoL 92.0 ± 16.14 97.6 ± 17.4 106.1 ± 17.8 103.8 ± 17.14 
     
QoL by Age     
30-40 86.7 ± 3.0 98.5 ± 7.2 99.3 ± 6.5 105.3 ± 7.7 
41-50 82.5 ± 12.7 90.8 ± 11.9 97.2 ± 23.1 98.6 ± 15.1 
51-60  95.6 ± 18.44 100.6 ± 17.8 110.5 ± 19.6 105.7 ± 18.9 
≥61 95.0 ± 17.48 96.6 ± 24.42 108.2 ± 15.2 103.2 ± 21.3 
QoL by Stage     
I 94.6 ± 16.4 98.1 ± 17.3 107.9 ± 17.1 107.1 ± 17.6 
II 91.2 ± 17.1 92.5 ± 21.9 109.1 ± 21.6 98.5 ± 18.5 
III 89.4 ± 16.8 101.9 ± 13.2 101.0 ± 16.1 104.8 ± 16.4 
QoL by Months After Treatment      
< 3 months 93.3 ± 14.2 103.0 ± 11.0 104.6 ± 19.1 107.0 ± 14.0 
≥ 3 months  90.6 ± 18.5 91.6 ± 21.4 107.8 ± 17.0 100.3 ± 20.0 
QoL by Sleep Aids in Use     
On  88.5 ± 14.7 93.1 ± 18.9 107.2 ± 20.5 99.2 ± 17.8 
Off 95.8 ± 17.4 102.5 ± 14.8 105.0 ± 15.2 108.7 ± 15.6 
QoL by Treatment Type     
Chemo only 113.8 ± 10.0 117.1 ± 13.9 117.8 ± 1.6 122.5 ± 9.1 
Chemo and radiation 122 ± 0.0 126 ± 0.0 126 ± 0.0 130 ± 0.0 
Radiation and surgery 79.5 ± 11.8 83.9 ± 13.0 100.9 ± 19.0 93.5 ± 18.1 
Surgery and chemo 86.0 ± 8.3 91.5 ± 1.5 102 ± 21 97.3 ± 5.5 
Surgery only 105.5 ± 0.0 114.1 ± 0.0 116.8 ± 0.0 124.6 ± 0.0 
All three  91.4 ± 14.1 97.8 ± 17.0 104.8 ± 19.1 102.6 ± 15.8 
QoL by Hormone Therapy     
Tamoxifen 100.0 ± 13.7 103.5 ± 14.4 109.7 ± 24.2 107.6 ± 12.7 
Aromatase Inhibitors 91.3 ± 14.2 94.6 ± 19.6 110.2 ± 12.3 104.7 ± 18.8 
None  86.1 ± 19.6 96.8 ± 17.6 97.2 ±17.1 99.2 ± 19.2 
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Table A.2. Descriptive statistics of the total fatigue (FACT-F) scores at respective time-points and independent variables’ categories in 
a sample of BCS, Saskatoon.  
 
Outcome Baseline Assessment 1 Assessment 2 Endpoint 
 Mean±SD Mean±SD Mean±SD Mean±SD 
Total Fatigue 28.0 ± 10.6 34.8 ± 7.6 35.8 ± 10.3 35.7 ± 8.3 
     
Fatigue by Age     
30-40 30.3 ± 11.2 34.7 ± 11.2 36.1 ± 12.7 36.3 ± 11.5 
41-50 21.5 ± 7.5 31.7 ± 2.8 28.7 ± 12.3 32.5 ± 3.8 
51-60  30.5 ± 12.3 35.2 ± 8.6 37.5 ± 11.0 35.9 ± 9.9 
≥61 27.3 ± 9.4 36.1 ± 7.7 37.5 ± 7.0 37.4 ± 7.3 
Fatigue by Stage     
I 27.3 ± 9.6 35.3 ± 8.0 38.2 ± 7.4 37.0 ± 8.9 
II 30.7 ± 11.6 36.0 ± 6.7 37.9 ± 12.1 36.7 ± 4.8 
III 26.4 ± 12.0 32.8 ± 8.7 30.5 ± 11.2 33.1 ± 10.6 
Fatigue by Months After 
Treatment      
< 3 months 28.0 ± 11.0 35.7 ± 8.1 35.2 ± 12.6 37.1 ± 8.5 
≥ 3 months  28.0 ± 10.7 33.7 ± 7.4 36.4 ± 7.7 34.2 ± 8.2 
Fatigue by Sleep Aids in Use    
 
On  26.8 ± 9.2 34.7 ± 6.1 38.4 ± 10.2 36.4 ± 8.1 
Off 29.4 ± 12.3 34.8 ± 9.3 32.9 ± 10.2 35.0 ± 8.9 
Fatigue by Treatment Type     
Chemo only 34.5 ± 14.8 45 ± 4.2 44.5 ± 0.7 45.2 ± 0.3 
Chemo and radiation 46 ± 0.0 43 ± 0.0 41 ± 0.0 42 ± 0.0 
Radiation and surgery 20 ± 3.5 28.8 ± 2.1 33.8 ± 4.8 31.4 ± 8.5 
Surgery and chemo 23.3 ± 11.0 27.6 ± 6.0 30.3 ± 13.5 28.3 ± 6.1 
Surgery only 36 ± 0.0 45 ± 0.0 47 ± 0.0 47 ± 0.0 
All three  29.5 ± 10.5 35.9 ± 6.8 35.1 ± 12.2 36.4 ± 7.4 
Fatigue by Hormone Therapy     
Tamoxifen 32.8 ± 12.4 39.0 ± 7.1 40.2 ± 13.9 39.4 ± 5.7 
Aromatase Inhibitors 28.0 ± 8.0 34.8 ± 6.7 37.3 ± 5.9 37.6 ± 6.6 
None  24 ± 12.17 31.1 ± 8.5 29.8 ± 10.7 30 ± 10.0 
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Table A.3. Descriptive statistics of stress (PSS) total score at respective time-points and independent variables’ categories in a sample 
of BCS, Saskatoon.  
 
Outcome Baseline Assessment 1 Assessment 2 Endpoint 
 Mean±SD Mean±SD Mean±SD Mean±SD 
Total Stress 20.9 ± 7.2 17.8 ± 6.0 17.9 ± 6.5 17.4 ± 6.6 
     
Stress by Age     
30-40 22.3 ± 3.2 18.3 ± 4.0 20.6 ± 0.57 16.3 ± 5.0 
41-50 21.5 ± 2.6 18.7 ± 2.8 23.5 ± 9.39 18.2 ± 0.9 
51-60  19.6 ± 9.2 17.6 ± 6.7 17.1 ± 5.7 17.5 ± 7.6 
≥61 22.1 ± 7.6 17.3 ± 8.2 14.1 ± 5.1 17.5 ± 8.9 
Stress by Stage     
I 22.3 ± 6.6 18.2 ± 7.2 15.8 ± 5.3 16.4 ± 8.2 
II 19.8 ± 8.8 17.1 ± 6.2 19.7 ± 8.6 19.0 ± 6.4 
III 20.2 ± 7.0 18.0 ± 5.0 18.7 ± 5.7 17.2 ± 5.0 
Stress by Months After Treatment     
 
< 3 months 19.2 ± 5.6 16.3 ± 5.6 18 ± 7.0 15.5 ± 5.8 
≥ 3 months  22.8 ± 8.4 19.4 ± 6.3 17.8 ± 6.2 19.5 ± 7.1 
Stress by Sleep Aids in Use     
On  21.6 ± 7.7 18.0 ± 6.0 18.1 ± 7.8 17.7 ± 8.2 
Off 20.1 ± 6.8 17.5 ± 6.1 17.6 ± 5.0 17.1 ± 4.6 
Stress by Treatment Type     
Chemo only 15 ± 1.4 7.5 ± 2.1 10.5 ± 0.7 10.5 ± 2.1 
Chemo and radiation 7 ± 0.0 10 ± 0.0 13 ± 0.0 13 ± 0.0 
Radiation and surgery 25.8 ± 5.6 19.4 ± 3.9 21.2 ± 7.3 20 ± 8.7 
Surgery and chemo 26.3 ± 0.5 23.3 ± 4.1 19.6 ± 5.1 20.3 ± 3.0 
Surgery only 16 ± 0.0 16 ± 0.0 15 ± 0.0 7 ± 0.0 
All three  20.0 ± 7.1 18.3 ± 5.6 18 ± 6.7 18.1 ± 5.9 
Stress by Hormone Therapy     
Tamoxifen 18 ± 7.0 15.1 ± 8.2 17.3 ± 8.5 16 ± 4.8 
Aromatase Inhibitors 22 ± 6.7 18.3 ± 5.1 17.3 ± 6.0 16.4 ± 7.5 
None  22 ± 8.3 19.4 ± 5.1 19.2 ± 6.1 20.2 ± 6.7 
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Table A.4. Descriptive statistics of SD readings (in minutes) at respective time-points and independent variables’ categories in a 
sample of BCS, Saskatoon. 
 
Outcome   Baseline  Assessment 1  Assessment 2  Endpoint  
 Mean±SD Mean±SD Mean±SD Mean±SD 
Total Sleep Duration (SD)  
(in minutes) 326.6 ± 108.6 255.0 ± 100.7 357.2 ± 105.9 277.5 ± 108.5 
     
SD by Age     
30-40 283.0 ± 110.2 228.7 ± 104.6 319.9 ± 88.1 252.7 ± 77.7 
41-50 344.7 ± 101.0 223.7 ± 56.4 401.3 ± 175.7 210.1 ± 62.6 
51-60  339.4 ± 109.2 266.9 ± 113.2 354.5 ± 85.4 283.8 ± 76.9 
≥61 315.1 ± 132.6 268.9 ± 116.5 351.2 ± 110.3 324.2 ± 172.2 
SD by Stage     
I 300.3 ± 111.3 250.8 ± 99.9 330.2 ± 75.5 290.5 ± 112.95 
II 352.5 ± 126.5 264.5 ± 94.2 417.9 ± 141.2 283.6 ± 132.8 
III 334.6 ± 94.1 250.7 ± 122.0 331.3 ± 86.0 254.7 ± 87.2 
SD by Months After Treatment      
< 3 months 322.1 ± 85.1 266.6 ± 61.3 368.1 ± 108.4 267.6 ± 102.4 
≥ 3 months  331.6 ± 134.0 242.3 ± 133.7 345.3 ± 107.08 288.2 ± 118.8 
SD by Sleep Aids in Use   
  
On  350.3 ± 129.7 269.3 ± 97.4 380.3 ± 118.5 303.8 ± 128.0 
Off 300.8 ± 77.7 239.3 ± 106.7 332.1 ± 88.9 248.8 ± 78.4 
SD by Treatment Type     
Chemo only 320.5 ± 150.5 343.8 ± 17.9 364.7 ± 85.4 354.4 ± 174.9 
Chemo and radiation 279.8 ± 0.0 175.2 ± 0.0 197 ± 0.0 148.0 ± 0.0 
Radiation and surgery 242.2 ± 88.4 248.4 ± 102.7 261.0 ± 19.3 264.2 ± 107.5 
Surgery and chemo 354.2 ± 113.7 221.5 ± 109.4 422.1 ± 17.2 326.1 ± 27.9 
Surgery only 336.3 ± 0.0 211.1 ± 0.0 408.6 ± 0.0 344.2 ± 0.0 
All three  362.0 ± 112.2 262.2 ± 113.4 391.8 ± 117.1 261.9 ± 117.0 
SD by Hormone Therapy     
Tamoxifen 332.8 ± 125.1 282.2 ± 65.7 402.1 ± 127.7 293.2 ± 11.0 
Aromatase Inhibitors 342.9 ± 105.5 248.4 ± 107.5 353.6 ± 103.6 279.6 ± 130.4 





Table A.5. Descriptive statistics of SE at respective time-points and independent variables’ categories in a sample of BCS, Saskatoon.  
Outcome Baseline Assessment 1 Assessment 2 Endpoint 
 Mean±SD Mean±SD Mean±SD Mean±SD 
Total Sleep Efficiency (SE) 92.0 ± 5.0 93.9 ± 3.0 91.3 ± 5.9 92.8 ± 4.6 
     
SE by Age     
30-40 94.8 ± 2.4 96.0 ± 2.0 89.3 ± 5.5 97.5 ± 0.8 
41-50 89.2 ± 3.2 92.3 ± 2.0 92.1 ± 6.9 90.7 ± 4.1 
51-60  92.2 ± 6.4 93.6 ± 3.9 90.1 ± 5.7 93.0 ± 5.1 
≥61 92.1 ± 4.3 94.2 ± 2.2 97.5 ± 0.8 91.5 ± 4.4 
SE by Stage     
I 91.8 ± 5.8 94.4 ± 2.9 92.1 ± 5.4 91.9 ± 4.2 
II 91.8 ± 3.8 93.5 ± 2.3 90.6 ± 5.3 92.7 ± 4.3 
III 92.4 ± 5.8 93.6 ± 4.1 91.0 ± 7.7 94.0 ±5.8 
SE by Months After Treatment     
 
< 3 months 92.9 ± 3.5 93.3 ± 1.9 90.4 ± 5.2 93.0 ± 4.0 
≥ 3 months  91.0 ± 6.4 94.5 ± 3.9 92.3 ± 6.9 92.6 ± 5.4 
SE by Sleep Aids in Use    
 
On  91.8 ± 5.0 94.3 ± 2.9 91.7 ± 4.6 92.0 ± 4.5 
Off 92.1 ± 5.3 93.4 ± 3.2 90.9 ± 7.2 93.6 ± 4.8 
SE by Treatment Type     
Chemo only 92.5 ± 3.2 93.3 ± 0.1 92.0 ± 0.3 89.3 ± 6.6 
Chemo and radiation 80.9 ± 0.0 87.1 ± 0.0 84.5 ± 0.0 83.3 ± 0.0 
Radiation and surgery 91.3 ± 2.9 94.4 ± 3.3 92.9 ± 3.9 91.5 ± 4.7 
Surgery and chemo 94.9 ± 1.1 95.6 ± 4.0 90.7 ± 11.4 94.0 ± 4.8 
Surgery only 95.0 ± 0.0 95.5 ± 0.0 90.0 ± 0.0 94.3 ± 0.0 
All three  92.1 ± 1.3 93.8 ± 2.6 91.3 ± 6.1 94.4 ± 3.6 
SE by Hormone Therapy     
Tamoxifen 92.6 ± 4.5 92.8 v 4.3 91.1 ± 4.8 91.5 ± 4.5 
Aromatase Inhibitors 92.5 ± 3.7 91.1 ± 4.8 91.1 ± 5.6 93.6 ± 3.8 
None  90.8 ± 7.3 91.1 ± 5.6 91.8 ± 7.8 92.7 ± 6.1 
 
 284 
Table A.6. Descriptive statistics of SOL at respective time-points and independent variables’ categories in a sample of BCS, 
Saskatoon.  
Outcome Baseline Assessment 1 Assessment 2 Endpoint 
 Mean±SD Mean±SD Mean±SD Mean±SD 
Total SOL 3.8 ± 2.4 2.0 ± 1.0 4.6 ± 1.8 3.9 ± 1.3 
     
SOL by Age     
30-40 1.4 ± 0.79 1.7 ± 0.9 6.4 ± 2.3 4.6 ± 1.5 
41-50 3.7 ± 2.3 1.3 ± 0.4 4.2 ± 2.2 3.1 ± 0.47 
51-60  4.0 ± 2.2 2.2 ± 1.3 4.9 ± 1.5 4.0 ± 1.6 
≥61 4.9 ± 2.7 2.3 ± 0.9 3.4 ± 1.4 4.1 ± 1.0 
SOL by Stage     
I 5.2 ± 2.6 2.3 ± 1.2 3.9 ± 1.4 4.0 ± 1.4 
II 2.9 ± 1.6 1.9 ± 0.8 5.2 ± 2.4 3.7 ± 0.8 
III 3.0 ± 2.0 1.7 ± 1.1 4.9 ± 1.5 4.1 ± 1.7 
SOL by Months After 
Treatment     
 
< 3 months 3.7 ± 2.5 1.8 ± 0.9 4.5 ± 1.9 3.4 ± 1.1 
≥ 3 months  4.0 ± 2.3 2.2 ± 1.2 4.6 ± 1.8 4.5 ± 1.3 
SOL by Sleep Aids in Use     
On  3.9 ± 2.7 2.3 ± 1.2 4.0 ± 1.6 3.8 ± 1.5 
Off 3.7 ± 2.0 1.8 ± 0.8 5.1 ± 2.0 4.0 ± 1.1 
SOL by Treatment Type     
Chemo only 6.0 ± 3.7 3.0 ± 1.3 3.16 ± 1.3 3.7 ± 1.0 
Chemo and radiation 5.2 ± 0.0 1.6 ± 0.0 4.7 ± 0.0 4 ± 0.0 
Radiation and surgery 4.3 ± 3.0 1.9 ± 1.5 3.2 ± 2.0 4.6 ± 1.0 
Surgery and chemo 1.0 ± 1.1 1.9 ± 1.2 5.1 ± 0.1 4.2 ± 1.8 
Surgery only 7.0 ± 0.0 1.5 ± 0.0 3.1 ± 0.0 1.8 ± 0.8 
All three  3.6 ± 1.7 2.0 ± 0.9 5.4 ± 1.8 3.9 ± 1.2 
SOL by Hormone Therapy     
Tamoxifen 3.7 ± 2.9 2.5 ± 0.9 5.0 ± 2.2 3.9 ± 0.9 
Aromatase Inhibitors 4.0 ± 2.5 1.6 ± 0.9 4.1 ± 1.8 3.7 ± 1.4 
None  3.7 ± 2.1 2.3 ± 1.3 4.9 ± 1.5 4.2 ± 1.6 
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Table A.7. Descriptive statistics of WASO at respective time-points and independent variables’ categories in a sample of BCS, 
Saskatoon. 
 
Outcome Baseline Assessment 1 Assessment 2 Endpoint 
 Mean±SD Mean±SD Mean±SD Mean±SD 
Total WASO 36.7 ± 22.3 20.7 ± 11.1 39.8 ± 27.9 26.9 ± 17.7 
     
WASO by Age     
30-40 54.1 ± 13.6 15.3 ± 11.2 38.9 ± 29.8 16.3 ± 6.4 
41-50 34.6 ± 9.7 28.4 ± 5.4 59.9 ± 35.9 25.8 ± 15.0 
51-60  38.4 ± 24.2 21.9 ± 14.0 28.9 ± 22.3 26.6 ± 17.9 
≥61 15.3 ± 23.0 16.3 ± 5.6 44.8 ± 28.6 33.5 ± 23.1 
WASO by Stage     
I 37.8 ± 24.9 15.5 ± 6.8 34.3 ± 26.2 30.9 ± 19.9 
II 38.9 ± 18.7 24.2 ± 6.6 47.0 ± 34.5 24.7 ± 11.0 
III 33.2 ± 25.1 23.9 ± 16.8 39.5 ± 25.3 24.0 ± 21.5 
WASO by Months After 
Treatment      
< 3 months 33.3 ± 18.1 23.3 ± 8.1 40.8 ± 25.1 24.5 ± 19.1 
≥ 3 months  40.5 ± 26.5 17.9 ± 13.5 38.7 ± 31.9 29.5 ± 16.6 
WASO by Sleep Aids in Use   
 
 
On  38.8 ± 19.8 19.2 ± 9.0 39.5 ± 28.0 28.4 ± 19.2 
Off 34.5 ± 25.6 22.3 ± 13.3 40.1 ± 29.1 25.3 ± 16.7 
WASO by Treatment Type     
Chemo only 34.9 ± 27.6 17.8 ± 7.6 33.3 ± 5.7 46.9 ± 35.4 
Chemo and radiation 77.8 ± 0.0 49.9 ± 0.0 45.9 ± 0.0 63.5 ± 0.0 
Radiation and surgery 39.4 ± 26.6 18.6 ± 9.6 30.7 ± 23.5 30.4 ± 15.2 
Surgery and chemo 23.0 ± 11.5 17.4 ± 18.1 53.4 ± 32.0 25.6 ± 16.7 
Surgery only 27.5 ± 0.0 11.8 ± 0.0 45.5 ± 0.0 23.2 ± 0.0 
All three  36.7 ± 21.7 21.2 ± 8.0 40.3 ± 34.2 19.1 ± 11.4 
WASO by Hormone Therapy     
Tamoxifen 33.9 ± 22.5 22.2 ± 8.6 41.3 ± 33.6 31.1 ± 22.6 
Aromatase Inhibitors 36.8 ± 18.5 16.5 ± 6.0 40.8 ± 27.8 23.7 ± 12.5 
None  39.1 ± 29.6 25.3 ± 16.8 36.9 ± 27.22 27.9 ± 21.4 
 
